Download full issue
ORIGINAL RESEARCH
REVIEWS
ORGANIZATION OF HEALTHCARE
PRACTICAL EXPERIENCE
___
ORIGINAL RESEARCH
UDC 615.065:615.281.8 DOI: 10.20969/VSKM.2025.18(4).7-13
Hepatotoxicity of antiretroviral drugs: Risk assessment based on spontaneous reports of adverse reactions
Asan M. Beitullaev1, Elena A. Egorova1, Alexander V. Matveev2, Asie N. Useinova1, Kseniya V. Danilova1, Diana E. Rashidova1
1 Order of the Red Banner of Labour Medical Institute named after S. I. Georgievsky, V. I. Vernadsky Crimean Federal University, 5/7 Lenin Blvd., 295021 Simferopol, Republic of Crimea, Russia
2 Russian Medical Academy of Continuous Professional Education, 2/1 Barrikadnaya Str., 125993 Moscow, Russia
Abstract. Introduction. The chronic nature of human immunodefi ciency virus infection necessitates long-term antiretroviral therapy, which may be accompanied by the development of adverse reactions, including hepatotoxicity. Hepatic injury adversely aff ects treatment outcomes, increases the risk of therapy discontinuation, and reduces patients’ quality of life. Aim. To assess the frequency of liver-related adverse reactions associated with the administration of antiretroviral drugs, based on an analysis of spontaneous reports of adverse reactions. Materials and Methods. The study was conducted using data from a regional adverse reactions reporting database covering the period from 2018 to 2020. Reports were included if they met the following criteria: Presence of antiretroviral drugs in the “Suspected Drug” category and liver-related clinical manifestations in the category “Description of adverse reactions” category. Duplicates and invalid entries were excluded. Statistical analysis was performed using Microsoft Excel 2021, with frequency and percentage values calculated. Results and Discussion. In total, 83 hepatotoxicity cases were identifi ed. Adverse reactions were most frequently associated to atazanavir (59.1%) and efavirenz (33.7%). The majority of patients were aged 31–45 years (50.6%). The main clinical manifestations included elevated alanine aminotransferase levels (33.7%), hyperbilirubinemia (28.9%), and jaundice (22.9%). Full recovery was observed in 68.7% of cases. These fi ndings partially contradict the existing literature, which generally considers protease inhibitors to be less hepatotoxic. The role of various contributing factors in the development of adverse reactions is discussed. Conclusions. Hepatotoxicity associated with antiretroviral drugs remains a signifi cant concern requiring enhanced pharmacovigilance and personalized treatment strategies that take into account age, co morbidities, and genetic factors. The use of modern antiretroviral agents with improved safety profi les is recommended. The fi ndings highlight the need for further research.
Keywords: hepatotoxicity, antiretroviral drugs, adverse reactions, human immunodeficiency virus infection, pharmacotherapy
For citation: Beitullaev, A.M.; Egorova, E.A.; Matveev, A.V.; et al. Hepatotoxicity of antiretroviral drugs: Risk assessment based on spontaneous reports of adverse reactions. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4), 7-13. DOI: 10.20969/VSKM.2025.18(4).7-13.
References
1. Постановление Главного государственного санитарного врача РФ от 11 января 2011 г. № 1 «Об утверждении СП 3.1.5.2826-10 «Профилактика ВИЧ-инфекции». – М., 2011. Postanovlenie Glavnogo gosudarstvennogo sanitarnogo vracha RF ot 11 yanvarya 2011 goda № 1 «Ob utverzhdenii SP 3.1.5.2826-10 «Profi laktika VICh-infekcii» [Resolution No 1 of the Chief State Sanitary Doctor of the Russian Federation dated January 11, 2011 «On approval of Sanitary Rules 3.1.5.2826-10 «Prevention of HIV infection»]. Moskva [Moscow]. 2011. (In Russ.) Режим доступа [URL]: https://www.garant.ru/products/ipo/prime/doc/12084824
2. Референс-центр по мониторингу за ВИЧ и ВИЧ-ассоциированными инфекциями ФБУН ЦНИИ Эпидемиологии Роспотребнадзора. ВИЧ-инфекция. Информационный бюллетень №49. – Москва, 2024. Referens-centr po monitoringu za VICh i VIChassociirovannymi infekciyami FBUN CNII Epidemiologii Rospotrebnadzora. VICh-infekciya. Informacionnyj byulleten’ №49 [Reference Center for Monitoring HIV and HIV-associated Infections of the Central Research Institute of Epidemiology of Rospotrebnadzor. HIV infection; Newsletter No 47]. Moskva [Moscow]. 2024. (In Russ.). Режим доступа [URL]: http://www.hivrussia.info/wpcontent/uploads/2024/11/hiv-infection-info-bulletin-49.pdf
3. Гуриева З.С., Гипаева Г.А. Анализ результатов и осложнений антиретровирусной терапии. Обзор литературы // Материалы Всероссийской научно-практической конференции «Наука и социум». – 2020. – №XV. – С.72-87. Gurieva ZS, Gipaeva GA. Analiz rezul’tatov i oslozhnenij antiretrovirusnoj terapii: obzor literatury [Analysis of the results and complications of antiretroviral therapy: literature review]. Materialy Vserossijskoj nauchno-prakticheskoj konferencii «Nauka i socium» [Materials of the All-Russian scientifi c and practical conference “Science and Society”]. 2020; XV: 72–87. DOI: 10.38163/978-5-6043859-4-4_2020_72
4. Чухнина Е.А., Игнатьева Т.В., Кашуба Э.А., [и др]. Оценка эффективности и частоты развития побочных эффектов на фоне антиретровирусной терапии // Вятский медицинский вестник. – 2020. – №3 (67). – С.51-57. Chuhnina EA, Ignat’eva TV, Kashuba EA, еt al. Ocenka eff ektivnosti i chastoty razvitiya pobochnyh eff ektov na fone antiretrovirusnoj terapii [Evaluation of the eff ectiveness and frequency of side eff ects on the background of antiretroviral therapy]. Vyatskij medicinskij vestnik [Vyatka Medical Bulletin]. 2020; 3 (67): 51–57. (In Russ.). DOI: 10.24411/2220-7880-2020-10106
5. Otto AO, Rivera CG, Zeuli JD, Temesgen Z. Hepatotoxicity of Contemporary Antiretroviral Drugs: A Review and Evaluation of Published Clinical Data. Cells. 2021; 10 (5): 1263. DOI: 10.3390/cells10051263
6. Качанов Д.А., Атангулов Г.И., Хамаде Х., [и др]. Особенности назначения антиретровирусных препаратов при лечении вич-инфицированных пациентов // Международный научно-исследовательский журнал. – 2021. – №2-3 (104). – С.25–30. Kachanov DA, Atangulov GI, Hamade H, еt al. Osobennosti naznacheniya antiretrovirusnyh preparatov pri lechenii vich-inficirovannyh pacientov [Features of prescribing antiretroviral drugs in the treatment of HIV-infected patients]. Mezhdunarodnyy nauchnoissledovatel’skiy zhurnal [International Scientifi c Research Journal]. 2021; 2-3 (104): 25–30. (In Russ.). DOI: 10.23670/IRJ.2021.103.2.066
7. Tuyama AC, Hong F, Saiman Y, et al. Human immunodeficiency virus (HIV)-1 infects human hepatic stellate cells and promotes collagen I and monocyte chemoattractant protein-1 expression: implications for the pathogenesis of HIV/hepatitis C virus-induced liver fibrosis. Hepatology. 2010; 52 (2): 612-622. DOI: 10.1002/hep.23679
8. Shrestha LB, Yadav GK, Pradhan S, et al. Co-infection of Hepatitis B and Hepatitis C among HIV-infected patients: A cross-sectional study from tertiary care hospital of eastern Nepal. PLoS One. 2022; 17 (3): e0264791. DOI: 10.1371/journal.pone.0264791
9. Ахмеджанова З.И., Урунова Д.М., Каримов Д.А. Проблема побочных эффектов антиретровирусных препаратов при ВИЧ-инфекции // Общество и инновации. – 2020. – №1/S. – С.604–617. Ahmedzhanova ZI, Urunova DM, Karimov DA. Problema pobochnyh eff ektov antiretrovirusnyh preparatov pri VIChinfekcii [The problem of side eff ects of antiretroviral drugs in HIV infection]. Obshchestvo i innovatsii [Society and innovations]. 2020; 1/S: 604–617. (In Russ.). DOI: 10.47689/2181-1415-vol1-iss1/s-pp604-617
10. Singh H, Samani D. MDR1 polymorphisms and modulation of ARV drug induced hepatotoxicity. PREPRINT (Ver si on 1). Research Square. 2021. URL: https://www.researchgate.net/publication/356008763_MDR1_Polymorphisms_and_Modulation_of_ARV_Drug_Induced_Hepatotoxicity DOI: 10.21203/rs.3.rs-1019782/v1
11. Цыбикова Э.Б., Гадирова М. Э. Заболеваемость туберкулёзом и ВИЧ-инфекцией взрослого населения России // Здравоохранение РФ. – 2022. – №3. – С.221–226. Cybikova EB, Gadirova ME. Zabolevaemost’ tuberkulyozomi VICh-infekciej vzroslogo naseleniya Rossii [The incidence of tuberculosis and HIV infection in the adult population of Russia]. Zdravoohranenie RF [Healthcare of the Russian Federation]. 2022; 3: 221–226. (In Russ.) DOI: 10.47470/0044-197X-2022-66-3-221-226
12. Кравченко А.В., Максимов С.Л. Вопросы антиретровирусной терапии и терапии хронического гепатита с у больных с ВИЧ-инфекцией // Инфекционные болезни: Новости. Мнения. Обучение. – 2014. – №1 (6). – С.70–76. Kravchenko AV, Maksimov SL. Voprosy antiretrovirusnoj terapii i terapii hronicheskogo gepatita C u bol’nyh s VIChinfekciej [Issues of antiretroviral therapy and treatment of chronic hepatitis C in patients with HIV infection]. Infekcionnye bolezni: Novosti; Mneniya; Obuchenie [Infectious diseases: News; Opinions; Training]. 2014; 1 (6): 70–76. (In Russ.).
13. Ситдиков И.И., Москалева А.В., Власова Т.И. Гепатотоксические эффекты антиретровирусной терапии – миф или реальность (обзорная статья) // Вестник СМУС74. – 2017. – Т. 2, №4 (19). – С.50–55. Sitdikov II, Moskaleva AV, Vlasova TI. Gepatotoksicheskie effekty antiretrovirusnoj terapii - mif ili real’nost’ (obzornaya stat’ya) [Hepatotoxic eff ects of antiretroviral therapy - myth or reality (review article)]. Vestnik SMUS74 [Herald SMUS74]. 2017; 2(4(19)): 50–5. (In Russ.).
14. Amblard F, Patel D, Michailidis E, Coats SJ, Kasthuri M, Biteau N, Tber Z, Ehteshami M, Schinazi RF. HIV nucleoside reverse transcriptase inhibitors. Eur J Med Chem. 2022; 240: 114554. DOI: 10.1016/j.ejmech.2022.114554
15. Вавилова В.А., Шекунова Е.В., Джайн Е.А., [и др]. Экспериментальное изучение токсических свойств препарата vmu-2012-05 - оригинального ненуклеозидного ингибитора обратной транскриптазы ВИЧ-1 // Фармация и фармакология. – 2021. – №3. – С.205–221. Vavilova VA, Shekunova EV, Dzhajn EA, еt al. Eksperimental’noe izuchenie toksicheskih svojstv preparata vmu-2012-05 - original’nogo nenukleozidnogo ingibitora obratnoj transkriptazy VICh-1 [Experimental study of toxic properties of vmu drug-2012-05 - the original non-nucleoside HIV-1 reverse transcriptase inhibitor]. Farmaciya i farmakologiya [Pharmacy and Pharmacology]. 2021; 3: 205–221. (In Russ.). DOI: 10.19163/2307-9266-2021-9-3-205-221
16. Lungu GN, Diaconescu GI, Dumitrescu F, et al. Liver Damage During Treatment with Reverse-Transcriptase Inhibitors in HIV Patients. Curr Health Sci J. 2024; 50(2):181-197. DOI: 10.12865/CHSJ.50.02.03
17. Abu-Awwad S-A, Abu-Awwad A, Suba M-I, et al. Evaluating Hepatotoxicity: A Comparative Analysis of New Generation versus Historical Antiretroviral Agents. Infectious Disease Reports. 2024; 16(3): 423-434. DOI: 10.3390/idr16030031
UDC: 616.322:579.87]-053.2 DOI: 10.20969/VSKM.2025. 18(4).14-19
Prevalence of tonsillar actinomyces in children
Natalia V. Boiko1, Irina V. Stagnieva1, Elena L. Gukasyan1, Vadim N. Kolesnikov1, Larisa I. Markwo1, Paula A. Stateshnaya1
1 Rostov State Medical University, 29 Nakhichevansky Lane, 344022 Rostov-on-Don, Russia
Abstract. Introduction. Actinomyces occupy the third place in prevalence in the palatine tonsils, sharing it with staphylococci. The role of these microorganisms in tonsillar pathology is poorly understood so far. Aim. To determine the prevalence of tonsillar actinomycosis in pediatric tonsillectomies performed for chronic tonsillitis based on the degree of tonsil hypertrophy. Materials and Methods. Palatine tonsils of 121 children aged 8 to 14 years were examined histologically. The patients were divided into 2 groups: Group 1 included 60 children with grade 2 hypertrophy of the palatine tonsils, and Group 2 included 61 children with grade 3 hypertrophy of the palatine tonsils. Histological analysis of the specimens was performed using direct microscopy and hematoxylin and eosin staining. The results were processed using mathematical statistics methods with the statistical criterion to evaluate contingency tables. Results and Discussion. Actinomycetes were found in 17 of 121 palatine tonsil specimens examined, which amounted to 14% of the total number of patients. In patients with grade 2 hypertrophy of the palatine tonsils, actinomycetes were detected in 11.6% of cases, while in those with grade 3 hypertrophy in 16.4%. The diff erence in the incidence of Actinomycosis between two groups was not statistically signifi cant. Conclusion. Actinomycetes are the part of the tonsillar microbiota, which do not actively interact with lymphoid tissue.
Keywords: actinomyces, palatine tonsils, histological analysis, chronic tonsillitis , tonsillar hypertrophy
For citation: Boiko, N.V.; Stagnieva, I.V.; Gukasyan, E.L.; et al. Prevalence of tonsillar actinomyces in children. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4), 14-19. DOI: 10.20969/VSKM.2025.18(4).14-19.
References
1. Борисова О.Ю., Алешкин В.А., Пименова А.С., [и др.]. Микробный состав микрофлоры у больных с тонзиллярной патологией // Инфекция и иммунитет. – 2015. - Т. 5, № 3. – С.225-232. Borisova OYu, Aleshkin VA, Pimenova AS, et al. Mikrobny`j sostav mikrofl ory` u bol`ny`x s tonzillyarnoj patologiej [Microbial landscape of microfl ora of a pharynx at patients with tonsillit’s pathology]. Infektsiya i immunitet [Russian Journal of Infection and Immunity]. 2015; 5 (3): 225–232. (In Russ.). DOI: 10.15789/2220-7619-2015-3-225-232
2. Бойко Н.В., Ким А.С., Стагниева И.В., [и др.]. Значение показателей антистрептолизина O при определении показаний к тонзиллэктомии у детей // Вестник оториноларингологии. – 2018. – Т. 83, No 4. – С. 73-77. Boiko NV, Kim AS, Stagnieva IV, et al. Znachenie pokazatelej antistreptolizina O pri opredelenii pokazanij k tonzille`ktomii u detej [The signifi cance of antistreptolysin O characteristics for the determination of indications for tonsillectomy in the children]. Vestnik Otorinolaringologii [Bulletin of Otorhinolaryngology]. 2018; 83 (4): 73-77. (In Russ.). DOI: 10.17116/otorino201883473
3. Atkinson TP, Centor RM, Xiao L, et al. Analysis of the tonsillar microbiome in young adults with sore throat reveals a high relative abundance of Fusobacterium Necrophorum with low diversity. PLoS One. 2018; 19 (1): e0189423. DOI: 10.1371/journal.pone.0189423
4. Galli J, Calo L, Ardito F, et al. Biofilm formation by Haemophilus infl uenzae isolated from adeno-tonsil tissue samples, and its role in recurrent adenotonsillitis. Acta Otorhinolaryngol Ital. 2007; 27 (3): 134-138.
5. Jensen A, Fago-Olsen H, Sørensen CH, Kilian M. Molecular mapping to species level of the tonsillar crypt microbiota associated with health and recurrent tonsillitis. PLoS One. 2013; 8 (2): e56418. DOI: 10.1371/journal.pone.0056418
6. Galli J, Calo L, Posteraro B, et al. Pediatric oropharyngeal microbiome: Mapping in chronic tonsillitis and tonsillar hypertrophy. Int J Pediatr Otorhinolaryngol. 2020; 139:110478. DOI: 10.1016/j.ijporl.2020.110478
7. Борисова О.Ю., Гуров А.В., Гадуа Н.Т., [и др.]. Микробиоценоз небных миндалин у практи чес ки здоровых лиц // Вестник оториноларин го логии. – 2018. – Т. 83, No 5. – C.31-35. Borisova OYu, Gurov AV, Gadua NT, et al. Mikrobiocenoz nebny`x mindalin u prakticheski zdorovy`x licz [The microbiocenosis of the palatal tonsils in the practically healthy people]. Vestnik otorhinolaryngology [Bulletin of Otorhinolaryngology]. 2018; 83 (5): 31-35. (In Russ.). DOI: 10.17116/otorino20188305131
8. Бойко Н.В., Бачурина А.С., Оксенюк О.С., Колмакова Т.С. Лечение послеоперационного воспаления после тонзиллэктомии у детей // Педиатрия. Журнал им. Г.Н. Сперанского. – 2016. – Т. 95, No 1. – С. 93-96. Boiko NV, Bachurina AS, Oksenyuk OS, Kolmakova TS. Lechenie posleoperacionnogo vospaleniya posle tonzille`ktomii u detej [Postoperative inflammation treatment after tonsillectomy in children]. Pediatriya; Zhurnal imeni GN Speranskogo [Pediatrics; Journal named after GN Speransky]. 2016; 95 (1): 93-96. (In Russ.).
9. Urbá n E, Gajdacs M. Microbiological and Clinical Aspects of Actinomyces Infections: What Have We Learned? Antibiotics. 2021; 10: 151. DOI: 10.3390/antibiotics10020151
10. Stá jer A, Barrak I, Gajdá cs M, et al. Diagnosis and Management of Cervicofacial Actinomycosis: Lessons from Two Distinct Clinical Cases. Antibiotics. 2020; 9 (4): 139. DOI: 10.3390/antibiotics9040139
11. D’Amore F, Franchini R, Moneghini L, et al. Actinomycosis of the Tongue: A Case Report and Review of Literature. Antibiotics. 2020; 9 (4): 124. DOI: 10.3390/antibiotics9030124
12. Gajdá cs M, Urbá n E. The Pathogenic Role of Actinomyces spp. and Related Organisms in Genitourinary Infections: Discoveries in the New, Modern Diagnostic Era. Antibiotics. 2020, 9 (8): 524. DOI: 10.3390/antibiotics9080524
13. Akbik OS, Cabamilla MG, Picket BP, Ricks CB. Mastoiditis and Tegmen Tympani Defect Leading to Intracranial Abscess with Actinomyces odontolyticus. International journal of surgical case reports. 2020; 2 (4): 2-4. DOI: 10.31487/j.IJSCR.2020.04.02
14. Gazzano E, Chanteret C, Duvillard C, et al. A case of actinomycosis of the middle ear and a rewview of the literature. Int J Pediatr Otorhinolaryngol Extra. 2010; 5 (2): 70-73. DOI: 10.1016/j.pedex.2009.03.001
15. Mechel E, Sheikh A, Rodgers R, et al Actinomyces ductular dacryoadenitis resulting in a lacrimal gland abscess. Orbit. 2021; 41 (1): 105-107. DOI: 10.1080/01676830.2021.1939728
16. Ravishankara S, Madhumitha S Sreedevi NT. Actinomyces causing chronic tonsillitis: a retrospective study. Int J Otorhinolaryngol Head Neck Surg. 2021; 7 (4): 653-656. DOI: 10.18203/issn.2454-5929.ijohns20211188
17. Brodsky L. Modern assessment of tonsils and adenoids. Pediatric Clinics of North America. 1989; 36 (6): 1551-1569. DOI: 10.1016/s0031
18. Vaulor F, Sé né cha, A, Dupieux C, et al. Actinomycosis: Etiology, clinical features, diagnosis, treatment, and management. Infect. Drug Res. 2014; 7: 183–197. DOI: 10.2147/IDR.S39601
19. Gajdacs M, Urban E, Terhes G. Microbiological and clinical aspects of cervicofacial Actinomyces infections: an overview. Dentistry Journal. 2019; 7 (3): 85-97. DOI: 10.3390/dj7030085
20. Riff at F, Walker P. Prevalence of tonsillar Actinomyces in children undergoing tonsillectomy for sleep disordered breathing compared with recurrent tonsillitis. International Journal of Pediatric Otorhinolaryngology. 2009; 73: 1111–1113. DOI: 10.1016/j.ijporl.2009.04.015
21. Kutluhan A, Salviz M, Yalciner O. The role of the actinomyces in obstructive tonsillar hypertrophy and recurrent tonsillitis in pediatric population. Int J Pediatr Otorhinolaryngol. 2011; 75: 391-394. DOI: 10.1016/j.ijporl.2010.12.014
22. Gunizi OC, Gunizi H. Actinomyces in Tonsillectomy Materials. Acta Med Alanya. 2020; 4 (3): 260-263. DOI: 10.30565/medalanya.791230
23. Bhargava D, Bhusnurmath B, Sundaram KR et al. Tonsillar actinomycosis: a clinicopathological study. Acta Trop 2001; 80: 163-168. DOI: 10.1016/S0001-706X(01)00172-3
24. Toh ST, Yuen HW, Goh YH. Actinomycetes colonization of tonsils: a comparative study between patients with and without recurrent tonsillitis. J laryngol Otol. 2007; 121: 775-778. DOI: 10.1017/S0022215106003185
25. Gaff ney R, Harrison M, Walsh M, et al. The incidence and role of actinomyces in recurrent acute tonsillitis. Clin Otolaryngol Allied Sci. 1993; 18 (4): 268-271. DOI: 10.1111/j.1365-2273.1993.tb00845.x
26. Sosroseno W, Bird PS, Gemmell E, Seymour GJ. The role of CD4+ and CD8+ T cells on antibody production by murine Peyer’s patch cells following mucosal presentation of Actinomyces viscosus, Oral Microbiol. Immunol. 2006; 21 (6): 411–414. DOI: 10.1111/j.1399-302X.2006.00308.x
27. Kansu L. Relation of Actinomyces with Tonsillar Hypertrophy and Antibiotic Use. Turk Arch Otorhinolaryngol. 2017; 55: 17-21. DOI: 10.5152/tao.2017.2176
28. Aydin A, Erkilic S, Bayazit YA, et al. Relation between actinomycosis and histopathological and clinical features of the palatine tonsils: a comparative study between adult and pediatric patients. Rev Laryngol Otol Rhinol. 2005; 126 (2): 95-98.
29. van Lierop AC, Prescott CAJ, Sinclair-Smith CC. An investigation of the signifi cance of Actinomycosis in tonsil disease. Int J Pediatr Otorhinolaryngol. 2007; 71: 1883-1888. DOI: 10.1016/j.ijporl.2007.08.021
30. Melgarejo MP, Hellin MD, Marco GA, et al. A correlation between age and Actinomyces in the adenotonsillar tissue in children. B-ENT. 2006; 2: 95-97.
UDC:616.36-002.2; 615.281.8 DOI: 10.20969/VSKM.2025.18(4).20-27
Direct-acting antiviral drugs in the treatment of patients with liver cirrhosis due to chronic hepatitis C
Nelli V. Galeeva1,2, Dina R. Semenova2, Elena N. Petrushkina2, Kamilla O. Barysheva1, Jsylu I. Timergaleeva1, Gilyana M Laktionova1
1 Kazan State Medical University, 49 Butlerov str., 420012 Kazan, Russia
2 Republican Clinical Infectious Diseases Hospital named after Professor A.F. Agafonov, 83 Pobedy Ave., 420140 Kazan, Russia
Abstract. Introduction. Natural course of chronic hepatitis C can be complicated by liver cirrhosis in 20% of cases. Development of liver cirrhosis is accompanied by complications that often lead to a fatal outcome. Modern direct-acting antiviral drugs have a therapeutic effi cacy of above 98%. Achieving aviremia in patients with chronic hepatitis C reduces the risk of developing cirrhosis and its progression. Aim. To analyze the practical experience of using a combined regimen of direct-acting antiviral drugs with pangenotypic activity, i. e., Velpatasvir/Sofosbuvir, in patients with liver cirrhosis due to chronic hepatitis C. Materials and Methods. The study included 122 patients (83 men; 39 women) with liver cirrhosis classifi ed as A in 86.9% and B in 13.1%. The fi rst hepatitis C virus genotype was found in 40.2% of patients, the second in 5.7%, and the third in 54.1%. Hypoalbuminemia <35 g/L was detected in 13.1% of patients, hyperbilirubinemia >34.0 μmol/L was detected in 8.2%, thrombocytopenia <150x10^9/L in 57.4%, and <50x10^9/L in 5.7% of patients. All patients received a combined regimen of antiviral therapy, i. e. a tablet containing 400 mg of sofosbuvir and 100 mg of velpatasvir, orally once a day during 12 weeks. Patients with the third hepatitis C virus genotype were given Ribavirin in addition to their essential therapy. The results obtained were processed using the STATISTICA 10 software program. The results obtained were also expressed as the median and interquartile ranges in the Me format (25%; 75%). Wilcoxon test was used to compare the groups. Results and Discussion. All patients completed the full course of treatment. Biochemical and virological responses were obtained as a result of the treatment. There was a significant decrease in alanine aminotransferase (p=0.00) and bilirubin (p=0.05) relative to the baseline data by the end of antiviral therapy. The number of platelets increased by 8% (p=0.00) by the end of treatment. As the levels of the blood platelets decreased, the coagulation hemostasis in the observed patients changed towards hypocoagulation. Averaged coagulation hemostasis indicators before therapy did not deviate from the normal range and remained at this level throughout the course of treatment. A sustained virological response was obtained in all patients 12 weeks after the completion of the treatment. Conclusions. The use of a fixed combination of Sofosbuvir / Velpatasvir with and without ribavirin in patients with liver cirrhosis due to chronic hepatitis C for 12 weeks proved to be a highly effi cient (sustained virological response 100%), well-tolerated, and safe antiviral therapy regimen. Virological response to antiviral therapy was associated with a positive eff ect on liver function. The number of platelets refl ected the activity of the infectious process in patients with chronic hepatitis C.
Keywords: chronic hepatitis C, antiviral therapy, direct-acting antiviral agents, hemostasis.
For citation: Galeeva, N.V.; Semenova, D.R.; Petrushkina, E.N.; et al. Direct-action antiviral drugs in the treatment of patients with liver cirrhosis due to chronic hepatitis C. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4), 20-27. DOI: 10.20969/VSKM.2025.18(4).20-27.
References
1. Lingala S, Ghany MG. Natural history of hepatitis C. Gastroenterol. Clin. North Am. 2015; 44(4): 717–734. DOI: 10.1016/j. gtc.2015.07.003
2. Jung YK, Yim HJ. Reversal of liver cirrhosis: current evidence and expectations. Korean J. Intern. Med. 2017; 32(2): 21-218. DOI: 10.3904/kjim.2016.268
3. Макашова В.В., Омарова Х.Г., Понежева Ж.Б., [и др.]. Хронический гепатит С и его исходы: цирроз печени, гепатоцеллюлярная карцинома // Эпидемиология и инфекционные болезни. Актуальные вопросы. – 2023. – Т. 13, № 1. – С. 99-104. Makashova VV, Omarova KhG, Ponezheva ZhB, et al. Hronicheskij gepatit S i ego iskhody: cirroz pecheni, gepatocellyulyarnaya karcinoma [Cirrhosis of the liver and hepatocellular carcinoma in the outcome of chronic hepatitis C: a case report]. Epidemiologiya i infekcionnye bolezni. Aktual’nye voprosy [Epidemiology and infectious diseases. Current items]. 2023; 13(1): 99–104. (In Russ). DOI: 10.18565/epidem.2023.13.1.99-104
4. Гарбузенко Д.В. Роль противовирусной терапии в лечении больных циррозом печени, ассоциированным с хронической HBV- и HCV-инфекцией // Вопросы вирусологии. – 2021. – T. 66, №5. – С. 331-339. Garbuzenko DV. Rol’ protivovirusnoj terapii v lechenii bol’nyh cirrozom pecheni, associirovannym s hronicheskoj HBV- i HCV-infekciej [The role of antiviral therapy in the management of patients with liver cirrhosis associated with chronic HBV and HCV infection]. Voprosy virusologii [Problems of Virology]. 2021; 66(5): 331-339. (In Russ.). DOI:10.36233/0507-4088-70
5. Ивашкин В.Т., Чуланов В.П., Мамонова Н.А., [и др.]. Клинические рекомендации Российского общества по изучению печени, Российской гастроэнтерологической ассоциации, Национального научного общества инфекционистов по диагностике и лечению хронического вирусного гепатита С // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2023. – Т. 33, №1. – С. 84-124. Ivashkin VT, Chulanov VP, Mamonova NA, et al. Klinicheskie rekomendacii Rossijskogo obshchestva po izucheniyu pecheni, Rossijskoj gastroenterologicheskoj associacii, Nacional’nogo nauchnogo obshchestva infekcionistov po diagnostike i lecheniyu hronicheskogo virusnogo gepatita S [Clinical Practice Guidelines of the Russian Society for the Study of the Liver, the Russian Gastroenterological Association, the National Scientifi c Society of Infectious Disease Speci alists for the Diagnosis and Treatment of Chronic Hepatitis C]. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii [Russian journal of gastroenterology, hepatology, coloproctology]. 2023; 33(1): 84-124. (In Russ.). DOI: 10.22416/1382-4376-2023-33-1-84-124
6. Miyaki E, Imamura M, Hiraga N, et al. Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fi brosis markers in chronic hepatitis C patients. Hepatol. Res. 2016; 46(8): 758-64. DOI: 10.1111/hepr.12621
7. Rockey DC, Friedman SL. Fibrosis Regression After Eradication of Hepatitis C Virus: From Bench to Bedside. Gastroenterology. 2021; 160(5): 1502-1520. DOI: 10.1053/j.gastro.2020.09.065
8. Черепнин М.А., Цуканов В.В., Савченко А.А., [и др.]. Клинические проявления у пациентов с генотипами 1 и 3 вируса гепатита С в зависимости от выраженности фиброза печени // Доктор. Ру. – 2023. – Т. 22, №2. – С. 32-38. Cherepnin MA, Cukanov VV, Savchenko AA, et al. Klinicheskie proyavleniya u pacientov s genotipami 1 i 3 virusa gepatita S v zavisimosti ot vyrazhennosti fi broza pecheni [Clinical proyavlenia u pacientov s genotipami 1 i 3 virus gepatita S v zavisimosti ot vyrazhennosti fi brosa pecheni]. Doktor. Ru [Doctor. Ru]. 2023; 22(2): 32-38. (In Russ.). DOI: 10.31550/1727–2378-2023-22-2-32-38
9. Галеева Н.В. Роль тромбоцитов как одного из маркеров активности инфекционного процесса у больных хроническим гепатитом С с обострением естественного течения болезни // Практическая медицина. – 2020. – Т. 18, №6. – С.143-149. Galeeva NV. Rol’ trombocitov kak odnogo iz markerov aktivnosti infekcionnogo processa u bol’nyh hronicheskim gepatitom S s obostreniem estestvennogo techeniya bolezni [Role of platelets as one of the markers of the infectious process activity in patients with chronic hepatitis C with an exacerbation]. Prakticheskaya medicina [Practical medicine]. 2020; 18 (6): 143-149. (In Russ.)]. DOI: 10.32000/2072-1757-2020-6-143-149
10. Luo JC, Hwang SJ, Chang FY, et al. Simple blood tests can predict compensated liver cirrhosis in patients with chronic hepatitis C. Hepatologastroenterology. 2002; 49 (44): 478–481.
11. Ровный В.Б., Жарков А.В., Катичева А.В., Мастерова И.Ю. Роль пангенотипных препаратов прямого противовирусного действия в лечен ии хронического вирусного гепатита С // Инфекционные болезни: новости, мнения, обучение. – 2024. – Т. 13, № 3. – С. 83-88. Rovnyj VB, Zharkov AV, Katicheva AV, Masterova IYu. Rol’ pangenotipnyh preparatov pryamogo protivovirusnogo dejstviya v lechenii hronicheskogo virusnogo gepatita S [The role of pan-genotypic direct acting antivirals for the treatment of chronic hepatitis C virus infection]. Infekcionnye bolezni: novosti, mneniya, obuchenie [Infectious diseases: news, opinions, training]. 2024; 13(3): 83-88. (InRuss.). DOI: 10.33029/2305-3496-2024-13-3-83-88
12. Lisman T, Hernandez-Gea V, Magnusson M, et al. The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. J Thromb Haemost. 2021;19(4):1116–1122. DOI: 10.1111/jth.15239.
13. Куркина И.А., Маевская М.В., Ивашкин Т.В. Особенности гемостаза п ри нарушениях функции печени // Поликлиника. – 2015. – № 11. – С. 7-10. Kurkina IA, Maevskaya MV, Ivashkin TV. Osobennost i gemostaza pri narusheniyah funkcii pecheni [Features of hemostasis in patients with impaired liver function]. Poliklinika [Polyclinic]. 2015; 11:7-10. (In Russ.).
14. Бакулин И.Г., Шарабанов А.С., Моляренко Е.В., [и др.]. Тромбоцитопении у больных хроническим гепатитом C // Гастроэнтерология. – 2010. – №5. – С.52-60. Bakulin IG, Sharabanov AS, Molyarenko EV, et al. Trombocitopenii u bol’nyh hronicheskim gepatitom C [Thrombocytopenia in patients with chronic hepatitis C]. Gastroenterologiya [Gastroenterology]. 2010; 5:52-60. (InRuss.).
15. Iga D, Tomimatsu M, Endo H, et al. Improvement of thrombocytopenia with disappearance of HCV RNA in patients treated by interferon-alpha therapy: possible etiology of HCV-associated immune thrombocytopenia. Eur J Haematol. 2005; 75(5): 417-423. DOI: 10.1111/j.1600-0609.2005. 00524.x
16. Валутите Д.Э., Семенов А.В., Останкова Ю.В., [и др.]. Выявление мутаций лекарственной устойчивости вируса гепатита С у пациентов с неэффективной терапией препаратами прямого противовирусного действия // Журнал микробиологии, эпидемиологии и иммунобиологии. – 2021. – Т98, №1. – С. 18-27. Valutite DE, Semenov AV, Ostankova YUV, et al. Vyyavlenie mutacij lekarstvennoj ustojchivosti virusa gepatita S u pacientov s neeff ektivnoj terapiej preparatami pryamogo protivovirusnogo dejstviya [Identifi cation of mutations of drug resistance of hepatitis C virus in patients with ineff ective therapy with direct antiviral drugs]. ZHurnal mikrobiologii, epidemiologii i immunobiologii [Journal of Microbiology, Epidemiology and Immunobiology]. 2021;98(1): 18-27. (InRuss.). DOI: 10.36233/0372-9311-47
17. Practice Guideline. EASL Recommendations on Treatment of Hepatitis C. J Hepatol. 2018; 69(2): 461–511. DOI: 10.1016/j.jhep.2018.03.026
18. Ahumada A, Rayón L, Usón C, et al. Hepatocellular carcinoma risk after viral response in hepatitis C virus-advanced fi brosis: Who to screen and for how long? World J Gastroenterol. 2021; 27(40): 6737–6749. DOI: 10.3748/wjg. v27.i40.6737
19. Abulitifu Y, Lian J, Adilijiang M, et al. Eff ectiveness and safety of sofosbuvir-velpatasvir in patients with cirrhosis associated with genotype 3 hepatitis C infection in Xinjiang, China. Infect. Drug. Resist. 2022; 15: 6463-6470. DOI: 10.2147/IDR.S385071
UDC 614.273:658.71 DOI: 10.20969/VSKM.2025.18(4) .28-36
Predictive modeling of drug procurement for treatment of patients with chronic myeloid leukemia at the level of a constituent entity of the Russian Federation (exemplified by the Tyumen Oblast)
Artem V. Zhuravlev1, Olga I. Knysh1, Irina A. Zarubina1
1Tyumen State Medical University, 54 Odesskaya str., 625023 Tyumen, Russian Federation
Abstract. Introduction. Arranging procurement of drugs to provide pharmacotherapy for cancer patients is a focus area in the development of medicine and pharmacy. Large amounts of money are allocated to purchase drugs for the therapy of this group of patients. To save and rationally use fi nancial resources, it is important to timely and accurately identify the needs and competently schedule the procurement. Aim. To develop prognostic models of drug procurement for the pharmacotherapy of patients with chronic myeloid leukemia in the Tyumen region till 2026. Materials and Methods. The data provided by the Tyumen Oblast Department of Health Care and the Tyumen Oblast Territorial Compulsory Medical Insurance Fund were used, as well as those obtained from Goszakupki, the unifi ed information system in procurement. Scientific forecasting methods were used, namely: Trend extrapolation method and the normative predictive model building technique. Data were processed using computer technologies and mathematical methods. Results and Discussion. Based on the analysis of data on the procurement of medicines and the data provided, predictive models were built using scientifi c prognosis techniques, the changes in indicators were analyzed and the reasons for these changes were identifi ed. Conclusions. Predictive models can be used to forecast procurement, provided that the forecast is made based on the need for a specifi c drug. The normative scientifi c prognosis method is more accurate, taking into account chain growth, as it allows tracing the dynamics of changes in the need, considering the balance of medicines at the end of the reporting period. The trend extrapolation method refl ects only seasonality of changes in indicators.
Keywords: need for drugs, prognostic model, chronic myeloid leukemia, tyrosine kinase inhibitors.
For citation: Zhuravlev, A.V.; Knysh, O.I.; Zarubina, I.A. Predictive modeling of drug procurement for treatment of patients with chronic myeloid leukemia at the level of a constituent entity of the Russian Federation (exemplified by on the example of the Tyumen Oblast). The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4), 28-36. DOI: 10.20969/VSKM.2025.18(4).28-36.
References
1. Каприн А.Д. (ред.). Клинические рекомендации «Хронический миелолейкоз». – Ассоциация онкологов России, Национальное гематологическое общество, 2020. – 78 с. Kaprin AD. Klinicheskie rekomendacii «Hronicheskij mielolejkoz» [Clinical Guidelines “Chronic Myeloleukemia”]. Associaciya onkologov Rossii, Nacional’noe gematologicheskoe obshchestvo [Association of Oncologists of Russia, National Hematology Society]. 2020; 78 p. (In Russ.).
2. Afaf EO, Michael WD. Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions. Blood Reviews. 2021; 49 (100825): 1-14. DOI: 10.1016/j.blre.2021.100825
3. Петрухина И.К., Рязанова Т.К., Гладунова Е.П., [и др.]. Продажи противоопухолевых препаратов в розничном сегменте российского фармацевтического рынка // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. – 2023. – Т. 16, вып. 4. – С.619-629. Petruhina IK, Ryazanova TK, Gladunova EP, et al. Prodazhi protivoopuholevyh preparatov v roznichnom segmente rossijskogo farmacevticheskogo rynka [Sales of antitumor drugs in the retail segment of the Russian pharmaceutical market]. Farmakoekonomika; Sovremennaya farmakoekonomika i farmakoepidemiologiya [Farmakoekonomika; Modern Pharmacoeconomics and Pharmacoepidemiology]. 2023; 16(4): 619-629. (In Russ.). DOI: 10.17749/2070-4909/farmakoekonomika.2023.212
4. Шуваев В.А., Абдулкадыров К.М., Туркина А.Г., [и др]. Фармакоэкономический анализ ремиссии хронического миело лейкоза без лечения // Гематология и трансфузиология. – 2015. – Т. 60, вып. 4. – С.14-20. Shuvaev VA, Abdulkadyrov KM, Turkina AG, et al. Farmakoekonomicheskij analiz remissii hronicheskogo mielolejkoza bez lecheniya [Pharmacoeconomic analysis of untreated remission of chronic myeloleukemia]. Gematologiya i transfuziologiya [Hematology and transfusiology]. 2015; 60(4): 14-20. (In Russ.).
5. Журавлев А.В., Кныш О.И. Ключевые принципы лекарственной терапии у пациентов с хроническим миелоидным лейкозом // Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. – 2023. – Т.16, вып. 2. – С.332-344. Zhuravlev AV, Knysh OI. Klyuchevye principy lekarstvennoj terapii u pacientov s hronicheskim mieloidnym lejkozom [Key principles of drug therapy in patients with chronic myeloid leukemia]. Farmakoekonomika; Sovremennaya farmakoekonomika i farmakoepidemiologiya [Farmakoekonomika; Modern Pharmacoeconomics and Pharmacoepidemiology]. 2023; 16(2):332-344. (In Russ.). DOI: 10.17749/2070-4909/farmakoekonomika.2023.166
6. Журавлев А.В., Кныш О.И. STEP-анализ факторов макросреды, влияющих на медицинскую и лекарственную помощь пациентам с хроническим миелоидным лейкозом. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. – 2024. – Т.17, вып. 1. – С.30-47. Zhuravlev AV, Knysh OI. STEP-analiz faktorov makrosredy, vliyayushchih na medicinskuyu i lekarstvennuyu pomoshch’ pacientam s hronicheskim mieloidnym lejkozom. [STEP analysis of macro-environmental factors aff ecting medical and drug care for patients with chronic myeloid leukemia]. Farmakoekonomika; Sovremennaya farmakoekonomika i farmakoepidemiologiya [Farmakoekonomika; Modern Pharmacoeconomics and Pharmacoepidemiology]. 2024; 17(1):30-47. (In Russ.). DOI: 10.17749/2070-4909/farmakoekonomika.2024.230
7. Romero M, Chávez D, Ríos M, Alvis GN. Cost-effectiveness of nilotinib, dasatinib and imatinib as first-line treatment for chronic myeloid leukemia in Colombia. Biomedica. 2014; 34(1):48-59. DOI: 10.1590/S0120-41572014000100008
8. Scopel CT, Chaves GC. Induction of hospital indebtedness due to medicine purchases under monopoly conditions: the case of imatinib mesylate. Cad Saude Publica. 2015; 31(3):575-85. DOI: 10.1590/0102-311x00080314
9. Taylo r MJ, Scuff ham PA. Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia. Expert Review of Pharmacoeconomics & Outcomes Research. 2009; 9(2):117-21. DOI: 10.1586/er p.09.1
10. Marsh K, Xu P, Orfanos P, et al. Model-based cost-effectiveness analyses for the treatment of chronic myeloid leukaemia: a review and summary of challenges. Pharmacoeconomics. 2014; 32(9):853-64. DOI: 10.1007/s40273-014-0177-3
11. Муратова Л.И., Баков Н.Х., Хоружий В.И., [и др.]. Нормативные системы в прогнозировании развития предпринимательского сектора экономики // Управление экономическими системами: электронный научный журнал. – 2009. – Т.20, вып. 4. – С. 1-12. Muratova LI, Bakov NH, Horuzhij VI, et al. Normativnye sistemy v prognozirovanii razvitiya predprinimatel’skogo sektora ekonomiki [Normative systems in forecasting the development of the entrepreneurial sector of the economy]. Upravlenie ekonomicheskimi sistemami: elektronnyj nauchnyj zhurnal [Management of economic systems: electronic scientifi c journal]. 2009; 20(4):1-12. (In Russ.).
12. Arrieta O, Catalán R, Guzmán-Vazquez S, et al. Cost-effectiveness analysis of fi rst and second-generation EGFR tyrosine kinase inhibitors as fi rst line of treatment for patients with NSCLC harboring EGFR mutations. BMC Cancer. 2020; 20(1):829. DOI: 10.1186/s12885-020-07329-8
13. Андриевская Н. К., Мартыненко Т. В., Васяева Т. А. Применение статистических методов, кластерного анализа и нейро-сетевых технологий при прогнозировании закупочных цен лекарств // Проблемы искусственного интеллекта. – 2023. – Т.31, вып. 4. – С. 41-55. Andrievskaya NK, Martynenko TV, Vasyaeva TA. Primenenie statisticheskih metodov, klasternogo analiza i nejro-setevyh tekhnologij pri prognozirovanii zakupochnyh cen lekarstv [Application of statistical methods, cluster analysis and neural network technologies in forecasting procurement prices of medicines]. Problemy iskusstvennogo intellekta [Problems of artificial intelligence]. 2023; 31(4):41-55. (In Russ.).
14. Мустяцэ В. Г. Современные медицинские технологии при хроническом миелолейкозе // Гематология и трансфузиология. – 2014. – Т.59, вып. 1. – С. 106. Mustyace VG. Sovremennye medicinskie tekhnologii pri hronicheskom mielolejkoze [Modern medical technologies in chronic myeloleukemia]. Gematologiya i transfuziologiya [Hematology and transfusiology]. 2014; 59(4):106. (In Russ.).
15. Дремова Н. Б., Кобзарь Л. В., Коржавых Э. А. Методология отечественных исследований потребности в лекарственных средствах и их потребления // Фармация и фармакология. – 2015. – №3. – С. 4-9. Dremova NB, Kobzar’ LV, Korzhavyh EA. Metodologiya otechestvennyh issledovanij potrebnosti v lekarstvennyh sredstvah i ih potrebleniya [Methodology of domestic studies on the need for and consumption of medicines]. Farmaciya i farmakologiya [Pharmacy and Pharmacology]. 2015; (3):4-9. (In Russ.).
UDC: 616.36–003.826–073.43 DOI: 10.20969/VSKM.2025.18(4).37-44
Hepatic steatosis: Methods of noninvasive diagnostics exemplified by clinical cases
Elena A. Kradinova1, Vladimir A. Chernorotov1, Vladimir A. Kubyshkin1, Viktor S. Kostenich1, Karina B. Dovgopolaya1
1V.I. Vernadsky Crimean Federal University, Order of the Red Banner of Labor S.I. Georgievsky Medical Institute, Lenin Boulevard, 5/7, Simferopol, 295051 Russia
Abstract. Introduction. Currently, liver steatosis detected by visual diagnostic methods or histologically, in combination with one or more cardiometabolic risk factors, is considered a serious condition in terms of prognosis. The clinical need for the use of non-invasive methods is determined by fact that timely diagnosis of liver steatosis may tend towards a favorable outcome. Aim. To evaluate various non-invasive diagnostic methods for liver steatosis and to identify the most informative and readily available quantitative assessments for clinical practice. Materials and Methods. For the purposes of this study, patients were selected, diagnosed with diff use changes in the liver parenchyma using ultrasound, magnetic resonance imaging, and computed tomography, or those suspicious for such changes. In a prospective study, patients were evaluated based on their gender, age, anthropometric parameters, degree of liver steatosis, comorbid pathology, and fi ndings obtained by laboratory and instrumental examination methods. SPSS 23 software package was used for statistical analysis. The median, as well as the fi rst and third quartiles (Me [Q1; Q3]), were used as a measure of central tendency in the population. Mann-Whitney test, χ2 were used to assess diff erences between two independent samples. The sensitivity and specifi city of the research methods used and the area under the ROC curve were computed. Results and Discussion. As a result of examining 60 patients with the diagnosed liver steatosis, it was found that most of them had cardiometabolic risk factors and changes in biochemical liver indicators. According to B-mode ultrasound, the frequency of hepato- and splenomegaly increased in patients with S2 (33.3% and 25.1%, respectively, χ2) and S3 (50.0% and 41.7%, respectively, χ2), compared with no steatosis. Analysis of magnetic resonance imaging and computed tomography of the liver revealed both diff use and focal forms of steatosis. Fat fraction test using magnetic resonance imaging showed that in 19 people (48.7%), the number of fat cells exceeded 6.5%. Among the reviewed archival data, S1 degree of steatosis was determined in 5 people (12.8%), S2 in 6 people (15.4%), and S3 in 8 people (20.5%). In ultrasound steatometry, the degree S2 steatosis was detected in 12 people (26.8%), while S3 was found in 24 people (52.2%). Conclusions. A comprehensive innovative study confi rmed the usability of quantitative ultrasound steatometry. The result showed a good sound attenuation coeffi cient (TAI) (AUROC 0.722) for detecting steatosis S1 compared to the absence of steatosis.
Keyword s: liver steatosis, magnetic resonance imaging, ultrasound steatometry, MRI steatometry, computed tomography.
For citation: Kradinova, E.A.; Chernorotov, V.A.; Kubyshkin, V.A.; et al. Hepatic steatosis: Methods of noninvasive diagnostics exemplifi ed by clinical cases. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4), 37-44. DOI: 10.20969/VSKM.2025.18(4).37-44.
References
1. Ma X, Holalkere NS, Kambadakone RA, et al. Imaging-based Quantifi cation of Hepatic Fat: Methods and Clinical Applications. RadioGraphics. 2009; 29(5): 1253–1277. DOI: 10.1148/rg.295085186
2. Лазебник Л.Б., Голованова Е.В., Туркина С.В., [и др.]. Неалкогольная жировая болезнь печени у взрослых: клиника, диагностика, лечение. Рекомендации для терапевтов, третья версия // Экспериментальная и клиническая гастроэнтерология. – 2021. - 1(1). – С.4–52. Lazebnik LB, Golovanova EV, Turkina SV, et al. Nealkogol’naya zhirovaya bolezn’ pecheni u vzroslyh: klinika, diagnostika; Recommendations for therapists, the third version lechenie [Non-alcoholic fatty liver disease in adults: Clinic, diagnostics, treatment; Guidelines for therapists, third version]. Eksperimental’naya i klinicheskaya gastroenterologiya [Experimental and Clinical Gastroenterology]. 2021; 1(1): 4–52. (In Russ.). DOI: 10.31146/1682-8658-ecg-185-1-4-52
3. Ивашкин В.Т., Жаркова М.С., Корочанская Н.В., [и др.]. Фенотипы неалкогольной жировой болезни печени в различных регионах Российской Федерации, диагностические и лечебные подходы в клинической практике // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. – 2023. - 33(2). – С.7–18. Ivashkin VT, Zharkova MS, Korochanskaya NV, et al. Fenotipy nealkogol’noj zhirovoj bolezni pecheni v razlichnyh regionah Rossijskoj Federacii, diagnosticheskie i lechebnye podhody v klinicheskoj praktike [Phenotypes of non-alcoholic fatty liver disease in diff erent regions of the Russian Federation, diagnostic and therapeutic approach in clinical practice]. Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii [Russian Journal of Gastroenterology, Hepatology, Coloproctology]. 2023; 33(2): 7–18. (In Russ.). DOI: 10.22416/1382-4376-2023-33-2-7-18
4. Райхельсон К.Л., Маевская М.В., Жаркова М.С., [и др.]. Жировая болезнь печени: новая номенклатура и ее адаптация в Российской Федерации // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. - 2024. – T.34, вып. 2. – С.35-44. [Raikhelson KL, Mayevskaya MV, Zharkova MS, et al. Zhirovaya bolezn’ pecheni: novaya nomenklatura i ee adaptaciya v Rossijskoj Federacii [Fatty liver disease: a new nomenclature and its adaptation in the Russian Federation] Rossijskij zhurnal gastroenterologii, gepatologii, koloproktologii [Russian Journal of Gastroenterology, Hepatology, and Coloproctology]. 2024; 34(2): 35-44. (In Russ.). DOI: 10.22416/1382-4376-2024-961
5. Stern C, Castera L. Non-invasive diagnosis of hepatic steatosis. Hepatol Int. 2017; 11: 70–78. DOI: 10.1007/s12072-016-9772-z
6. Терновой С.К., Ширяев Г.А., Устюжанин Д.В., Абдурахманов Д.Т. Определение содержания жира в печени у пациентов с жировым гепатозом и стеатогепатитом методом протонной МР-спектроскопии // Медицинская визуализация. – 2018. - №4. – С.50-58. Ternovoy SK, Shiryaev GA, Ustyuzhanin DV, Abdurakhmanov DT. Opredelenie soderzhaniya zhira v pecheni u pacientov s zhirovym gepatozom i steatogepatitom metodom protonnoj MR-spektroskopii [Determination of liver fat content in patients with fatty hepatosis and steatohepatitis by proton MR spectroscopy]. Medicinskaya vizualizaciya [Medical imaging]. 2018; (4): 50-58. (In Russ.). DOI: 10.24835/1607-0763-2018-4-50-58
7. Крадинова Е.А., Черноротов В.А., Крадинов А.И., [и др.]. Мультимодальная диагностика у пациентов с компонентами МС, перенесших интерстициальную пневмонию, ассоциированную с COVID-19 // Вестник Современной клинической медицины. – 2023. – Т.16, вып. 1. - С.40-46. Kradinova EA, Chernorotov VA, Kradinov AI, et al. Mul’timodal’naya diagnostika u pacientov s komponentami MS, perenesshih intersticial’nuyu pnevmoniyu, associirovannuyu s COVID-19 [Multimodal diagnosis in patients with MS components who have had interstitial pneumonia associated with COVID-19]. Vestnik sovremennoy klinicheskoy meditsiny [The Bulletin of Contemporary Clinical Medicine]. 2023; 16 (1): 40-46. (In Russ.). DOI: 10.20969/VSKM.2023.16(1).40-46
8. de Moura Almeida A, Cotrim HP, Barbosa DB, et al. Fatty liver disease in severe obese patients: diagnostic value of abdominal ultrasound. World J Gastroenterol. 2008; 14(9): 1415-8. DOI: 10.3748/wjg.14.1415
9. van Werven JR, Marsman HA, Nederveen AJ, et al. Assessment of hepatic steatosis in patients undergoing liver resection: comparison of US, CT, T1-weighted dual-echo MR imaging, and point-resolved 1H MR spectroscopy. Radiology. 2010; 256(1): 159-68. DOI: 10.1148/radiol.10091790
10. Van Vucht N, Santiago R, Lottmann B, et al. The Dixon technique for MRI of the bone marrow. Skeletal Radiol. 2019; 48 (12): 1861–1874. DOI: 10.1007/s00256-019-03271-4
11. Mendler MH, Bouillet P, Le Sidaner A, et al. Dual-energy CT in the diagnosis and quantifi cation of fatty liver: limited clinical value in comparison to ultrasound scan and single-energy CT, with special reference to iron overload. J Hepatol. 1998; 28 (5): 785–794. DOI: 10.1016/s0168-8278(98)80228-6
12. Dixon WT. Simple proton spectroscopic imaging. Radiology. 1984; 153(1): 189-94. DOI: 10.1148/radiology.153.1.6089263
13. Панина О.Ю., Громов А.И., Ахмад Е.С., [и др.]. Определение точности оценки фракции жира с использованием Dixon: экспериментальное фантомное исследование // Медицинская визуализация. – 2022. – Т.26, Вып. 4. – С.147-158. Panina OYu, Gromov AI, Akhmad ES, et al. Opredelenie tochnosti ocenki frakcii zhira s ispol’zovaniem Dixon: eksperimental’noe fantomnoe issledovanie [Determining the accuracy of fat fraction estimation using Dixon: an experimental phantom study]. Medicinskaya vizualizaciya [Medical imaging]. 2022; 26(4): 147-158. (In Russ.). DOI: 10.24835/1607-0763-1160
14. Венидиктова Д.Ю., Борсуков А.В., Алипенкова А.В., [и др.]. Методика ультразвуковой стеатометрии при неалкогольной жировой болезни печени: пилотные результаты // Клиническая практика. – 2019. – Т.10, вып. 1. – С.23-29. Venediktova DYu, Borsukov AV, Alipenkova AV, et al. Metodika ul’trazvukovoj steatometrii pri nealkogol’noj zhirovoj bolezni pecheni: pilotnye rezul’taty [Ultrasound osteometry technique for non-alcoholic fatty liver disease: pilot results]. Klinicheskaya praktika [Clinical practice]. 2019; 10(1): 23-29. (In Russ.). DOI: 10.17816/clinpract10123–29
15. Pickhardt PJ, Park SH, Hahn L, et al. Specificity of unenhanced CT for non-invasive diagnosis of hepatic steatosis: implications for the investigation of the natural history of incidental steatosis. Eur Radiol. 2012; 22(5): 1075–82.DOI: 10.1007/s00330-011-2349-2
16. Гончар А.П., Гомболевский В.А., Елизаров А.Б., [и др.]. Возможности оценки плотности печени по данным бесконтрастной компьютерной томографии // Вестник рентгенологии и радиологии. – 2020. – Т.101, вып. 1. – С.58-66. Gonchar AP, Gombolevsky VA, Elizarov AB, et al. Vozmozhnosti ocenki plotnosti pecheni po dannym beskontrastnoj komp’yuternoj tomografi i [The possibilities of assessing liver density according to contrast-free computed tomography]. Vestnik rentgenologii i radiologii [Bulletin of Radiology and Radiology]. 2020; 101 (1): 58-66. (In Russ.). DOI: 10.20862/0042-4676-2020-101-1-58-66
17. Бакулин И. Г., Сандлер Ю. Г., Кейян В. А., [и др.]. Оценка стеатоза печени с помощью неинвазивного метода: миф или реальность? // Доктор.Ру. Гастроэнтерология. – 2015. – № 12 (113). – С.57–64. Bakulin IG, Sandler Yu. G, Kejyan VA, et al. Ocenka steatoza pecheni s pomoshch’yu neinvazivnogo metoda: mif ili real’nost’? [Assessment of liver steatosis using a noninvasive method: myth or reality?]. Doktor Ru: Gastroenterologiya. [Doktor Ru: Gastroenterology]. 2015; 12 (113): 57-64. (In Russ.).
UDC: 543.24/582.893.6 DOI: 10.20969/VSKM.2025.18(4).45-52
Biologically active compounds contained in the herbal substances based on lovage growing in the Arkhangelsk Region
Elena D. Kubasova1, Anton E. Sukhanov1, Roman V. Kubasov1, Olga V. Dolgikh1, Andrey V. Safronenko2, Nikolay V. Kochubeynik2, Dmitry V. Safonov3, Andrey Yu. Yeroshenko2, Anastasia D. Lukonina2, Anastasia V. Golovinova2, Sofia V. Stepanova2, Sergey N. Linchenko4, Natalia V. Sukhorukova2, Sergey M. Groshilin2
1Northern State Medical University, 51 Troitskiy Ave., 163000 Arkhangelsk, Russia
2Rostov State Medical University, 29 Nakhichevansky Lane, 344022 Rostov-on-Don, Russia
3Taganrog Municipal Clinical Emergency Hospital, 16 Bolshoy Ave., 347930 Taganrog, Rostov Region, Russia
4Kuban State Medical University, 4 Sedin str., 350063 Krasnodar, Russia
Abstract. Introduction. Centuries of studying the chemical compositions of plants, especially those classified as medicinal ones, have revealed the presence of biologically active compounds that can be identifi ed in various ways. There is a wide range of pharmacognostic interest globally regarding lovage (Levisticum officinale). This interest is based on to the knowledge accumulated about the therapeutic properties of this plant. Thanks to the presence of biologically active substances, it demonstrated anti-tumor, neuroprotective, antithrombotic, anti-infl ammatory, and other beneficial effects on the body. Lovage is found to contain the highest amounts of terpenoids, fl avonoids, tannins, phenolic acids, polyacetylenes, and steroids. In the pharmaceutical production of some countries, lovage is included in the composition of drug substances. In the context of the active development of the domestic pharmaceutical industry, the study of the phytochemical composition of lovage could be quite promising in terms of its inclusion in the cohort of pharmacopeial plants and of using various parts thereof in medical practice. The aim of the study is to determine the biologically active compounds in lovage grown in the Arkhangelsk Region to potentially approbate this plant as a medicinal agent. Materials and Methods. Using various methods of chemical analysis, the presence of biologically active compounds was determined in the herbal substances (roots) of lovage grown in the Arkhangelsk Region. Results and Discussion. The vast majority of chemical experiments performed was positive; biologically active compounds were identifi ed in suffi cient quantities. The presence of fl avonoids was confi rmed by Shinoda reactions: With 2% lead acetate solution, with iron (III) chloride, with 5% ammonia solution, with boron-citric and boron-oxalic solutions, and with aluminum chloride. The presence of coumarins was proven using the lactone test and the reaction with diazo reagent in an alkaline medium. Tannins were proven using reactions with 1% gelatin solution, with 1% ferric ammonium alum solution, and with sodium nitrite in an acidic medium. The presence of saponins in the raw material studied was proven by foaming reactions (with the solutions of sodium hydroxide and hydrochloric acid), as well as using tests with the addition of lead acetate and with the addition of a mixture of acetic anhydride with concentrated sulfuric acid (Liebermann-Burchard test). Conclusions. The results of this study are an important part of the pharmacognostic study of lovage growing in the region under investigation. Further exploration of the phytochemical composition and pharmacological action suggests presenting lovage to the group of medicinal herbs and creates the prerequisites for developing and producing phytopreparations based on its extracts.
Keywords: Levisticum offi cinale, fl avonoids, coumarins, tannins, saponins.
For citation: Kubasova, E.D.; Sukhanov, A.E.; Kubasov, R.V.; et al. Biologically active compounds contained in the herbal substances based on lovage growing in the Arkhangelsk Region. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4), 45-52. DOI: 10.20969/VSKM.2025.18(4).45-52.
References
1. Самбукова Т.В., Овчинников Б.В., Ганапольский В.П., [и др.]. Перспективы использования фитопрепаратов в современной фармакологии // Обзоры по клинической фармакологии и лекарственной терапии. – 2017. – Т. 15, № 2. – С.56-63. Sambukova TV, Ovchinnikov BV, Ganapol’skij VP, et al. Perspektivy ispol’zovaniya fi topreparatov v sovremennoj farmakologii [Prospects for phytopreparations (botanicals) use in modern pharmacolog y]. Obzory po klinicheskoj farmakologii i lekarstvennoj terapii [Reviews on Clinical Pharmacology and Drug Therapy]. 2017; 15(2): 56-63. (In Russ.). DOI: 10.17816/RCF15256-63
2. Gijbels MJ, Scheff er JJ, Baerheim SA. Phthalides in the essential oil from roots of Levisticum offi cinale. Planta Med. 1982; 44(4): 207-211. DOI: 10.1055/s-2007-971448
3. Roslon W, Osińska E, Wajs-Bonikowska A. Effect of plantation establishment and raw material stabilization on the usefull traits of Lovage leaves (Levisticum offi cinale Koch). Acta Scientiarum Polonorum-hortorum Cultus. 2013; 12(1): 141-155.
4. Santos P, Figueiredo A, Oliveira M, et al. Growth and essential oil composition of hairy root cultures of Levisticum officinale W.D.J. Koch (Lovage). Plant Science. 2005; 168: 1089-1096. DOI: 10.1016/J.PLANTSCI.2004.12.009
5. Sprea RM, Fernandes Â, Calhelha RC, et al. Chemical and bioactive characterization of the aromatic plant Levisticum officinale W.D.J. Koch: a comprehensive study. Food & function. 2020; 11(2): 1292-1303. DOI: 10.1039/c9fo02841b
6. Пастушенков Л.В., Пастушенков А.Л., Пастушенков В.Л. Лекарственные растения. Использование в народной медицине и в быту // СПб.: БХВ -Петербург, 2012. – 432 с. Pastushenkov LV, Pastushenkov AL, Pastushenkov VL. Lekarstvennye rasteniya. Ispol’zovanie v narodnoj medicine i v bytu [Medicinal plants. Use in Traditional medicine and in life]. SPb.: BHV -Peterburg [SPb.: BHV-Peterburg]. 2012; 432 р. (In Russ.).
7. Assessment report on Levisticum offi cinale Koch, radix. 27 March 2012. EMA/HMPC/524623/2011 Committee on Herbal Medicinal Products (HMPC). URL: https://www.ema.europa.eu/en/documents/herbal-report/draft-assessment-report-levisticum-offi cinale-koch-radix_en.pdf
8. Amraie E, Pouraboli I, Rajaei Z. Neuroprotective effects of Levisticum offi cinale on LPS-induced spatial learning and memory impairments through neurotrophic, antiinfl ammatory, and antioxidant properties. Food Funct. 2020; 11(7): 6608-6621. DOI: 10.1039/d0fo01030h
9. Benameur T, Soleti R, Porro C. The Potential neuroprotective role of free and encapsulated quercetin mediated by Mirna against neurological diseases. Nutrients. 2021; 13(4): 1318. DOI: 10.3390/nu13041318
10. Rahbardar MG, Amin B, Mehri S, et al. Rosmarinic acid attenuates development and existing pain in a rat model of neuropathic pain: evidence of anti-oxidative and antiinfl ammatory eff ects. Phytomedicine. 2018; 40: 59-67. DOI: 10.1016/j.phymed.2018.01.001
11. Martynyuk L, Martynyuk L, Ruzhitska O, Martynyuk O. Effect of the herbal combination Canephron N on diabetic nephropathy in patients with diabetes mellitus: results of a comparative cohort study. Journal of alternative and complementary medicine. 2014; 20(6): 472-478. DOI: 10.1089/acm.2013.0400
12. Nausch B, Pace S, Pein H, et al. The standardized herbal combination BNO 2103 contained in Canephron (R) N alleviates infl ammatory pain in experimental cystitis and prostatitis . Phytomedicine. 2019; 60: 152987. DOI: 10.1016/j.phymed.2019.152987
13. Yarnell E. Bota nical medicines for the urinary tract. World J Urol. 2002; 20(5): 285-293. DOI: 10. 1007/s00345-002-0293-0
14. Donkor PO, Chen Y, Ding L, Qiu F. Locally and traditionally used Ligusticum species - A review of their phytochemistry, pharmacology and pharmacokinetics. J Ethnopharmacol. 2016; 24(194): 530-548. DOI: 10.1016/j.jep.20 16.10.012
15. Novak I, NemethE. Eff ect of harvesting time and plant age on some quality parameters of lovage (Levisticum offi cinale Koch).Acta Horticulturae. 2001; 576: 311-314. DOI: 10.17660/ActaHortic.2002.576.46
16. Ваулина К .И., Нестерова О.В. Исторический опыт и перспективы использования любистока лекарственного в медицине // Журнал научных статей Здоровье и образование в XXI веке. – 2019. – Т. 21, № 3. – С. 49-51. Vaulina KI, Nesterova OV Istoricheskij opyt i perspektivy ispol’zovaniya lyubistoka lekarstvennogo v medicine [Historical information and prospects of use Levisticum Offi cinale Koch. in medicine]. Zhurnal nauchnyh statej Zdorov’e i obrazovanie v XXI veke [The Journal of scientific articles Health and Education Millennium]. 2019; 21(3): 49-51. (In Russ.). DOI: 10.26787/nydha-2226-7425-2019-21-3-49-51
17. Глумова Н.В., Грунина Е.Н., Рублевкая И.С. [и др.]. О качестве и перспективах производства эфирного масла из семян любистка (Levisticum offi cinalis Koch.) // Научные труды южного филиала национального университета биоресурсов и природопользования Украины «Крымский агротехнологический университет». Серия: технические науки. – 2013. – № 156. – С. 128-133. Glumova NV, Grunina HN, Rublevskaya IS, et al. O kachestve i perspektiva h proizvodstva efi rnogo masla iz semyan lyubistka (Levisticum officinalis Koch) [About the quality and perspectives of processing lovage seeds (Levisticum offi cinalis Koch)]. Nauchnye trudy yuzhnogo filiala nacional’nogo universiteta bioresursov i prirodopol’zovaniya Ukrainy “Krymskij agrotekhnologicheskij universitet”; Seriya: tekhnicheskie nauki [Proceedings of the Southern Branch of the National University of Life and Environmental Sciences of Ukraine «Crimean Agro technological University»; Series: Technical sciences]. 2013; 156: 128-133. (In Russ.).
18. Правила сбора и сушки лекарственных растений: сборник инструкций / отв. ред. А. И. Шретер и др. – М.: Медицина, 1985. – 328 с.
Ed by Shreter AI, et al. Pravila sbora i sushki lekarstvennyh rastenij: sbornik instrukcij [Rules for Picking and drying medicinal plants: a collection of instructions]. Moskva: Medicina [Moscow: Medicine]. 1985; 328 p. (In Russ.).
19. Государственная фармакопея РФ XV изд. [Электронное издание]. 2023. Gosudarstvennaya farmakopeya Rossiysko y Federatsii [State Pharmacopoeia of the Russian Federation]. 2023; XV. [Electronic resource] (In Russ.). Режим доступа [URL]: http://femb.ru/feml
20. Калинкина Г.И., Сальникова Е.Н., Исайкина Н.В., Коломиец Н.Э. Методы фармакогностического анализа лекарственного растительного. – Томск: СибГМУ, 2008. – 55 с. Kalinkina GI, Sal’nikova EN, Isajkina NV, Kolomiec NE. Metod y farmakognosticheskogo analiza lekarstvennogo rastitel’nogo [Methods of pharmacognostic analysis of medicinal plant]. Tomsk: SibGMU [Tomsk: Siberian State Medical University]. 2008; 55 p. (In Russ.).
21. Корулькин Д.Ю., Абилов Ж.А., Музычкина Р.А., Толстиков Г.А. Природные флавоноиды. РАН, Сиб. отд., Новосиб. институт органической химии. – Новосибирск: Академическое издательство «Тео». – 2007. – 232 с. Korul’kin DYu, Abilov ZhA, Muzychkina RA, Tolstikov GA. Prirodnye fl avonoidy [Natural fl avonoids]. Novosibirsk: Akademicheskoye izdatel’stvo «Teo» [Novosibirsk: Academic Publishing House «Teo»]. 2007: 232 p. (In Russ.).
UDC: 616.127-005.4-073.756.8 DOI: 10.20969/VSKM.2025.18(4) .53-61
Final results of studying COVID-19 convalescent plasma in the treatment of the novel coronavirus infection involving lung damage
Anastasya S. Perkina1,3, Vladimir P. Baklaushev2,1, Alexander V. Chernyak1, Gauhar M. Yusubalieva3,2, Nadezhda A. Kolyshkina3, Kirill A. Zykov1,4
1 Research Institute of Pulmonology, Federal Medical and Biological Agency of Russia, 28 Orekhovy Blvd., 115682 Moscow, Russia
2 Federal Center of Brain and Neurotechnology, Federal Medical and Biological Agency of Russia, 1 Ostrovityanova str., 117513 Moscow, Russia
3 Federal Scientific and Clinical Center of Specialized Types of Medical Care and Medical Technologies, Federal Medical and Biological Agency of Russia, 28 Orekhovy Blvd., 115682 Moscow, Russia
4 Russian University of Medicine, 4 Dolgorukovskaya str., 127006 Moscow, Russia.
Abstract. Introduction. During the novel coronavirus infection COVID-19 pandemic, scientists were forced to resort to searching for an optimal therapy. Hyperimmune plasma occupied a separate niche, having established itself as an effective and safe method in the treatment of previous infections. Aim. To study the eff ectiveness and safety of pathogen-reduced hyperimmune plasma for the treatment of coronavirus infection COVID-19. Materials and Methods. The study included 106 patients divided into two groups based on the disease severity. Group I: 40 patients in the extremely severe condition (of which 20 people received hyperimmune plasma therapy, and 20 did not receive hyperimmune plasma). Group II: 66 patients randomized at the 2:1 ratio. Of them, 46 people were treated with hyperimmune plasma, and 20 were treated with fresh frozen non-immune plasma. All patients also received therapy in accordance with the then-current Methodological Recommendations of the Ministry of Health of the Russian Federation for the diagnosis, prevention and treatment of coronavirus infection COVID-19. Results and Discussion. The use of hyperimmune plasma in patients with moderate to severe COVID-19 statistically signifi cantly reduced fever and interleukin-6 levels on day 3, as well as C-reactive protein levels on day 7 after the start of therapy, which cannot be said for patients on mechanical ventilation. Hyperimmune plasma did not statistically signifi cantly aff ect the reduction of mortality or the duration of mechanical ventilation, oxygen therapy, and hospitalization. 17 adverse events were recorded, including a severe one that had caused death (TRALI). Conclusions. In our population of patients, the use of hyperimmune plasma did not statistically signifi cantly aff ect mortality, duration of need for oxygen, or hospitalization, as well as the reduction of the infl ammatory response in patients in extremely severe condition. In p atients with moderate to severe disease, a statistically signifi cant decrease was detected in fever and interleukin-6 levels on the third day and C-reactive protein levels on the seventh day after the start of therapy.
Keywords: COVID-19, hyperimmune plasma, effi cacy, safety.
For citation: Perkina, A.S.; Baklaushev, V.P.; Chernyak, A.V.; et al. Final results of studying COVID-19 convalescent plasma in the treatment of the novel coronavirus infection. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4), 53-61. DOI: 10.20969/VSKM.2025.18(4).53-61.
References
1. Баклаушев В.П., Аверьянов А.В., Сотникова А.Г., [и др.]. Предварительные итоги исследования безопасности и эффективности плазмы реконвалесцентов в терапии COVID-19 // Клиническая практика. - 2020. – Т. 11 - № 2. – C.38–50. Baklaushev VP, Averyanov AV, Sotnikiva AG, et al. Predvaritelnyye itogi issledovaniya bezopasnosti i eff ektivnosti plazmy rekonvalestsentov v terapii COVID-19 [Safety and Efficacy of Convalescent Plasma for COVID-19: The First Results of A Clinical Study]. Klinicheskaya praktika [Journal of Clinical Practice]. 2020;11(2): 38-50. (In Russ.). DOI: 10.17816/clinpract35168
2. Luke TC, Kilbane EM, Jackson, JL, et al. Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? Ann Intern Med. 2006; 145(8):599–609. DOI: 10.7326/0003-4819-145-8-200610170-00139
3. Hung IF, To KK, Lee CK, et al. Convalescent plasma treatment reduced mortality in patients with severe pandemic infl uenza A (H1N1) 2009 virus infection. Clin Infect Dis. 2011; 52(4): 447-456. DOI: 10.1093/cid/ciq106
4. Cheng Y, R Wong, Y O Y Soo, et al. Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis. 2005; 24(1): 44–46. DOI: 10.1007/s10096-004-1271-9
5. Ko JH, Seok H, Cho SY, et al. Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience. Antivir Ther. 2018; 23(7): 617-622. DOI: 10.3851/IMP3243
6. Zhang B, Liu S, Tan T, et al. Treatment with convalescent plasma for critically ill patients with SARS-CoV-2 infection. Chest. 2020; 158(1): e9-e13. DOI: 10.1016/j.chest.2020.03.039
7. Duan K, Liu B, Li C, et al. Eff ectiveness of convalescent plasma therapy in severe COVID-19 patients. Proceedings of the National Academy of Sciences of the United States of America; 117(17): 9490–9496. DOI: 10.1073/pnas.2004168117
8. Estcourt LJ, Turgeon AF, McQuilten ZK, et al. Writing Committee for the REMAP-CAP Investigators. Effect of Convalescent Plasma on Organ Support-Free Days in Critically Ill Patients With COVID-19: A Randomized Clinical Trial. JAMA. 2021 Nov 2; 326(17): 1690-1702. DOI: 10.1001/jama.2021.18178
9. RECOVERY Collaborative Group. Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial. Lancet. 2021 May 29; 397(10289):2049-2059. DOI: 10.1016/S0140-6736(21)00897-7
10. Ling RR, Sim JJL, Tan FL, et al. Convalescent Plasma for Patients Hospitalized With Coronavirus Disease 2019: A Meta-Analysis With Trial Seque ntial Analysis of Randomized Controlled Trials. Transfus Med Rev. 2022 Jan; 36(1):16-26. DOI: 10.1016/j.tmrv.2021.09.001
11. Libster R, Pérez Marc G, Wappner D, et al. Fundación INFANT–COVID-19 Group. Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults. The New England journal of medicine. 2021; 384(7): 610–618. DOI: 10.1056/NEJMoa2033700
12. Salazar E, Christensen PA, Graviss EA, et al. Signifi cantly Decreased Mortality in a Large Cohort of Coronavirus Disease 2019 (COVID-19) Patients Transfused Early with Convalescent Plasma Containing High-Titer Anti-Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Protein IgG. Am J Pathol. 2021 Jan;191(1):90-107. DOI: 10.1016/j.ajpath.2020.10.008
13. 13. Senefeld J W, Franchini M, Mengoli C, et al. COVID-19 Convalescent Plasma for the Treatment of Immunocompromised Patients: A Systematic Review and Meta-analysis. JAMA network open. 2022; 6(1): e2250647. DOI: 10.1001/jamanetworkopen.2022.50647
14. Thompson MA., Henderson JP, Shah PK, et al. Association of Convalescent Plasma Therapy With Survival in Patients With Hematologic Cancers and COVID-19. JAMA oncology. 2021; 7(8): 1167–1175. DOI: 10.1001/jamaoncol.2021.1799
15. Denkinger CM, Janssen M, Schäkel U, et al. Anti-SARSCoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial. Nature cancer. 2023; 4(1): 96–107. DOI: 10.1038/s43018-022-00503-w
UDC: 618.179 DOI: 10.20969/VSKM.2025.18(4).62-70
Preconception preparation of patients with bacterial vaginosis and chronic genital herpes infection
Ulyana V. Stolyarova1, Irina E. Rogozhina1, Natalia F. Khvorostukhina1, Denis A. Novichkov1, Oksana S. Odnokozova1
1Saratov State Medical University named after V.I. Razumovsky, 112 Bolshaya Kazachya str., 410012 Saratov, Russian Federation
Abstract. Introduction. Bacterial vaginosis is one of the most common types of infectious pathology of the female genital organs (10-70%), increasing the likelihood of complications during pregnancy and childbirth, which also aff ects the health of newborns. Viral infection is also a signifi cant factor in the etiology of genital and obstetric disorders. Aim. To evaluate the eff ectiveness of using a combined drug with interferon alpha-2b, metronidazole, and fl uconazole in conjunction with traditional comprehensive therapy of bacterial vaginosis combined with recurrent genital herpes in a pre-pregnancy preparation program. Materials and Methods. The study included 120 women aged 18 to 35 years suffering from recurrent genital herpes and bacterial vaginosis, who became pregnant within 12 months after completing the proposed therapy and gave birth. In Group I (n=60), standard antiviral therapy was used with acyclovir at a dose of 200 mg 5 times a day for a period of 5 days, along with the topical application of interferon alpha-2b, metronidazole, and fl uconazole intravaginally for 10 days. In Group II (n=60), similar antiviral therapy was used, along with clindamycin suppositories for 3 days. The patient examination program included traditional diagnostic methods, such as microscopy, vaginal discharge pH measurement, and virus DNA detection, as well as questionnaires. Additionally, the concentration of cytokines in cervical mucus was tested using enzyme-linked immunosorbent assay (ELISA). MS Excel and Statistica 7.0 software programs were used for statistical processing. Diff erences were considered statistically signifi cant at p<0.05. Results and Discussion. A higher clinical eff ectiveness of treatment of bacterial vaginosis was noted in Group I compared to Group II: 2 times higher after 10 days, 4.8 times higher after 30 days, and 4 times higher after 6 months; while for genital herpes, the respective fi gures were 1.8; 2.3; and 2.6 times higher. A greater microbiological eff ect was achieved after 6 months in Group I: 4.4 times higher for bacterial vaginosis and 2.8 times higher for herpes. A more signifi cant decrease in cytokine concentration was established on the 10th day of therapy in Group I compared to the indicators of Group II (Il-10 was 1.4 times lower, IL-6 was 3 times lower, IL-1β was 2 times lower, TNFα was 2.7 times lower, and IFN-γ was 1.8 times lower) (p<0.001), with the immunomodulatory eff ect persisting for 30 days. Conclusions. The use of the proposed pre-pregnancy preparation option contributes to reducing the risk of genital herpes exacerbation during pregnancy by 3.8 times (p<0.001), bacterial vaginosis by 1.9 times (p<0.001), and intrauterine infection markers were detected 4.9 times less often on ultrasound examination (p<0.001), which improves pregnancy outcomes, increasing newborn health indicators by 4.7 times (p<0.001).
Keywords: preconception preparation, bacterial vaginosis, recurrent genital herpes infection, cytokines.
For citation: Stolyarova, U.V.; Rogozhina, I.E.; Khvorostukhina, N.F.; et al. Preconception preparation of patients with bacterial vaginosis and chronic genital herpes infection. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4), 62-70. DOI: 10.20969/VSKM.2025.18(4).62-70.
References
1. Дикке Г.Б., Баранов И.И., Байрамова Г.Р. Бактериальный вагиноз: парадокс XXI века // Акушерство и гинекология. Новости. Мнения. Обучение. – 2021. – Т. 9, № 4(34). – С. 52-62. Dikke GB, Baranov II, Bayramova GR. Bakterial`ny`j vaginoz: paradoks XXI veka [Bacterial vaginosis: paradox of the XXI century]. Akusherstvo i ginekologiya; Novosti; Mneniya; Obuchenie [Obstetrics and gynecology; News; Views; Education]. 2021; 9 (4(34)): 52-62. (In Russ.). DOI: 10.33029/2303-9698-2021-9-4-52-62
2. Sousa LGV, Pereira SA, Cerca N. Fighting polymicrobial biofi lms in bacterial vaginosis. Microb Biotechnol. 2023; 16(7): 1423-1437. DOI: 10.1111/1751-7915.14261
3. Abou Chacra L, Ly C, Hammoud A, et al. Relationship between Bacterial Vaginosis and Sexually Transmitted Infections: Coincidence, Consequence or Co-Transmission? Microorganisms. 2023; 11(10): 2470. DOI: 10.3390/microorganisms11102470
4. Chen X, Lu Y, Chen T, Li R. The Female Vaginal Microbiome in Health and Bacterial Vaginosis. Front Cell Infect Microbiol. 2021; 11: 631972. DOI: 10.3389/fcimb.2021.631972
5. Ahmed M, Admassu Ayana D, Abate D. Bacterial Vaginosis and Associated Factors Among Pregnant Women Attending Antenatal Care in Harar City, Eastern Ethiopia. Infect Drug Resist. 2022; 15: 3077-3086. DOI: 10.2147/IDR.S364229
6. Островская А.Е., Хворостухина Н.Ф., Степанова Н.Н., Василевич Л.К. Бактериологический пейзаж и инфекционный скрининг при миоме матки, осложненной геморрагическим синдромом // Врач-аспирант. – 2017. – Т. 81, № 2.1. – С.108-115. Ostrovskaya AE, Khvorostukhina NF, Stepanova NN, Vasilevich LK. Bakteriologicheskij pejzazh i infekcionny`j skrining pri miome matki, oslozhnennoj gemorragicheskim sindromom [Bacteriological landscape and infectious screening with uterine fi broids complicated by hemorrhagic syndrome]. Vrach-aspirant [Postgraduate Doctor]. 2017; 81 (2.1): 108–115. (In Russ.). Режим доступа [URL]: https://www.elibrary.ru/item.asp?id=28843118
7. Хворостухина Н.Ф., Михеева Ю.В., Новичков Д.А., [и др.]. Анализ причин рецидивирования эктопии шейки матки после коагуляции // Фундаментальные исследования. – 2014. – № 10-3. – С. 562-566. Khvorostukhina NF, Mikheeva YV, Novichkov DA, еt al. Analiz prichin recidivirovaniya e`ktopii shejki matki posle koagulyacii [Analisis of causes of relapse of cervix ectopia after coagulation]. Fundamental`ny`e issledovaniya [Fundamental research]. 2014; 10-3: 562-566. (In Russ.). Режим доступа [URL]: https://www.elibrary.ru/item.asp?id=22270960
8. Хворостухина Н.Ф., Степанова Н.Н., Новичков Д.А., Силкина А.А. Особенности течения пуэрперия при преждевременных родах с длительным безводным промежутком // Медицинский совет. – 2021. – № 3. – С.82-88. Khvorostukhina NF, Stepanova NN, Novichkov DA, Silkina AA. Osobennosti techeniya pue`rperiya pri prezhdevremenny`x rodax s dlitel`ny`m bezvodny`m promezhutkom [Features of the course of puerperium in preterm birth with a long anhydrous interval]. Medicinskij sovet [Medical Council]. 2021; 3: 82-88. (In Russ.). DOI: 10.21518/2079-701X-2021-3-82-88
9. Хворостухина Н.Ф., Бахмач В.О., Трушина О.В., [и др.]. Факторы риска родового травматизма шейки матки при срочных родах, осложненных преждевременным разрывом плодных оболочек // Российский вестник акушера-гинеколога. – 2024. – Т. 24, № 1. – С. 61-68. Khvorostukhina NF, Bakhmach VO, Trushina OV, еt al. Faktory` riska rodovogo travmatizma shejki matki pri srochny`x rodax, oslozhnenny`x prezhdevremenny`m razry`vom plodny`x obolochek [Risk factors of labor traumatism of the cervix in term labor complicated by premature rupture of the fetal membranes]. Rossijskij vestnik akushera-ginekologa [Russian bulletin of obstetrician-gynecologist]. 2024; 24(1): 61-68. (In Russ.). DOI: 10.17116/rosakush20242401161
10. Alareeki A, Osman AMM, Khandakji MN, et al. Epidemiology of herpes simplex virus type 2 in Europe: systematic review, meta-analyses, and meta-regressions. Lancet Reg Health Eur. 2022; 25: 100558. DOI: 10.1016/j.lanepe.2022.100558
11. Романовская А.В., Давыдов А.И., Хворостухина Н.Ф., [и др.]. Фетоплацентарная недостаточность и сроки ее коррекции у беременных с гриппом // Вопросы гинекологии, акушерства и перинатологии. – 2018. – Т. 17, № 3. – С. 41-44. Romanovskaya AV, Davydov AI, Khvorostukhina NF, еt al. Fetoplacentarnaya nedostatochnost` i sroki ee korrekcii u beremenny`x s grippom [Fetoplacental insuffi ciency and terms of its management in pregnant women with infl uenza]. Voprosy` ginekologii, akusherstva i perinatologii [Gynecology, obstetrics and perinatology]. 2018; 17(3): 41-44. (In Russ.). DOI: 10.20953/1726-1678-2018-3-41-44
12. Workowski KA, Bachmann LH, Chan PA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. MMWR Recomm Rep. 2021; 70(4): 1-187. DOI: 10.15585/mmwr.rr7004a1
13. Пшеничная Н.Ю., Романова Е.Б., Твердохлебова Т.И., [и др.]. Клинико-патогенетические аспекты генитальной герпетической инфекции // Эпидемиология и инфекционные болезни. Актуальные вопросы. – 2024. – Т. 14, № 1. – С. 97-101. Pshenichnaya NYu, Romanova EB, Tverdokhlebova TI, еt al. Kliniko-patogeneticheskie aspekty` genital`noj gerpeticheskoj infekcii [Clinical and pathogenetic aspects of genital herpetic infection]. E`pidemiologiya i infekcionny`e bolezni: Aktual`ny`e voprosy` [Epidemiology and infectious diseases: Current items]. 2024; 14(1): 97-101. (In Russ.). DOI: 10.18565/epidem.2024.14.1.97-101
14. Минздрав России. Клинические рекомендации «Аногенитальная герпетическая вирусная инфекция». – Москва, 2024. – 50 с. Minzdrav Rossii [Ministry of Health of the Russian Federation]. Klinicheskiye rekomendatsii «Anogenital’naya gerpeticheskaya virusnaya infektsiya» [Clinical guidelines “Anogenital herpes viral infection”]. Moskva [Moscow]. 2024; 50 p. Режим доступа [URL]: https://roag-portal.ru/recommendations_gynecology
15. Management of Genital Herpes in Pregnancy: ACOG Practice Bulletinacog Practice Bulletin, Number 220. Obstet Gynecol. 2020; 135 (5): e193-e202. DOI: 10.1097/AOG.0000000000003840
16. Хворостухина Н.Ф., Плеханов А.А., Новичков Д.А., [и др.]. Эндотоксикоз и плацентарная дисфункция при остром пиелонефрите у беременных // Вопросы гинекологии, акушерства и перинатологии. – 2020. – Т. 19, № 6. – С. 22-27. Khvorostukhina NF, Plekhanov AA, Novichkov DA, еt al. E`ndotoksikoz i placentarnaya disfunkciya pri ostrom pielonefrite u beremenny`x [Endotoxicosis and placental dysfunction in pregnant women with acute pyelonephritis]. Voprosy` ginekologii, akusherstva i perinatologii [Gynecology, obstetrics and perinatology]. 2020; 19(6): 22-27. (In Russ.). DOI: 10.20953/1726-1678-2020-6-22-27
17. Кира Е.Ф., Расторгуева Л.И., Халтурина Ю.В., Пушкина В.В. Инфекции влагалища. Двухэтапный метод лечения // Акушерство и гинекология. – 2020. – № 4. – С. 201-209. Hra EF, Rastorgueva LI, Khalturina YuV, Pushkina VV. Infekcii vlagalishha. Dvuxe`tapny`j metod lecheniya [Vaginal infections. Two-step treatment]. Akusherstvo i ginekologiya [Akusherstvo i ginekologiya]. 2020; 4: 201-209. (In Russ.). DOI: 10.18565/aig.2020.4.201-208
18. Lee SWH, Gottlieb SL, Chaiyakunapruk N. Healthcare resource utilisation pattern and costs associated with herpes simplex virus diagnosis and management: a systematic review. BMJ Open. 2022; 12(1): e049618. DOI: 10.1136/bmjopen-2021-049618
19. Пестрикова Т.Ю., Юрасова Е.А., Шматкова А.С., Ковалева Т.Д. Проблемы диагностики и профилактики рецидивов при хронических цервицитах и вагинитах // Доктор.Ру. – 2020. – Т. 19, № 6. – С. 57-62. Pestrikova TYu, Yurasova EA, Shmatkova AS, Kovaleva TD. Problemy` diagnostiki i profilaktiki recidivov pri xronicheskix cervicitax i vaginitax [Diffi culties in diagnosing and preventing recurrence of chronic cervicitis and vaginitis]. Doktor Ru [Doctor Ru]. 2020; 19(6): 57-62. (In Russ.). DOI: 10.31550/1727-2378-2020-19-6-57-62
20. Smagulova AA, Khismetova ZA, Kamaliyeva AK, Sagdatbek NS. Bacterial vaginosis and desquamative infl ammatory vaginitis: choice of an eff ective therapy method. Review. Science & Healthcare. 2022; 24 (4): 216-223. DOI: 10.34689/SH.2022.24.4.026
21. Минздрав России. Клинические рекомендации «Бактериальный вагиноз». – 2022. – 16 с. Minzdrav Rossii [Ministry of Health of the Russian Federation]. Klinicheskiye rekomendatsii «Bakterial`ny`j vaginoz» [Clinical guidelines «Bacterial vaginosis»]. 2022: 16 p. (In Russ.). Режим доступа [URL]: https://gkb8.ru/userfiles/video/123/%D0%9A%D0%A0/_%20-%20Copy%202.pdf
22. Бойко Е.Л., Малышкина А.И. Опыт использования комбинированного лекарственного препарата Вагиферон® для местного применения у небеременных женщин // Инфекционные болезни: новости, мнения, обучение. – 2017. – № 1(18). – С. 57-64. Boyko EL, Malyshkina AI. Opy`t ispol`zovaniya kombinirovannogo lekarstvennogo preparata Vagiferon® dlya mestnogo primeneniya u neberemenny`x zhenshhin [Experience of the combined medication Vagiferon® in non-pregnant women]. Infekcionny`e bolezni: novosti, mneniya, obuchenie [Infectious diseases: news, views, education]. 2017; 1(18): 57-64. (In Russ.). Режим доступа [URL]: https://www.elibrary.ru/item.asp?id=28825475
23. Кравченко Е.Н., Куклина Л.В., Кривчик Г.В., [и др.]. Оценка эффективности лечения женщин с высоким риском рецидивов смешанных вагинитов // Акушерство и гинекология. Новости. Мнения. Обучение. – 2023. – Т. 11, № 4(42). – С. 14-20. Kravchenko EN, Kuklina LV, Krivchik GV, еt al. Ocenka e`ffektivnosti lecheniya zhenshhin s vy`sokim riskom recidivov smeshanny`x vaginitov [Assessment of treatment eff ectiveness in women at high relapse risk for mixed vaginitis]. Akusherstvo i ginekologiya. Novosti. Mneniya. Obuchenie [Obstetrics and gynecology. News. Views. Education]. 2023; 11(4(42)): 14-20. (In Russ.). DOI: 10.33029/2303-9698-2023-11-4-14-20
24. Кравченко Е.Н., Кривчик Г.В., Куклина Л.В., [и др.]. Эффективность комбинированного препарата интерферона альфа-2b, метронидазола и флуконазола в терапии вагинальных инфекций // Акушерство и гинекология. Новости. Мнения. Обучение. – 2023. – Т. 11, № 2(40). – С. 28-34. Kravchenko EN, Krivchik GV, Kuklina LV, еt al. E`ff ektivnost` kombinirovannogo preparata interferona al`fa-2b, metronidazola i fl ukonazola v terapii vaginal`ny`x infekcij [The eff ectiveness of the combined medicine interferon alpha-2b + metronidazole + fl uconazole in the treatment of vaginal infections]. Akusherstvo i ginekologiya; Novosti; Mneniya; Obuchenie [Obstetrics and gynecology; News; Views; Education]. 2023; 11(2(40)): 28-34. (In Russ.). DOI: 10.33029/2303-9698-2023-11-2-28-34
UDC: 616.23/.233-06-091-072.1:616.98: 578.834.1 DOI: 10.20969/VSKM.2025.18( 4).71-78
Anatomical abnormalities of the tracheobronchial tree in patients with new coronavirus infection (COVID-19): Bronchoscopy findings
Michail L. Steiner1,2, Alexandr V. Zhestkov3, Yury I. Biktagirov2, Elena V. Makova1,3, Anna A. Kazakova3, Vera V. Kulagina3
1 Samara City Hospital No. 4, 125 Michurin str., 443056 Samara, Russia
2 Samara State Medical University, 89 Chapaevskaya str., 443099 Samara, Russia
3 Samara Medical University REAVIZ, 227 Chapaevskaya str., 443001 Samara, Russia
Abstract. Introduction. Despite recommendations for possible limitation of the use of bronchoscopy due to epidemiological reasons, the traditional decision-making algorithm for employing this method was used in the coronavirus hospital established at Samara City Hospital No. 4. This approach revealed that the primary indications for initial bronchoscopies and the endobronchial fi ndings varied based on the specifi c epidemiological situation, i.e., the dominance of diff erent coronavirus strains at diff erent times. This also applied to the anatomical abnormalities of the tracheobronchial tree that had been identifi ed. Aim. To study the frequency of the anatomical abnormalities of the tracheobronchial tree, detected as incidental fi ndings during bronchoscopy, depending on the specifi c epidemiological situation. Materials and Methods. The results of 668 initial bronchoscopies (100 %) were analyzed that had been performed during the functioning of the coronavirus hospital. The study period was conditionally divided into two time periods. The beginning of the second period coincided with the dominance of the Omicron strain. We examined the comparative frequency of incidental detection of anatomical abnormalities of the tracheobronchial tree. For this purpose, Pearson’s chi-square test (χ2) was used to test the hypotheses about the equality of proportions. Results and Discussion. 278 initial diagnostic and therapeutic bronchoscopies were performed during the fi rst time period, anatomical abnormalities of the tracheobronchial tree were identifi ed in 162 cases. For the second time period, the relevant fi gures were 390 and 50, respectively. Calculation of the Pearson χ2 criterion showed that the higher frequency of detecting anatomical abnormalities of the tracheobronchial tree in the fi rst period reached statistical signifi cance, compared to the second one. Conclusions. It is evident that the diff erences in the frequency of detecting anatomical abnormalities of the tracheobronchial tree are associated with changes in the epidemiological situation during the pandemic, i.e., the dominance of the British, Indian, and African coronavirus strains at the beginni ng of the pandemic and the dominance of the Omicron strain towards its end.
Keywords: new coronavirus infection COVID-19, bronchoscopy, anatomical abnormalities of the tracheobronchial tree, specific epidemiological situation
For citation: Shteiner, M.L.; Zhestkov, A.V.; Biktagirov, Yu.I; et al. Anatomical abnormalities of the tracheobronchial tree in patients with new coronavirus infection (COVID-19): bronchoscopy fi ndings. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4), 71-78. DOI: 10.20969/VSKM.2025.18(4).71-78.
References
1. Klein U, Karzai W, Zimmerman P, et al. Changes in pulmonary Mechanics after Fiberoptic Bronchoalveolar Lavage in mechanically ventilated Patients. Intensive Care Med. 1998; 24 (12): 1289-1293. DOI: 10.1007/s001340050764
2. Ершов А.Л. Обеспечение проходимости дыхательных путей при острой дыхательной недостаточности вне стационара ⁄⁄ Скорая медицинская помощь. – 2018. – №3. – С. 62-69. Yershov AL. Obespecheniye prokhodimosti dykhatel’nykh putey pri ostroy dykhatel’noy nedostatochnosti vne statsionara [Airway management during out-of-hospital acute respiratory insuffi ciently]. Skoraya meditsinskaya pomoshch’ [Emergency medical care]. 2018; 3: 62-69. (In Russ.). DOI: 10.24884/2072-6716-2018-19-3-62-69
3. Nakstad ER, Opdahl H, Skjonsberg OH, Borchsenius F. Intrabronchial airway pressures in intubated patients during bronchoscopy under volume controlled and pressure controlled ventilation. Anaesth Intensive Care. 2011; 39 (3): 431-439. DOI: 10.1177/ 0310057X1103900314
4. Lentz S, Roginski MA, Montrief T, et al. Initial emergency department mechanical ventilation strategies for COVID-19 hypoxemic respiratory failure and ARDS. Amer J Emerg Med. 2020; 38 (10): 2194-2202. DOI: 10.1016/j.ajem.2020.06.082
5. Reddy PD, Nguyen SA, Deschler D. Bronchoscopy, Laryngoscopy, and Esophagoscopy During the COVID-19 Pandemic. Head & Neck. 2020; 10: 1-4. DOI: 10.1002/hed.26221
6. Репичи А., Никонов Е.Л., Кашин С.В. [и др.] Коронавирусная инфекция: инфекционная безопасность в эндоскопическом отделении ⁄⁄ Доказательная гастроэнтерология. – 2020. – Т. 9, № 1. – С. 5-13. Repichi A, Nikonov YeL, Kashin SV, еt al. Koronavirusnaya infektsiya: infektsionnaya bezopasnost’ v endoskopicheskom otdelenii [Coronavirus (COVID-19): control and prevention in endoscopy department]. Dokazatel’naya gastroenterologiya [Russian Journal of Evidence-Based Gastroenterology]. 2020; 9 (1): 5-13. (In Russ.). DOI: 10.17116/ dokgastro202090115
7. Darwiche K, Ross B, Gesierich W, et al. Empfehlungen zur Durchführung einer Bronchoskopie in Zeiten der COVID-19-Pandemie. Pneumologie. 2020; 74 (5): 260-262. DOI: 10.1055/a-1154-1814
8. Guedes F, Boléo-Tomé JP, Rodrigues LV, et al. Recommendations for interventional pulmonology during COVID-19 outbreak: a consensus statement from the Portuguese Pulmonology Society. Pulmonology. 2020; 26 (6): 386-397. DOI: 10.1016/j.pulmoe.2020.07.007
9. Liao M, Liu Y, Yuan J, et al. Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19. Nat Med. 2020; 26 (6); 842-844. DOI: 10.1038/s41591-020-0901-9
10. Иванцова М.А., Белова Г.В., Щербаков П.Л., Верник Н.В. Риски рабочей среды в обеспечении безопасности медицинской деятельности в эндоскопии ⁄⁄ Экспериментальная и клиническая гастроэнтерология. – 2020. – №184 (12). – С.5-15. Ivantsova MA, Belova GV, Shcherbakov PL, Vernik NV. Riski rabochey sredy v obespechenii bezopasnosti meditsinskoy deyatel’nosti v endoskopii [Risks of the working environment in the safety ensuring in endoscopy]. Eksperimental’naya i klinicheskaya gastroenterologiya [Experimental and clinical gastroenterology]. 2020; 184 (12): 5-15. (In Russ.). DOI: 10.31146/1682-8658-ecg-184-12-5-15
11. Глебов К.Г., Аносов В.Д., Вечорко В.И. Особенности работы эндоскопической службы ГКБ №15 им. О.М. Филатова ДЗМ при эпидемии новой коронавирусной инфекции COVID-19 и перепрофилирования больницы в инфекционную. Первые итоги ⁄⁄ Профилактическая медицина. – 2020. – №23 (7). – С. 52-55. Gleb ov KG, Anosov VD, Vechorko VI. Osobennosti raboty endoskopicheskoy sluzhby GKB №15 im. O.M. Filatova DZM pri epidemii novoy koronavirusnoy infektsii COVID-19 i pereprofi lirovaniya bol’nitsy v infektsionnuyu; Pervyye itogi [Endoscopic service specifi cs in the Filatov’s State Clinical Hospital 15 of the Moscow Health Care Department for new coronavirus COVID-19 epidemic and the re-profi ling of the regular hospital into an infectious hospital; First results]. Profi lakticheskaya meditsina [The Russian Journal of Preventive Medicine]. 2020; 23 (7): 52-55. (In Russ.). DOI: 10.17116/ profmed20202307152
12. Штейнер М.Л. Фибробронхоскопия: алгоритм применения ⁄⁄ Уральский медицинский журнал. – 2011. – №14 (92). – С. 29-33. Shteyner ML. Fibrobronkhoskopiya: algoritm primeneniya [Fiberoptic bronchoscopy: an algorithm for use]. Ural’s kiy meditsinskiy zhurnal [Ural Medical Journal]. 2011; 14 (92): 29-33. (In Russ.).
13. Филиппов В.П., Черниченко Н.В. Бронхоскопия при заболеваниях лёгких [монография]. – Москва: БИНОМ, 2014. – 184 с. Filippov VP, Chernichenko NV. Bronkhoskopiya pri zabolevaniyakh logkikh (monografi ya) [Bronchoscopy at Lung diseases (Monograph)]. Moskva: BINOМ [Moscow: BINOM]. 2014; 184 р. (In Russ.).
14. Паламарчук Г.Ф., Акопов А.Л., Арсеньев А.И. [и др.] Бронхоскопия в диагностике и лечении заболеваний органов дыхания (монография). – Санкт-Петербург, Издательство: ″Фолиант″, 2019. – 328 с. Palamarchuk GF, Akopov AL, Arsen’yev AI. Bronkhoskopiya v diagnostike i lechenii zabolevaniy organov dykhaniya (monografiya) [Bronchoscopy in the diagnosis and treatment of respiratory diseases]. Sankt-Peterburg, Izdatel’stvo: ″Foliant″ [S-Petersburg, Publisher: ″Foliant″]. 2019; 328 р. (In Russ.).
15. Akash K, Sharma A, Kumar D, et al. Molecular aspects of Omicron, vaccine development, and recombinant strain XE: A review. J Med Virol. 2022; 94 (10): 4628-4643. DOI: 10.1002/jmv.27936
16. Чуланов В.П. «Опыт преодоления пандемии поможет нам более эффективно реагировать на будущие угрозы» ⁄⁄ Безопасность и риск фармакотерапии. – 2022. – Т. 10, № 4. – С. 322-325. Chulanov VP. Opyt preodoleniya pandemii pomozhet nam boleye eff ektivno reagirovat’ na budushchiye ugrozy [Our experience with overcoming the pandemic will help us eff ectively address future threats]. Bezopasnost’ i risk farmakoterapii [Safety and Risk of Pharmacotherapy]. 2022; 10 (4): 322-325. (In Russ.). DOI: 0.30895/2312-7821-2022-10-4-522-525
17. Штейнер М.Л. Аномалии ветвления бронхов в общей бронхоскопической практике: «двойные» бронхи ⁄⁄ Известия высших учебных заведений. Поволжский регион. Медицинские науки. – 2018. – № 4 (48). – С. 116-121. Shteyner ML. Anomalii vetvleniya bronkhov v obshchey bronkhoskopicheskoy praktike: “dvoynyye” bronchi [Bronchial branching anomalies in general bronchoscopic practice: the “double” bronchi]. Izvestiya vysshikh uchebnykh zavedeniy; Povolzhskiy region; Meditsinskiye nauki [University proceedings; Volga region; Medical sciences.]. 2018; 4 (48): 116-121. (In Russ.). DOI: 10.21685/2072-3032-2018-4-12
18. Campbell I. Chi-squared and Fisher-Irwin tests of two-by-two tables with small sample recommendations. Stat Med. 2007; 26: 3661-3675. DOI: 10.1002/sim.2832
19. Richardson JTE The analysis of 2 x 2 contingency tables – Yet again. Stat Med. 2011; 30 (8): 890. DOI: 10.1002/sim.4116
20. Brest P, Refae S, Mograbi B, et al. Host polymorphisms may impact SARS-CoV-2 infectivity. Trends Genet. 2020; 36 (11): 813-815. DOI: 10.1016/j.tig.2020.08.003
21. Deb P, Zannat KE, Talukder S, et al. Association of HLA gene polymorphism with susceptibility, severity, and mortality of COVID-19: A systematic review. HLA. 2022; 99 (4): 281-312. DOI: 10.1111/tan.14560
22. Delanghe JR, Speeckaert MM. Host polymorphisms and COVID-19 infection. Adv Clin Chem. 2022; 107: 41-77. DOI: 10.1016/bs.acc.2021.07.002
REVIEWS
UDC 616.361-089.819.1 DOI: 10. 2096 9/VSKM.2025.18(4).79-87
Endoscopic treatment methods for papillary stenosis
B.A. Sakhabetdinov1, A.I. Kurbangaleev1, A.A. Danilin1, D.R. Sayapova1, A.A. Kurbangaleev2
1 Kazan State Medical University, 49 Butlerov str., 420012 Kazan, Russia
2 Central City Clinical Hospital No. 18 named after Professor K. Sh. Zyatdinov in Kazan, 2 Mavlyutov str., 420101 Kazan, Russia
Abstract. Introduction. According to statistical data, from among all benign cholelithiasis-associated changes in the bile ducts, up to 25% are attributed to stenosis of the major duodenal papilla. It is important to note that papillary stenosis often (in 75–80% of cases) precedes choledocholithiasis. Aim. To review domestic and foreign literature on methods of diagnosis and treatment of papillary stenosis; to analyze instrumental endoscopic methods available in practice, to evaluate the eff ectiveness of using them, and to identify the advantages and disadvantages of various endoscopic methods for the treatment of papillary stenosis. Materials and Methods. The review includes data from domestic and foreign studies published in electronic bibliographic databases, such as Pubmed, Web of Science, and Google Scholar, over the past 38 years. An analysis was conducted of publications containing information on various treatment methods for papillary stenosis. Results and Discussion. Nine core methods of endoscopic treatment for papillary stenosis were analyzed: Endoscopic papillosphincterotomy, laparoscopic laser papillosphincterotomy, radial papillosphincterotomy, fi stulotomy with a needle knife, stenting, antegrade choledochoscopy with papillosphincterotomy combined with laparoscopic cholecystectomy, antegrade endoscopic choledochoscopy with bougienage, endoscopic partial papillosphincterotomy with balloon dilation, and pancreatic duct stenting using the rendezvous technique from the minor papilla to the major papilla. This paper provides a brief description and technique for each method, as well as their advantages and disadvantages. Conclusions. It has been found that the most relevant and effi cient technique is ant egrade endoscopic choledochoscopy with bougienage.
Keywords: papillary stenosis, surgery, endoscopy, mechanical jaundice, choledocholithiasis.
For citation: Sakhabetdinov, B.A.; Kurbangaleev, A.I.; Danilin, A.A.; et al. Endoscopic treatment methods for papillary stenosis. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4),79-87. DOI: 10.20969/VSKM.2025.18(4).79-87.
References
1. Бурдюков М.С., Нечипай А.М. Холедохолитиаз: обзор литературы // Доказательная гастроэнтерология. – 2020. – Т. 9. – № 4. – С. 55-66. Burdyukov MS, Nechipai AM. Holedoholitiaz: obzor literatury [Choledocholithiasis: literature review]. Dokazatel’naya gastroenterologiya [Evidence-based gastroenterology]. 2020; 9 (4): 55-66. (In Russ.).
2. Barbara L, Sama C, Morselli Labate AM, et al. A population study on the prevalence of gallstone disease: the Sirmione Study. Hepatology. 1987; 7 (5): 913-917. DOI: 10.1002/hep.1840070520
3. Portincasa P, Moschetta A, Petruzzelli M, et al. Gallstone disease: Symptoms and diagnosis of gallbladder stones. Best Practice & Research Clinical Gastroenterology. 2006; 20 (6): 1017-1029. DOI: 10.1016/j.bpg.2006.05.005
4. Натрошвили А.Г., Шулутко А.М., Байчоров Э.Х., [и др.]. Дооперационная диагностика холедохолитиаза: возможности и перспективы // Медицинский вестник Северного Кавказа. – 2021. – Т. 16. – № 1 – С. 1-5. Natroshvili AG, Shulutko AM, Baychorov EH, et al. Dooperacionnaya diagnostika holedoholitiaza: vozmozhnosti i perspektivy [Preoperative diagnosis of common bile duct stones: possibilities and opportunities]. Medicinskij vestnik Severnogo Kavkaza [Medical news of North Caucasus]. 2021; 16 (1): 1-5. (In Russ.).
5. Загидуллина Г.Т., Курбангалеев А.И. Современные технологии в диагностике холедохолитиаза // Практическая медицина. – 2015. – Т. 89 – № 4 – С. 45-49. Zagidullina GT, Kurbangaleev AI. Sovremennye tekhnologii v diagnostike holedoholitiaza [Modern technologies in the diagnosis of choledocholithiasis]. Prakticheskaya medicina [Practical medicine]. 2015; 4 (89): 45-49. (In Russ.).
6. Molvar C, Glaenzer B. Choledocholithiasis: Evaluation, treatment, and outcomes. Seminars in Interventional Radiology. 2016; 33 (4): 268–276. DOI: 10.1055/s-0036-1592329.
7. Cianci P, Restini E. Management of cholelithiasis with choledocholithiasis: Endoscopic and surgical approaches. World Journal of Gastroenterology. 2021; 27 (28): 4536-4554. DOI: 10.3748/wjg.v27.i28.4536
8. Шаповальянц С.Г., Мыльников А.Г., Паньков А.Г., [и др.]. Диагностика холедохолитиаза и папиллостеноза у больных острым калькулезным холециститом //Анналы хирургической гепатологии. – 2004. – Т. 9. – №2. – С. 33-39. Shapovaliants SG, Mylnikov AG, Pankov AG, et al. Diagnostika holedoholitiaza i papillostenoza u bol’nyh ostrym kal’kuleznym holecistitom [Diagnostics of choledocholithiasis and papillostenosis in patients with acute calculous cholecystitis]. Annaly hirurgicheskoj gepatologii [Annals of surgical hepatology]. 2004; 9 (2): 1-12. (In Russ.).
9. Иванов В.А., Малярчук В.И. Ультразвуковая диагностика заболеваний органов билиопанкреатодуоденальной зоны. – М.: Камерон, 2004. – 136 c. Ivanov VA, Malyarchuk VI. Ul’trazvukovaya diagnostika zabolevanij organov biliopankreatoduodenal’noj zony [Ultrasound diagnostics of diseases of the biliopancreatoduodenal zone organs]. Moskva: Kameron [Moscow: Cameron.]. 2004; 136 p. (In Russ.).
10. Павелец К.В., Гацко Д.В., Русанов Д.С. Современный подход к лечению холедохолитиаза // Медицина: теория и практика. – 2018. – Т. 3. – № 3. – С. 27-33. Pavelets KV, Gatsko DV, Rusanov DS. Sovremennyj podhod k lecheniyu holedoholitiaza [Modern approach to the treatment of choledocholithiasis]. Medicina: teoriya i praktika [Medicine: theory and practice]. 2018; 3 (3): 27-33. (In Russ.).
11. Подолужный В.И. Механическая желтуха: принципы диагностики и современного хирургического лечения // Фундаментальная и клиническая медицина. – 2018. – Т. 3. – № 2. – С. 82-92. Podoluzhny VI. Mekhanicheskaya zheltuha: principy diagnostiki i sovremennogo hirurgicheskogo lecheniya [Mechanical jaundice: principles of diagnosis and modern surgical treatment]. Fundamental’naya i klinicheskaya medicina [Fundamental and clinical medicine]. 2018; 3 (2): 82-92. (In Russ.).
12. Шаповальянц С.Г., Паньков А.Г., Будзинский С.А., [и др.]. Место транспапиллярных эндоскопических вмешательств при остром холецистите, осложненном патологией желчных протоков //Анналы хирургической гепатологии. – 2020. – Т. 25. – № 3. – С. 48-54. Shapovaliants SG, Pankov AG, Budzinsky SA, et al. Mesto transpapillyarnyh endoskopicheskih vmeshatel’stv pri ostrom holecistite, oslozhnennom patologiej zhelchnyh protokov [The place of transpapillary endoscopic interventions in acute cholecystitis complicated by bile duct pathology]. Annaly hirurgicheskoj gepatologii [Annals of Surgical Hepatology]. 2020; 25 (3): 48-54. (In Russ.).
13. Arregui ME, Davis CJ, Arkush AM, Nagan RF. Laparoscopic cholecystectomy combined with endoscopic sphincterotomy and stone extraction or laparoscopic choledochoscopy and electrohydraulic lithotripsy for management of cholelithiasis with choledocholithiasis. Surgical Endoscopy. 1992; 6 (1): 10-15. DOI: 10.1007/BF02291377
14. Gurusamy KS, Davidson BR. Surgical treatment of gallstones. Gastroenterology Clinics of North America. 2010; 39 (2): 229-244. DOI: 10.1016/j.gtc.2010.02.004
15. Schirmer BD, Winters KL, Edlich RF. Cholelithiasis and cholecystitis. Journal of Long-term Effects of Medical Implants. 2005; 15 (3): 329-338. DOI: 10.1615/jlongtermeff medimplants.v15.i3.90
16. Berthou JC, Dron B, Charbonneau P, et al. Evaluation of laparoscopic treatment of common bile duct stones in a prospective series of 505 patients: Indications and results. Surgical Endoscopy. 2007; 21 (11): 1970-1974. DOI: 10.1007/s00464-007-9387-5
17. Кондак О.И., Крючков С.А., Корнелюк Д.С. Трансдуоденальная папиллосфинктеротомия в лечении осложнений желчнокаменной болезни // Сборник материалов конференции студентов и молодых ученых, посвященной 100-летию со дня рождения АЗ Нечипоренко. – 2016. – С. 463-464. Kondak OI, Kryuchkov SA, Kornelyuk DS. Trans duode nal’naya papillosfinkterotomiya v lechenii oslozhne nij zhelchnokamennoj bolezni [Transduodenal papillosphincterotomy in the treatment of complications of cholelithiasis]. Sbornik materialov konferencii studentov i molodyh uchenyh, posvyashchennoj 100-letiyu so dnya rozhdeniya AZ Nechiporenko [Collection of materials from the conference of students and young scientists dedicated to the 100th anniversary of the birth of AZ Nechiporenko]. 2016; 463-464. (In Russ.).
18. Глебов К.Г., Котовский А.Е. Эндоскопическое лечение папиллостеноза //Анналы хирургической гепатологии. – 2010. – Т. 15. – № 1. – С. 34-36. Glebov KG, Kotovsky AE. Endoskopicheskoe lechenie papillostenoza [Endoscopic treatment of papillostenosis]. Annaly hirurgicheskoj gepatologii [Annals of surgical hepatology]. 2010; 15 (1): 34-36. (In Russ.).
19. Котовский А.Е., Глебов К.Г., Сюмарева Т.А., [и др.]. Эндоскопические методы диагностики и лечения папиллостеноза //Вестник хирургии имени ИИ Грекова. – 2016. – Т. 175. – № 2. – С. 21-24. Kotovsky AE, Glebov KG, Syumareva TA, et al. Endoskopicheskie metody diagnostiki i lecheniya papillostenoza [Endoscopic methods of diagnostics and treatment of papillostenosis]. Vestnik hirurgii imeni II Grekova [Bulletin of Surgery named after I.I. Grekov]. 2016; 175 (2): 21-24. (In Russ.).
20. Гусев А.В., Соловьёв А.Ю., Лебедев А.К., [и др.]. Непосредственные и отдаленные результаты эндоскопической папиллосфинктеротомии //Современные проблемы науки и образования. – 2015. – № 5. – С. 323-323. Gusev AV, Soloviev AYu, Lebedev AK, et al. Neposredstvennye i otdalennye rezul’taty endoskopicheskoj papillosfinkterotomii [Immediate and remote results of endoscopic papillosphincterotomy]. Sovremennye problemy nauki i obrazovaniya [Modern problems of science and education]. 2015; (5): 323-323. (In Russ.).
21. Vesakis A, Fragulidis G, Polydorou A. Endoscopic retrograde cholangiopancreatography associated with perforations: Diagnosis and management. Surgical Endoscopy. 2011; 25 (10): 3436-3442. DOI: 10.1007/s00464-011-1720-3
22. Voiosu T, Bălănescu P, Voiosu A, et al. Measuring trainee competence in performing endoscopic retrograde cholangiopancreatography: A systematic review of the literature. United European Gastroenterology Journal. 2019; 7 (2): 239-249. DOI: 10.1177/2050640618817110
23. Kumbhari V, Sinha A, Reddy A, et al. An algorithm for the treatment of perforations associated with ERCP. Gastrointestinal Endoscopy. 2016; 83 (5): 934-943. DOI: 10.1016/j.gie.2015.09.039
24. Costi R, Gnocchi A, Di Mario F, Sarli L. Diagnosis and management of choledocholithiasis in the golden age of imaging, endoscopy and laparoscopy. World Journal of Gastroenterology. 2014; 20 (37): 13382-13401. DOI: 10.3748/wjg.v20.i37.13382
25. Freeman ML. Complications of Endoscopic Sphincterotomy. Endoscopy. 1998; 30 (9): 216-220. DOI: 10.1055/s-2007-1001443
26. Jakobsen HL. Endoscopic sphincterotomy for common bile duct stones during laparoscopic cholecystectomy is safe and eff ective. Surgical Laparoscopy, Endoscopy & Percutaneous Techniques. 2011; 21 (6): 450-452. DOI:10.1097/SLE.0b013e31823bada9
27. Юсиф-заде К.Р. Эффективность использования эндосокопической ретроградной холангиопанкреатографии и папиллосфинктеротомии при лечении заболеваний билиарной системы // Новости хирургии. – 2012. – Т. 20. – № 5. – С. 128-131. Yusif-zade KR. Eff ektivnost’ ispol’zovaniya endosokopicheskoj retrogradnoj holangiopankreatografi i i papillosfi nkterotomii pri lechenii zabolevanij biliarnoj sistemy [The effectiveness of using endoscopic retrograde cholangiopancreatography and papillosphincterotomy in the treatment of diseases of the biliary system]. Novosti hirurgii [Surgery news]. 2012; 20 (5): 128-131. (In Russ.).
28. Неборская Ю.А., Фатуллаева Г.А., Скрипаль Е.А. Эффективность проведения ретроградной холангиопанкреатографии и эндоскопической папиллосфинктеротомии с учетом профилактики осложнений антисекреторной терапией // Вестник Медицинских Интернет Конференций. – 2020. – Т. 10. – № 2. – С. 64. Neborskaya YuA, Fatullaeva GA, Skripal EA. Eff ektivnost’ provedeniya retrogradnoj holangiopankreatografii i endoskopicheskoj papillosfinkterotomii s uchetom profilaktiki oslozhnenij antisekretornoj terapiej [The effectiveness of retrograde cholangiopancreatography and endoscopic papillosphincterotomy, taking into account the prevention of complications with antisecretory therapy]. Vestnik Medicinskih Internet Konferencij [Bulletin of Medical Internet Conferences]. 2020; 10 (2): 64. (In Russ.).
29. Лопатин Н.А., Брацун А.Д. Сравнительный анализ эффективности эндоскопических ретроградной и антероградной папиллосфинктеротомий при лечении холедохолитиаза и папиллостеноза //Аллея науки. – 2021. – Т. 1. – № 4. – С. 327-332. Lopatin NA, Bratsun AD. Sravnitel’nyj analiz eff ektivnosti endoskopicheskih retrogradnoj i antero gradnoj papillosfinkterotomij pri lechenii holedo holitiaza i papillostenoza [Comparative analysis of the effectiveness of endoscopic retrograde and anterograde papillosphincterotomies in the treatment of choledocholithiasis and papillostenosis]. Alleya nauki [Alley of Science]. 2021; 1 (4): 327-332. (In Russ.).
30. Mo LR, Chang KK, Wang CH, et al. Preoperative endoscopic sphincterotomy in the treatment of patients with cholecystocholedocholithiasis. Journal of hepatobiliary-pancreatic surgery. 2002; (9): 191-195. DOI: 10.1007/s005340200017
31. Мирзоев А.Ф. Эндоскопическая коррекция патологии терминального отдела общего желчного протока //Илмва фановарї. – 2021. – Т. 8. – № 1. – С. 115-119. Mirzoev AF. Endoskopicheskaya korrekciya patologii terminal’nogo otdela obshchego zhelchnogo protoka [Endoscopic correction of pathology of the terminal section of the common bile duct]. Ilm va fanovarї [Ilm va fanovary]. 2021; 8 (1): 115-119. (In Russ.).
32. Левченко Н.В., Хрячков В.В., Шавалиев Р.Р., [и др.]. Антеградная лазерная папиллотомия под контролем видеохоледохоскопии у больных со стенозом большого дуоденального сосочка, осложненным механической желтухой / /Research’n Practical Medicine Journal. – 2018. – Т. 5. – № 2. – С. 19-25. Levchenko NV, Khryachkov VV, Shavaliev RR, et al. Antegradnaya lazernaya papillotomiya pod kontro lem videoholedohoskopii u bol’nyh so stenozom bol’shogo duodenal’nogo sosochka, oslozhnennym mekhanicheskoj zheltuhoj [Antegrade laser papillotomy under videocholedochoscopy control in patients with stenosis of the major duodenal papilla complicated by mechanical jaundice]. Research’n Practical Medicine Journal. 2018; 5 (2): 19-25. (In Russ.).
33. Кянан Ю.Р. Обоснование эффективности нового метода радиальной сфинктеротомии при обструкции внепеченочных жёлчных путей //Казанский медицинский журнал. – 2014. – Т. 95. – № 6. – С. 816-821. Kyanan YuR. Obosnovanie eff ektivnosti novogo metoda radial’noj sfi nkterotomii pri obstrukcii vnepechenochnyh zhyolchnyh putej [Justifi cation of the eff ectiveness of a new method of radial sphincterotomy for obstruction of extrahepatic bile ducts]. Kazanskij medicinskij zhurnal [Kazan Medical Journal]. 2014; 95 (6): 816-821. (In Russ.).
34. Facciorusso A, Gkolfakis P, Ramai D, et al. Endoscopic treatment of large bile duct stones: a systematic review and network meta-analysis. Clinical Gastroenterology and Hepatology. 2023; 21 (1): 33-44. DOI: 10.1016/j.cgh.2021.10.013
35. Doshi B, Yasuda I, Ryozawa S, et al. Current endoscopic strategies for managing large bile duct stones. Digestive Endoscopy. 2018; 30: 59-66. DOI: 10.1111/den.13019
36. Alsakarneh S, Brotherton T, Jaber F, et al. Needle-Knife Fistulotomy Versus Needle-Knife Papillotomy in Diffi cult Biliary Cannulation: A Systematic Review and Meta-Analysis. Gastroenterology Research. 2024; 17 (3): 101-108. DOI: 10.14740/gr1726
37. Zhang QS, Xu J, Dong Z, et al. Success and Safety of Needle Knife Papillotomy and Fistulotomy Based on Papillary Anatomy: A Prospective Controlled Trial. Dig Dis Sci. 2022; 67 (5): 1901-1909. DOI: 10.1007/s10620-021-06983-7
38. Веденин Ю.И., Зюбина Е.Н., Мандриков В.В., [и др.]. Стентирование главного панкреатического протока в профилактике острого постманипуляцитонного панкреатита при эндоскопических транспапиллярных вмешательствах // Эндокринная хирургия. – 2022. – Т. 28. – № 3. – С. 32-36. Vedenin YuI, Zyubina EN, Mandrikov VV, et al. Stentirovanie glavnogo pankreaticheskogo protoka v profi laktike ostrogo postmanipulyacitonnogo pankreatita pri endoskopicheskih transpapillyarnyh vmeshatel’stvah [Stenting of the main pancreatic duct in the prevention of acute post-manipulation pancreatitis during endoscopic transpapillary interventions]. Endokrinnaya hirurgiya [Endocrine surgery]. 2022; 28 (3): 32-36. (In Russ.).
39. Mandai K, Uno K, Yasuda K. Successful biliary stone removal after resolution of post-endoscopic sphincterotomy papillary stenosis using temporary covered metal stent placement. Endoscopy. 2022; 54 (5): E210-E211. DOI: 10.1055/a-1486-6659
40. Аванесян Р.Г., Королев М.П., Федотов Л.Е., [и др.]. Осложнения чрескожных миниинвазивных эндобилиарных операций //Анналы хирургической гепатологии. – 2019. – Т. 24. – № 2. – С. 88-99. Avanesyan RG, Korolev MP, Fedotov LE, et al. Oslozhneniya chreskozhnyh miniinvazivnyh endobiliarnyh operacij [Complications of percutaneous minimally invasive endobiliary operations]. Annaly hirurgicheskoj gepatologii [Annals of Surgical Hepatology]. 2019; 24 (2): 88-99. (In Russ.).
41. Старков Ю.Г., Стрекаловский В.П., Григорян Р.С., [и др.]. Антеградная папиллосфинктеротомия во время лапароскопической холецистэктомии //Анналы хирургической гепатологии. – 2001. – Т. 6. – № 1. – С. 99-106. Starkov YuG, Strekalovsky VP, Grigoryan RS, et al. Antegradnaya papillosfinkterotomiya vo vremya laparos kopicheskoj holecistektomii [Antegrade papillosphincterotomy during laparoscopic cholecys tectomy]. Annaly hirurgicheskoj gepatologii [Annals of Surgical Hepatology]. 2001; 6 (1): 99-106. (In Russ.).
42. Назаренко П.М., Назаренко Д.П., Канищев Ю.В., [и др.]. Сравнительные результаты применения антеградной и традиционной папиллосфинктеротомии при устранении холедохолитиаза //Эндоскопическая хирургия. –2016. – Т. 22. – № 4. – С. 25-29. Nazarenko PM, Nazarenko DP, Kanishchev YuV, et al. Sravnitel’nye rezul’taty primeneniya antegradnoj i tradicionnoj papillosfi nkterotomii pri ustranenii holedoholitiaza [Comparative results of the use of antegrade and traditional papillosphincterotomy in the elimination of choledocholithiasis]. Endoskopicheskaya hirurgiya [Endoscopic surgery]. 2016; 22 (4): 25-29. (In Russ.).
43. Takenaka M, Kudo M. Endoscopic papillotomy and papilloplasty: Eff ects on sphincter of Oddi functionality and outcomes. Digestive Endoscopy. 2021; 33 (6): 962-969. DOI: 10.1111/den.13931
44. Сахабетдинов Б.А., Курбангалеев А.И., Сахабетдинова К.Н. Антеградная холедохоскопия при лапароскопической холецистэктомии – метод диагностики и лечения папиллостеноза // Вестник медицинского института «Реавиз»: реабилитация, врач и здоровье. – 2024. – Т. 14. – № 2. – С. 60-66. Sakhabetdinov BA, Kurbangaleev AI, Sakhabetdinova KN. Antegradnaya holedohoskopiya pri laparoskopicheskoj holecistektomii – metod diagnostiki i lecheniya papillostenoza [Antegrade choledochodoscopy in laparoscopic cholecystectomy – a method for diagnosing and treating papillostenosis]. Vestnik medicinskogo instituta «Reaviz»: reabilitaciya, vrach i zdorov’e [Bulletin of the Reaviz Medical Institute: rehabilitation, doctor and health]. 2024; 14 (2): 60-66. (In Russ.).
45. Сахабетдинов Б.А., Абдуллина Д.Д., Гарифуллова А.Р., [и др.]. Антеградная холедохоскопия при лапароскопической холецистэктомии – метод диагностики и лечения папиллостеноза // Молодежный инновационный вестник. – 2024. – Т. 13. – № 1. – C. 43-47. Sakhabetdinov BA, Abdullina DD, Garifullova AR, et al. Antegradnaya holedohoskopiya pri laparoskopicheskoj holecistektomii – metod diagnostiki i lecheniya papillostenoza [Antegrade choledochoscopy in laparoscopic cholecystectomy – a method for diagnosing and treating papillostenosis]. Molodezhnyj innovacionnyj vestnik [Youth Innovation Bulletin]. 2024; 13 (1): 43-47. (In Russ.).
46. Ринчинов В.Б., Плеханов А.Н. Оценка эффективности эндоскопической парциальной папиллосфинктеротомии с баллонной дилатацией при крупном холедохолитиазе //Вестник Бурятского государственного университета. Медицина и фармация. – 2017. – № 1. – С. 62-68. Rinchinov VB, Plekhanov AN. Ocenka effektivnosti endoskopicheskoĭ parcial’noĭ papillosfinkterotomii s ballonnoĭ dilatacieĭ pri krupnom holedoholitiaze [Evaluation of the effectiveness of endoscopic partial papillosphincterotomy with balloon dilation in large choledocholithiasis]. Vestnik Buryatskogo gosudarstvennogo universiteta; Medicina i farmaciya [Bulletin of the Buryat State University; Medicine and Pharmacy]. 2017; (1): 62-68. (In Russ.).
47. Komatsu Y, et al. Endoscopic papillary balloon dilation for the management of common bile duct stones: Experience of 226 cases. Gastrointestinal Endoscopy. 1998; 48 (4): 396-401. DOI: 10.1016/S0016-5107(98)70007-5.
48. Ринчинов В.Б., Плеханов А.Н. Парциальная эндоскопическая папиллосфинктеротомия с баллонной дилатацией в лечении крупного холедохолитиаза // Вестник хирургии имени ИИ Грекова. – 2019. – Т. 178. – № 3. – С. 55-57. Rinchinov VB, Plekhanov AN. Parcial’naya endosko-picheskaya papillosfi nkterotomiya s ballonnoj dilataciej v lechenii krupnogo holedoholitiaza [Partial endoscopic papillosphincterotomy with balloon dilation in the treatment of large choledocholithiasis]. Vestnik hirurgii imeni II Grekova [Bulletin of surgery named after II Grekov]. 2019; 178 (3): 55-57. (In Russ.).
49. Ринчинов В.Б., Плеханов А.Н., Лудупова Е.Ю. Оценка эффективности различных эндоскопических транспапиллярных вмешательств по поводу крупного холедохолитиаза // Хирургия. Журнал им. Н.И. Пирогова. – 2019. – № 6. – С. 60 64. Rinchinov VB, Plekhanov AN, Ludupova EYu. Ocenka effektivnosti razlichnyh endoskopicheskih trans-papillyarnyh vmeshatel’stv po povodu krupnogo holedoholitiaza [Various endoscopic transpapillary inter ventions for choledocholithiasis]. Khirurgiya; Zurnal imeni NI Pirogova [Pirogov Russian Journal of Surgery]. 2019; (6): 60 64. (In Russ.).
50. Harai S, Fukasawa M, Fukasawa U, et al. Pancreatic duct stenting by the rendezvous technique from the minor to major papilla for severe pancreatitis due to papillary stenosis after endoscopic papillectomy. Endoscopy. 2023; 55 (S 01): E127-E128. DOI: 10.1055/a-1952-0436
UDC 616.127-005.8(07) DOI: 10.209 69/V SKM.2025.18(4).88-99
Relapse of the ischemic heart disease clinical manifestations in patients with coronary artery bypass grafting
Dinara R. Khusnullina1, Albert S. Galyavich2, Rustem N. Khairullin1
1 Interregional clinical diagnostic center, 12а Karbyshev str., 420101 Kazan, Russian Federation
2 Kazan State Medical University, 49 Butlerov str., 420012 Kazan, Russia
Abstract. Introduction. Ischemic heart disease is a leading cause of mortality, while coronary artery bypass grafting is an effective treatment method for it, but does not eliminate the risk of the disease recurrence. In this regard, it is necessary to improve approaches to the monitoring of patients before and after coronary artery bypass grafting by studying marker indicators to prevent ischemic heart disease recurrences. Aim. To substantiate the need to study the determinants and prevent the relapse of ischemic heart disease clinical manifestations in patients after coronary artery bypass grafting. Materials and Methods. Analysis of research literature describing the concept and clinical manifestations of ischemic heart disease and its treatment methods, as well as of the essence of coronary artery bypass grafting in the treatment of ischemic heart disease. Results and Discussion. Analysis of factors infl uencing the relapse of the ischemic heart disease clinical manifestations after coronary artery bypass grafting revealed key determinants, including insufficient control of modifi able risk factors, low patients’ awareness, and their non-adherence to therapy. Additional influences include psychosocial stress, decreased quality of life, as well as an increase in non-modifi able risk factors in the absence of an adequate preventive strategy. Conclusions. A comprehensive approach is needed to address the problem of the relapse of the ischemic heart disease clinical manifestations in patients after coronary artery bypass grafting. This involves parallel activities aimed at identifying the determinants of its relapse, initial and dynamic clinical, biochemical, and instrumental indicators thereof, controlling risk factors, as well as in the fi eld of increasing the awareness of patients with ischemic heart disease who have undergone coronary artery bypass grafting, regar ding their further organization of life and health preservation.
Keywords: ischemic heart disease, coronary artery bypass grafting, determinants, prevention of the relapse of the coronary heart disease clinical manifestations.
For citation: Khusnullina, D.R.; Galyavich, A.S.; Khairullin, R.N. Relapse of the ischemic heart disease clinical manifestations in patients with coronary artery bypass grafting. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4), 88-99. DOI: 10.20969/VSKM.2025.18(4).88-99.
References
1. Дидигова Р.Т., Инарокова А.М., Имагожева М.Я., Мамедов М.Н. Современные взгляды на этиологию и диагностику ишемической болезни сердца // Лечебное дело. – 2011. – №4. – С. 11–17. Didigova RT, Inarokova AM, Imagozheva MY, Mamedov MN. Sovremennye vzglyady na etiologiyu i diagnostiku ishemicheskoy bolezni serdtsa [Modern views on the etiology and diagnosis of ischemic heart disease]. Lechebnoe Delo [Medical practice]. 2011; 4: 11–17. (In Russ.).
2. Барбараш О.Л., Карпов Ю.А., Панов А.В., [и др.]. Стабильная ишемическая болезнь сердца. Клинические рекомендации 2024 // Российский кардиологический журнал. – 2024. – Т. 29. – №9. – Ст. 6110. Barbarash OL, Karpov YU, Panov AV, et al. Stabil’naya ishemicheskaya bolezn’ serdtsa: Klinicheskiye rekomendatsii 2024 [Stable ischemic heart disease: Clinical guidelines 2024]. Russian Journal of Cardiology. 2024; 29(9): 6110. (In Russ.). DOI: 10.15829/1560-4071-2024-6110
3. Жмуров Д.В., Парфентева М.А., Семенова Ю.В. Ишемическая болезнь сердц // Colloquium-journal. – 2020. – №29(81). – С. 32–37. Zhmurov DV, Parfenteva MA, Semenova YV. Ishemicheskaya bolezn’ serdtsa [Ischemic heart disease]. Colloquiumjournal. 2020; 29(81): 32–37. (In Russ.). DOI: 10.24412/2520-2480-2020-2981-32-37
4. Арсеничева О.В., Омельяненко М.Г. Ишемическая болезнь сердца. – Иваново: ФГБОУ ВО ИвГМА Минздрава России; 2021. – 109 с. Arsenicheva OV, Omelyanenko MG. Ishemicheskaya bolezn’ serdtsa [Ischemic heart disease]. Ivanovo: FGBOU VO IvGMA Minzdrava Rossii [Ivanovo: FGBOU VO IvSMA of the Ministry of Health of the Russian Federation]. 2021; 109 p. (In Russ.).
5. Поздняков Ю. М., Волков В. С. Стенокардия. – М.: Синергия, 2006. – 336 с. Pozdnyakov YM, Volkov VS. Stenokardiya [Angina]. Moskva: Sinerhiya [Moscow: Synergy]. 2006; 336 p. (In Russ.).
6. Карпов Ю. А., Сорокин Е. В. Стабильная ишемическая болезнь сердца. Стратегия и тактика лечения. – М.: Реафарм, 2003. – 256 с. Karpov YA, Sorokin EV. Stabil’naya ishemicheskaya bolezn’ serdtsa. Strategiya i taktika lecheniya [Stable ischemic heart disease. Strategy and tactics of treatment]. Moskva: Reafarm [Moscow: Reafarm]. 2003; 256 p. (In Russ.).
7. Хазов В.С. Системная концепция этиологии и патогенеза ишемической болезни сердца. Отдельные аспекты ее этиопатогенетической диагностики, профилактики и лечения // Архивъ внутренней медицины. – 2015. – №2. – С. 21–30. Khazov VS. Sistemychnaya kontseptsya etiologii i patogeneza ishemicheskoy bolezni serdtsa. Otdel’nye aspekty yeye etiopatogenezicheskoy diagnostiki, profi laktiki i lecheniya [Systematic concept of the etiology and pathogenesis of ischemic heart disease. Specific aspects of its etiopathogenetic diagnosis, prevention, and treatment]. Arkhiv vnutrenney meditsiny. 2015; 2: 21–30. (In Russ.). DOI: 10.20514/2226-6704-2015-0-2-21-30
8. Ершова А.И., Мешков А.Н., Деев А.Д., [и др.]. Атеросклеротическая бляшка в сонных артериях как маркер риска развития сердечно-сосудистых событий в популяции среднего возраста // Кардиоваскулярная терапия и профилактика. – 2018. – №17(4). – С. 34–39. Ershova AI, Meshkov AN, Deev AD, et al. Ateroskleroticheskaya blyashka v sonnykh arteriyakh kak marker riska razvitiya serdechno-sosudistykh sobytiy v populyatsii srednego vozrasta [Atherosclerotic plaque in the carotid arteries as a risk marker for cardiovascular events in middle-aged population]. Kardiovaskulyarnaya terapiya i profi laktika [Cardiovascular Therapy and Prevention]. 2018; 17(4): 34–39. (In Russ.).
9. Гома Т.В. Ишемическая болезнь сердца. Стенокардия напряжения / Т.В. Гома; Иркутский государственный медицинский университет, Кафедра факультетской терапии. – Иркутск: ИГМУ, 2022. – 46 с. Goma TV. Ishemicheskaya bolezn’ serdtsa; Stenokardiya napryazheniya [Ischemic heart disease; Stable angina]. Irkutsk: Irkutskiy gosudarstvennyy meditsinskiy universitet [Irkutsk: Irkutsk State Medical University]. 2022; 46 p. (In Russ.).
10. Бережнова Н.И. Патология сердечно-сосудистой системы. Часть II. Коронарная недостаточность. Ишемическая болезнь сердца. Инфаркт миокарда. – М.: РГМУ, 2014. – 25 с. Berezhnova NI. Patologiya serdtse-sosudistoy sistemy; Chast’ II: Koronarnaya nedostatochnost’, ishemicheskaya bolezn’ serdtsa, infarkt miokarda [Pathology of the cardiovascular system; Part II: Coronary insuffi ciency, ischemic heart disease, myocardial infarction]. Moskva: RGMU [Moscow: RSMU]. 2014; 25 p. (In Russ.).
11. Рагино Ю.И., Чернявский А.М., Еременко Н.В., [и др.]. Ключевые лабораторно-диагностические биомаркеры коронарного атеросклероза // Кардиология. – 2011. – Т. 51(3). – С. 42–46. Ragino YI, Chernyavskiy AM, Yeremenko NV, et al. Klyuchevye laboratorno-diagnosticheskie biomarkery koronarnogo atheroskleroza [Key laboratory-diagnostic biomarkers of coronary atherosclerosis]. Kardiologiya [Cardiology]. 2011; 51(3): 42–46. (In Russ.).
12. D’Agostino RB, Russel MW, Huse DM, et al. Primary and subsequent coronary risk appraisal: new results from the Framingham Study. Am Heart J. 2000; 139: 272–281.
13. Маль Г.С., Самко Г.Н. Современные взгляды на диагностику и лечение ишемической болезни сердца // Вестник науки. – 2024. – №1(70). – С. 304–308. Mal’ GS, Samko GN. Sovremennyye vzglyady na diagnostiku i lecheniye ishemicheskoy bolezni serdtsa [Modern views on the diagnosis and treatment of ischemic heart disease]. Vestnik nauki [Herald of Science]. 2024; 1(70): 304–308. (In Russ.).
14. Лупанов В.П. Сравнительная оценка функциональных методов исследования в диагностике ишемической болезни сердца // Атеросклероз и дислипидемии. – 2011. – №2. – C.18-25. Lupanov VP. Sravnitel’naya otsenka funktsional’nykh metodov issledovaniya v diagnostike ishemicheskoy bolezni serdtsa [Comparative assessment of functional methods in the diagnosis of ischemic heart disease]. Ateroskleroz i dislipidemiya [Atherosclerosis and dyslipidemia]. 2011; 2: 18-25. (In Russ.).
15. Нго Билонг Экеди Анж Вероник, Аксельрод А.С., Щекочихин Д.Ю., [и др.]. Современный алгоритм диагностики ишемической болезни сердца: достижения и перспективы // Кардиология и сердечно-сосудистая хирургия. – 2019. – №12(5). – С.418-428. Ngo Bilong Ekedi Anzh Veronik, Akselrod AS, Shchekochikhin DIu, et al. Sovremennyy algoritm diagnostiki ishemicheskoy bolezni serdtsa: dostizheniya i perspektivy [Contemporary diagnostic algorithm for coronary artery disease: achievements and prospects]. Kardiologiya i serdechno-sosudistaya khirurgiya [Cardiology and Cardiovascular Surgery]. 2019; 12(5): 418–428. (In Russ.). DOI: 10.17116/kardio201912051418
16. Аншелес А.А. Возрождение «ишемического» подхода в диагностике ишемической болезни сердца: анализ крупных мировых исследований // Кардиология. – 2023. – №63(1). – С. 60–67. Ansheles AA. Vozrozhdenie «ishemicheskogo» podkhoda v diagnostike ishemicheskoy bolezni serdtsa: analiz krupnykh mirovykh issledovaniy [The Revival of the “Ischemic” Approach in the Assessment of Ischemic Heart Disease: Analysis of Major World Research]. Kardiologiya [Cardiology]. 2023; 63(1): 60–67. (In Russ.). DOI: 10.18087/cardio.2023.1.n1478
17. Балахонова А. А., Сухинина Т. С., Веселова Т. Н., [и др.]. Роль компьютерной томографии в диагностике коронарного атеросклероза и его осложнений // Кардиологический вестник. – 2024. – №19(1). С.7-15 Balakhonova AA, Sukhinina TS, Veselova TN, et al. Rol’ komp’yuternoy tomografii v diagnostike koronarnogo atheroskleroza i ego oslozhneniy [Computed tomography in diagnosis of coronary atherosclerosis and its complications]. Kardiologicheskiy vestnik [Russian Cardiology Bulletin]. 2024; 19(1): 7–15. (In Russ.). DOI: 10.17116/Cardiobulletin2024190117
18. Стоногина Д.А., Желанкин А.В., Васильев С.В., [и др.] Диагностические возможности профилей циркулирующих микроРНК у пациентов с острым коронарным синдромом и стабильной ИБС // Кардиология и сердечно-сосудистая хирургия. – 2024. – 17(2). – С. 125-132. Stonogina DA, Zhelankin AV, Vasiliev SV, et al. Diagnosticheskie vozmozhnosti profiley tsirkuliruyushchikh mikroRNK u patsientov s ostrym koronarnym sindromom i stabil’noy IBS [Diagnostic capabilities of circulating microRNA profiles in patients with acute coronary syndrome and stable coronary artery disease]. Russian Journal of Cardiology and Cardiovascular Surgery. 2024; 17(2): С.125-132. (In Russ.). DOI: 10.17116/kardio202417021125
19. Гогин Е. Е. Нарушения микроциркуляции при гипертонической болезни, атеросклерозе, сахарном диабете // Терапевтический архив. – 2011. – №4. – С. 5–13. Gogin EE. Narusheniya mikrotsirkulyatsii pri gipertonicheskoy bolezni, ateroskleroze, sakharom diabete [Microcirculation disturbances in hypertension, atherosclerosis, and diabetes]. Terapevticheskiy arkhiv [Therapeutic archive]. 2011; 4: 5–13. (In Russ.).
20. Tashkenbaeva EN, Pulatova PK. Coronary heart disease and chronic kidney disease: prevalence and risk factors. J Cardiorespiratory Res. 2024; 5(1): 17–22.
21. Концевая А.В., Мырзаматова А.О., Полупанов А.Г., [и др.]. Этнические особенности распространенности основных сердечно-сосудистых факторов риска среди жителей сельской местности в Российском регионе и регионах Кыргызстана и Казахстана // Российский кардиологический журнал. – 2017. – №6. – С.113–121. Kontseva AV, Myrzamatova AO, Polupanov AG, et al. Etnicheskie osobennosti rasprostranennosti osnovnykh serdtse-sosudistykh faktorov riska sredi zhiteley selskoj mestnosti v Rossiyskom regione i regionakh Kyrgyzstana i Kazakhstana [Ethnic features of the prevalence of major cardiovascular risk factors among rural residents in Russian regions and regions of Kyrgyzstan and Kazakhstan]. Rossiyskiy kardiologicheskiy zhurnal [Russian journal of cardiology]. 2017; (6): 113–121. (In Russ.). DOI: 10.15829/1560-4071-2017-6-113-121
22. Родионова Л.В., Швецова Е.Н., Циванюк М.М., Павлов А.В., Шевчук Н.В., Родионова Л.В. Особенности диагностики и течения ишемической болезни сердца у лиц молодого возраста: клинический случай // Тихоокеанский медицинский журнал. – 2021. – №4 (86). – С. 95–97. Rodionova LV, Shvetsova EN, Tsivanyuk MM, Pavlov AV, Shevchuk NV, Rodionova LV. Osobennosti diagnostiki i tekhniya ishemicheskoy bolezni serdtsa u lits molodogo vozrasta: klinicheskiy sluchay [Features of the diagnosis and course of ischemic heart disease in young individuals: a clinical case]. Tikhookeanskiy meditsinskiy zhurnal [Pacifi c Medical Journal]. 2021; 4(86): 95–97. (In Russ.).
23. Сохавон М.Р. Этиология, диагностика и лечение ишемической болезни сердца у молодых пациентов // Современные проблемы науки и образования. – 2014. – №2. Sokhavon MR. Etiologiya, diagnostika i lecheniye ishemicheskoy bolezni serdtsa u molodykh patsiyentov [Etiology, diagnosis, and treatment of ischemic heart disease in young patients]. Sovremennyye problemy nauki i obrazovaniya [Modern problems of science and education]. 2014; 2. (In Russ.). Rezhim dostupa [URL]: https://science-education.ru/ru/article/view?id=12812
24. Останина Ю.О., Яхонтов Д.А. Современный взгляд на пациентов с ишемической болезнью сердца молодого и среднего возраста // Комплексные проблемы сердечно-сосудистых заболеваний. – 2017. – №S4. – С. 33–34. Ostanina YO, Yakhontov DA. Sovremennyye vzglyady na patsiyentov s ishemicheskoy bolezn’yu serdtsa molodogo i srednego vozrasta [Modern perspectives on patients with ischemic heart disease in young and middle-aged people]. Kompleksnyye problemy serdtse-sosudistykh zabolevaniy [Complex issues of cardiovascular diseases]. 2017; S4: 33–34. (In Russ.).
25. Щербакова А.В., Бараховская Т.В. Хроническая ишемическая болезнь сердца у пожилых: пособие для врачей. – Иркутск: РИО ГБОУ ДПО ИГМАПО, 2016. – 38 с. Shcherbakova AV, Barakhovskaya TV. Khronicheskaya ishemicheskaya bolezn’ serdtsa u pozhilykh: posobiye dlya vrachey [Chronic ischemic heart disease in elderly: a guide for doctors]. Irkutsk: Redaktsionno-izdatel’skiy otdel, Irkutskaya gosudarstvennaya meditsinskaya akademiya poslediplomnogo obrazovaniya [Irkutsk: Editorial and publishing department, Irkutsk State Medical Academy of Postgraduate Education]. 2016; 38 p. (In Russ.).
26. Гайсина Э.Ш., Дударев М.В., Чучкова Н.Н. Клиническая эффективность отечественного иммуномодулятора глюкозамилмурамилдипептида (ликопид) в комплексной терапии пожилых больных стабильной стенокардией // Практическая медицина. – 2011. – №52. – С. 80–85. Gaysina ESh, Dudarev MV, Chuchkova NN. Klinicheskaya effektivnost’ otechestvennogo immunomodyulyatora glyukozamilmuramildipeptida (likopid) v kompleksnoy terapii pozhilykh bol’nykh stabil’noy stenokardiyey [Clinical eff ectiveness of the domestic immunomodulator glycosaminylmuramyldipeptide (Likopid) in complex therapy of elderly patients with stable angina]. Prakticheskaya meditsina [Practical medicine]. 2011; 52: 80–85. (In Russ.).
27. Толпыгина С.Н., Полянская Ю.Н., Марцевич С.Ю. Лечение пациентов с хронической ишемической болезнью сердца в реальной клинической практике по данным регистра «Прогноз ИБС». (Часть 1) // Рациональная фармакотерапия в кардиологии. – 2013. – №9(2). – 138–142. Tolpygina SN, Polyanskaya YN, Martsevich SY. Lecheniye patsiyentov s khronicheskoy ishemicheskoy bolezn’yu serdtsa v real’noy klinicheskoy praktike po dannym registra «Prognoz IBC». (Chast’ 1) [Treatment of patients with chronic ischemic heart disease in real clinical practice based on the “Prognosis IHD” registry data]. Ratsional’naya farmakoterapiya v kardiologiia [Rational pharmacotherapy in cardiology]. 2013; 9(2): 138–142. (In Russ.). DOI: 10.20996/1819-6446-2013-9-2-138-142
28. Газизова В.П., Власова Э.Е., Дзыбинская Е.В., [и др.] Коронарное шунтирование в сочетании с протезированием аортального клапана у пациента с ранее установленной гепарин-индуцированной тромбоцитопенией // Кардиологический вестник. – 2024. – №19(1). – С. 73–78. Gazizova VP, Vlasova EE, Dzybinskaya EV, et al. Koronarnoe shuntirovanie v sochetanii s protezirovaniem aortal’nogo klapana u patsiyenta s ranee ustanovlennoy geparin-indutsirovannoy trombotsitopeniyey [Coronary artery bypass surgery with aortic valve replacement in a patient with previously diagnosed heparin-induced thrombocytopenia]. Kardiologicheskiy vestnik [Cardiology Bulletin]. 2024; 19(1): 73–78. (In Russ.). DOI: 10.17116/Cardiobulletin20241901173
29. Платонов Д.Ю., Костюк Т.Д., Брандт А.И., [и др.]. Детерминанты профилактического поведения в отношении сердечно-сосудистых заболеваний и факторов риска их развития пациентов с гипертонической болезнью и хронической ишемической болезнью сердца // Рациональная фармакотерапия в кардиологии. – 2011. – Т. 7(6). – С. 718–724. Platonov DY, Kostyuk TD, Brandt AI, et al. Determinanty profi lakticheskogo povedeniya v otnoshenii serdechno-sosudistykh zabolevaniy i faktorov riska ikh razvitiya patsientov s gipertonicheskoy boleznyu i khronicheskoy ishemicheskoy boleznyu serdtsa [Determinants of preventive behavior regarding cardiovascular diseases and risk factors for their development in patients with hypertension and chronic ischemic heart disease]. Ratsional’naya farmakoterapiya v kardiologiia [Rational pharmacotherapy in cardiology]. 2011; 7(6): 718–724. (In Russ.).
30. Ахмеджанов Н.М., Небиеридзе Д.В., Сафарян А.С. Коррекция гиперхолестеринемии в первичной и вторичной профилактике сердечно-сосудистых заболеваний: особенности и спорные вопросы // Рациональная фармакотерапия в кардиологии. – 2018. – №14(6). – С. 917–921. Akhmedzhanov NM, Nebieridze DV, Safaryan AS. Korrektsiya giperkholesterinemii v pervichnoy i vtorichnoy profi laktike serdtse-sosudistykh zabolevaniy: osobennosti i spornye voprosy [Correction of hypercholesterolemia in primary and secondary prevention of cardiovascular diseases: peculiarities and controversial issues]. Ratsional’naya farmakoterapiya v kardiologiia [Rational pharmacotherapy in cardiology]. 2018; 14(6): 917–921. (In Russ.). DOI: 10.20996/1819-6446-2018-14-6-917-921
31. Мансурова Д.А., Каражанова Л.К. Этиологические и клинические предикторы возвратной ишемии миокарда // Наука и здравоохранение. – 2015. – №6. – С. 83–91. Mansurova DA, Karazhanova LK. Etiologicheskiye i klinicheskiye prediktory vozvratnoy ishemii miokarda [Etiological and clinical predictors of recurrent myocardial ischemia]. Nauka i zdravookhraneniye [Science and Healthcare]. 2015; 6: 83–91. (In Russ.).
32. Lemos PA, Hoye A, Serrays PW. Recurrent angina after revascularization: an emerging problem for the clinician. Coronary Artery Dis. 2004; 15: 11–15.
33. Abbate A, Biondi-Zoccai GG, Agostoni P, et al. Recurrent angina after coronary revascularization: a clinical challenge. Eur Heart J. 2007; 28 (9): 1057–1065. DOI: 10.1093/eurheartj/ehl562
34. Бубнова М.Г., Аронов Д.М., Новикова Н.К., [и др.]. Изучение информированности о факторах риска и отношения к здоровью больных ишемической болезнью сердца. Новая технология «реабилитационное консультирование» – первый опыт применения // Профилактическая медицина. – 2019. – №22(4). – С. 114-123. Bubnova MG, Aronov DM, Novikova NK, et al. Izucheniye informirovannosti o faktorakh riska i otnosheniya k zdorov’yu bol’nykh ishemicheskoy bolezn’yu serdtsa; Novaya tekhnologiya «reabilitatsionnoye konsul’tirovaniye» – pervyy opyt primeneniya [Study of awareness of risk factors and attitudes towards health in patients with ischemic heart disease; New technology “rehabilitation counseling” - the first experience of application]. Profi lakticheskaya meditsina [Preventive medicine]. 2019; 22(4): 114–123. (In Russ.). DOI: 10.17116/profmed201922041114
35. Олейник Б.А., Плечев В.В., Стародубов В.И., [и др.]. Влияние периоперационной фармакологической стимуляции ангиогенеза препаратом 5-оксиметилурацил на отдаленные результаты хирургической реваскуляризации миокарда // Кардиология и сердечно-сосудистая хирургия. – 2024. – №17(1). – С. 22-28. Oleynik BA, Plechev VV, Starodubov VI, Evdakov VA, Izhbuldin RI, Abzalilova LR. Vliyaniye perioperatsionnoy farmakologicheskoy stimulyatsii angiogeneza preparatom 5-oksimetiluratsil na otdalennyye rezul’taty khirurgicheskoy revaskulyarizatsii miokarda [Infl uence of perioperative pharmacological stimulation of angiogenesis with 5-oxymethyluracil on long-term results of myocardial revascularization]. Kardiologiya i serdechno-sosudistaya khirurgiya [Cardiology and cardiovascular surgery]. 2024; 17(1): 22-28. (In Russ.). DOI: 10.17116/kardio20241701122
36. Стабильная ишемическая болезнь сердца. Клинические рекомендации // Российское кардиологическое общество. – 2023. Stabil’naya ishemicheskaya bolezn’ serdtsa; Klinicheskiye rekomendatsii [Stable ischemic heart disease; Clinical guidelines]. Rossiyskoye kardiologicheskoye obshchestvo [Russian Society of Cardiology]. 2023. Rezhim dostupa [URL]: https://scardio.ru/content/Guidelines/Proekt_2023_SIBS.pdf. (In Russ.).
37. Патеюк И.В. Рекомендации Европейского общества кардиологов по диагностике и лечению хронических коронарных синдромов (стабильной ишемической болезни сердца): обзор изменений 2019 года // Медицинские новости. – 2020. – №1. – С. 37–42. Pateyuk IV. Rekomendatsii Evropeyskogo obshchestva kardiologov po diagnostike i lecheniyu khronicheskikh koronarnykh sindromov (stabil’noy ishemicheskoy bolezni serdtsa): obzor izmeneniy 2019 goda [European Society of Cardiology recommendations on the diagnosis and treatment of chronic coronary syndromes (stable ischemic heart disease): overview of the 2019 changes]. Meditsinskie Novosti [Medical news]. 2020; 1: 37–42. (In Russ.).
38. Стабильная ишемическая болезнь сердца. Клинические рекомендации // Министерство здравоохранения Российской Федерации. – 2022. Stabil’naya ishemicheskaya bolezn’ serdtsa: Klinicheskiye rekomendatsii [Stable ischemic heart disease; Clinical guidelines]. Ministerstvo zdravookhraneniya Rossiyskoy Federatsii [Ministry of Health of the Russian Federation]. 2022. (In Russ.). Rezhim dostupa [URL]: https://cr.minzdrav.gov.ru/schema/155_1
39. Карпов Ю.А., Кухарчук В.В., Лякишев А.А., [и др.] Диагностика и лечение хронической ишемической болезни сердца: клинические рекомендации // Кардиологический вестник. – 2015. – Т. Х, №3. – С. 3-33. Karpov YUA, Kukharchuk VV, Lyakishev AA, [et al]. Diagnostika i lecheniye khronicheskoy ishemicheskoy bolezni serdtsa: klinicheskiye rekomendatsii [Diagnostics and treatment of chronic ischemic heart disease: clinical guidelines.]. Kardiologicheskiy vestnik [Cardiological Bulletin]. 2015; KH (3): 3-33. (In Russ.).
40. Карпов Ю.А., Барбараш О.Л., Бощенко А.А., [и др.]. Евразийские клинические рекомендации по диагностике и лечению стабильной ишемической болезни сердца (2020-2021) // Евразийский кардиологический журнал. – 2021. – № 3. – С.54-93. Karpov YA, Barbarash OL, Boshenko AA, et al. Evraziyskiye klinicheskiye rekomendatsii po diagnostike i lecheniyu stabil’noy ishemicheskoy bolezni serdtsa (2020–2021) [Eurasian clinical guidelines for the diagnosis and treatment of stable ischemic heart disease (2020–2021)]. Yevraziyskiy kardiologicheskiy zhurnal [Eurasian Journal of Cardiology]. 2021; 3: 54-93. (In Russ.).
41. Schirone L, D’Ambrosio L, Forte M, et al. Mitochondria and doxorubicin-induced cardiomyopathy: A complex interplay. Cells. 2022; 11(13): 2000. DOI: 10.3390/cells11132000
42. Halapas A, Cokkinos D. Aortic stenosis prevention: Is a new cardiovascular disease paradigm coming of age? J Clin Med. 2025; 14: 903. DOI: 10.3390/jcm14030903
43. Foulquier S, Daskalopoulos EP, Lluri G, et al. WNT signaling in cardiac and vascular disease. Pharmacol Rev. 2018; 70: 68–141.
44. Meagher PB, Lee XA, Lee J, et al. Cardiac fi brosis: key role of integrins in cardiac homeostasis and remodeling. Cells. 2021; 10: 770.
45. Moris D, Spartalis M, Spartalis E, et al. The role of reactive oxygen species in the pathophysiology of cardiovascular diseases and the clinical signifi cance of myocardial redox. Ann Transl Med. 2017 Aug; 5(16): 326. DOI: 10.21037/atm.2017.06.27
46. Панов А.В. Запись онлайн-семинара «Ишемическая болезнь сердца 2023». Panov AV. Zapis’ onlayn-seminara «Ishemicheskaya bolezn’ serdtsa 2023» [Recording of the online seminar “Coronary heart disease 2023”]. 2023. (In Russ.). Rezhim dostupa [URL]: https://youtu.be/XNnqDCEtoCM?si=3rXJzv1E86WWgKAG.
47. Плотникова, Мария Олеговна. Клинико-эпидемиологические и иммунопатофизиологические особенности острых форм ишемической болезни сердца у лиц молодого и среднего возраста: автореф. дисс.. канд. медицинских наук: 3.2.7. / Плотникова Мария Олеговна; [Место защиты: ФГБОУ ВО «Курский государственный медицинский университет» Министерства здравоохранения Российской Федерации; Диссовет 21.2.015.01 (Д 208.039.02)]. – Орёл, 2022. – 23 с. Plotnikova MO. Kliniko-epidemiologicheskiye i immuno patofiziologicheskiye osobennosti ostrykh form ishemicheskoy bolezni serdtsa u lits molodogo i sred nego vozrasta: avtoreferat dissertatsii kandidata meditsinskikh nauk [Clinical, epidemiological and immunopathophysiological features of acute forms of coronary heart disease in young and middle-aged individuals: abstract of the dissertation of a candidate of medical sciences]. Orol [Orel]. 2022; 23 p. (In Russ.).
48. Кокшарова М.О., Симонова В.Г. Изучение особенностей лечения ишемической болезни сердца у лиц пожилого и старческого возраста // Международный студенческий научный вестник. – 2022. – №6. Koksharova MO, Simonova VG. Izucheniye osobennostey lecheniya ishemicheskoy bolezni serdtsa u lits pozhilogo i starcheskogo vozrasta [Study of features of ischemic heart disease treatment in elderly and senile people]. Mezhdunarodnyy studencheskiy nauchnyy vestnik [International Student Scientifi c Bulletin]. 2022; 6. (In Russ.). Rezhim dostupa [URL]: https://eduherald.ru/ru/article/view?id=21014/
49. Гайворонская В.В., Оковитый С.В. Клиническая фармакология средств лечения ишемической болезни сердца // Обзоры по клинич. фармакол. и лек. терапии. – 2003. – №4. – С. 45–70. Gayvoronskaya VV, Okovity SV. Klinicheskaya farma kologiya sredstv lecheniya ishemicheskoy bolezni serdtsa [Clinical pharmacology of drugs for the treatment of ischemic heart disease]. Obzory po klinicheskoy farmakologii i lekarskoy terapii [Reviews on clinical pharmacology and drug therapy]. 2003; 4: 45–70. (In Russ.).
50. Островская Ю.И., Мелехов А.В. Реваскуляризация миокарда: ведение больных до и после вмешательства // Атмосфера. Новости кардиологии. – 2017. – №2. – С. 40–48. Ostrovskaya YI, Melekhov AV. Revasculyaryzatsiya miokarda: vedenie bol’nykh do i posle vmeshatel’stva [Myocardial revascularization: management of patients before and after intervention]. Atmosfera; Novosti kardiologii [Atmosphere; Cardiology news]. 2017; 2: 40–48. (In Russ.).
51. Реваскуляризация миокарда // Клиника эндоваскулярной хирургии. Revaskulyarizatsiya miokarda [Revascularization of the myocardium]. Klinika endovaskulyarnoy khirurgii [Endovascular Surgery Clinic]. Rezhim dostupa [URL]: https://endovascularclinic.ru/эндоваскулярное-лечение/реваскуляризация-миокарда. (In Russ.).
52. Латфуллин И.А. Ишемическая болезнь сердца: основные факторы риска, лечение / И.А. Латфуллин. – Казань: Изд-во Казан. ун-та, 2017. – 426 с. Latfullin IA. Ishemicheskaya bolezn’ serdtsa: osnovnye faktory riska, lecheniye [Ischemic heart disease: main risk factors, treatment]. Kazan’: Izdatel’stvo Kazanskogo universiteta [Kazan: Kazan University Publishing House].2017; 426 p. (In Russ.).
ORGANIZATION OF HEALTHCARE
UDC: 614.253.8:159.962.7:616.314-77DOI: 10.20969/VSKM.2025.18(4).100-106
Level of education as a determinant of patients’ sanogenic activity and their satisfaction with orthopedic dental care
Alexey A. Astafyev1, Oleg E. Konovalov1, Igor S. Kopetsky2, Alexey V. Shulaev3, Olga Yu. Guseva2, Andrey I. Kopetsky2
1 Peoples’ Friendship University of Russia named after Patrice Lumumba, 10 Miklukho-Maklay str, Bldg. 2, 117198 Moscow, Russia
2 Pirogov Russian National Research Medical University, 1 Ostrovityanova str., 117997 Moscow, Russia
3 Kazan State Medical University, 49 Butlerov str., 420012 Kazan, Russia
Abstract. Introduction. An important factor determining the patient’s attitude to their own health and the medical care they receive is the level of education. The aim of the study is to explore the sanogenic activity and satisfaction with orthopedic dental care of patients after dental implantation. Materials and Methods. For the period from 2020 to the present, a sociological study was conducted in the private dental clinic DK-32 in Moscow, in which 306 patients took part. All patients underwent implantological and orthopedic treatment for their bounded and free-end edentulous spaces. Sanogenic activity and satisfaction with the quality of medical care quality were assessed using the questionnaire method. Results and Discussion. The level of education of the study participants was quite high. Thus, in most cases (57.2%), patients had complete or undergraduate degrees. Respondents who have completed a vocational secondary education accounted for 34.2%, while 8.6% have completed general secondary education. All patients who participated in the study visited the dentist for preventive purposes. Most of them (87.0%) sought preventive examination once a year, while 13.0% two or more times a year. Patients with secondary education sought preventive dental care less often than those with higher education. At the same time, 11.8% of respondents fully followed the dentist’s recommendations on prevention of dental diseases, 87.5% partially followed them, and only 0.7% of respondents did not follow them at all. It was found that respondents with university or undergraduate degrees fully follow the dentist’s recommendations on prevention of dental diseases 3 times more often than those with secondary education. To assess satisfaction with dental care, we studied patients’ opinions on the quality of dental care they received. According to the results, no negative reviews were recorded from patients. Nevertheless, the care received by patients with university degrees was evaluated signifi cantly higher. Conclusions. Higher sanogenic activity and satisfaction with the orthopedic dental care received were identifi ed in individuals with university or undergraduate degrees compared to those who have only completed vocational or general secondary education. This allows us to draw a conclusion about the role of education as the determinants thereof.
Keywords: level of patient education, sanogenic activity, satisfaction with orthopedic c are
For citation: Astafi ev, A.A.; Konovalov, O.E.; Kopetsky, I.S.; et al. Level of education as a determinant of patients’ sanogenic activity and their satisfaction with orthopedic dental care. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4), 100-106. DOI: 10.20969/VSKM.2025.18(4).100-106.
References
1. Турусова Е.В., Булкина Н.В. Параметры качества жизни стоматологических пациентов различных психотипов // Саратовский медико-научный журнал. – 2016. – №1. – С. 49-51. Turusova EV, Bulkina NV. Parametry` kachestva zhizni stomatologicheskix pacientov razlichny`x psixotipov [Parameters of the quality of life of dental patients of different psychotypes]. Saratovskij mediko-nauchny`j zhurnal [Saratov Medical and Scientifi c Journal]. 2016; 1: 49-51. (In Russ.).
2. Ахметов Е.М. Качура Г.П., Федоров В.Е., [и др.]. Стоматологическое здоровье и качество жизни лиц пожилого и старческого возраста до и после реабилитации жевательно-речевого аппарата // Институт стоматологии. – 2019. – Т. 82, № 1. – С. 18-21. Axmetov EM, Kachura GP, Fedorov VE, et al. Stomatologicheskoe zdorov`e i kachestvo zhizni licz pozhilogo i starcheskogo vozrasta do i posle reabilitacii zhevatel`norechevogo apparata [Dental health and quality of life of elderly and senile persons before and after rehabilitation of the masticatory-speech apparatus]. Institut stomatologii [Institute of Dentistry]. 2019; 82(1): 18-21. (In Russ.).
3. Мартиросов А.В., Черкасов С.Н., Камаев Ю.О. Принципы оценки профессионализма врача // Кардиоваскулярная терапия и профилактика. – 2023. – Т. 22. № S6. – С. 80. Martirosov AV, Cherkasov SN, Kamaev YuO. Principy` ocenki professionalizma vracha [Principles of assessing the professionalism of a doctor]. Kardiovaskulyarnaya terapiya i profilaktika [Cardiovascular therapy and prevention]. 2023; 22(S6): 80. (In Russ.)]. DOI: 10.15829/1728-8800-2023-6S
4. Мартиросов А.В., Черкасов С.Н., Федяева А.В. Значимость уровня образования как социальной характеристики пациента в формировании его отношения к организации амбулаторной медицинской помощи // Вестник Российской Военно-медицинской академии. – 2023. – Т. 25, № 2. – С. 211-218. Martirosov AV, Cherkasov SN, Fedyaeva AV. Znachimost` urovnya obrazovaniya kak social`noj xarakteristiki pacienta v formirovanii ego otnosheniya k organizacii ambulatornoj medicinskoj pomoshhi [The importance of the level of education as a social characteristic of the patient in the formation of his attitude towards the organization of outpatient medical care]. Vestnik Rossijskoj Voennomedicinskoj akademii [Bulletin of the Russian Military Medical Academy]. 2023 ; 25(2): 211-218. (In Russ.). DOI: 10.17816/brmma303606
5. Черкасов С.Н., Черкасов П.С., Мешков Д.О. Уровень образования как социальная детерминанта здоровья на распространенность здоровьесберегающих форм поведения // Актуальные проблемы медицины и биологии. – 2023. – № 1. – С. 73-79. Cherkasov SN, Cherkasov PS, Meshkov DO. Uroven` obrazovaniya kak social`naya determinanta zdorov`ya na rasprostranennost` zdorov`esberegayushhix form povedeniya [The level of education as a social determinant of health on the prevalence of health-saving forms of behavior]. Aktual`ny`e problemy` mediciny` i biologii [Act ual problems of medicine and biology]. 2023; 1: 73-79. (In Russ.).
6. Chung S, Johns N, Zhao B, et al. Clocks Moving at Diff erent Speeds: Cultural Variation in the Satisfaction With Wait Time for Outpatient Care. Med Care. 2016; 54(3): 269-276. DOI: 10.1097/MLR.0000000000000473
7. Mead N, Roland M. Understanding why some ethnic minority patients evaluate medical care more negatively than white patients: a cross sectional analysis of a routine patient survey in English general practices. BMJ. 2009; 339: b3450. DOI: 10.1136/bmj.b 3450
8. Li L, Lee NJ, Glicksberg BS, et al. Data-Driven Identifi cation of Ri sk Factors of Patient Satisfaction at a Large Urban Academic Medical Center. PloS one. 2016; 11(5): E0156076. DOI: 10.1371/journal.pone.0156076
UDC 616-052:159.923 DOI: 10.20969/VSKM.2025 .18(4).107-112
Patient behavior patterns associated with making decisions for the need of seeking medical advice
Igor N. Banin1, Sergey N. Cherkasov2, Oleg E. Konovalov3, Alexey V. Shulaev4, Islam M. Aliev5
1Ministry of Health of Voronezh region, 52d str. Krasnoarmeyskaya, 394006 Voronezh, Russia
2Russian State Social University, 4 str. Wilhelm Pika,1129226 Moscow, Russia
3Peoples’ Friendship University of Russia named after Patrice Lumumba, 10 Miklukho-Maklaya str, Bldg. 2,
117198 Moscow, Russia
4Kazan State Medical University, 49 Butlerov str., 420012 Kazan, Russia
5Dagestan State Medical University, 1 Lenin Square str., 367012 Mahachkala, Russia
Abstract. Introduction. The most promising behavior pattern in terms of reducing the severity of the pathological process is an active model of patient behavior, which involves seeking medical advice even for preventive purposes. Aim of the study is to analyze patient behavior patterns when deciding on the need of seeking medical advice. Materials and Methods. The analysis was conducted in three comparison groups formed based on the observation and treatment technology. The fi rst one included 531 patients undergoing planned treatment on an outpatient basis, the second comparison group included 822 patients undergoing planned treatment in a hospital (specialized gastroenterology department), and the third group included 147 patients admitted to inpatient treatment at the Emergency Hospital on an emergency basis due to complications of the underlying disease (pathology of the digestive organs).Patient behavior patterns were identifi ed by analyzing patient responses to the authors’ questionnaire. Additionally, the time interval was assessed between the onset of symptoms and seeking medical care. The groups were compared using nonparametric criteria: Association coeffi cient (Ka) and the ꭕ2 criterion. Criteria were analyzed using standard approaches.Results and Discussion. It was found that the reactive passive model of patient behavior (wait-and-see attitude) associated with making a decision to seek medical care was more often recorded in patients of the third group (67.3%) versus 40.5% of patients in the second group and 35.6% in patients of the fi rst group. The reactive but active model of patient behavior is a more positive fact, which should contribute to a decrease in the number of complications according to the principle of secondary prevention. However, the prevalence of this type of behavior is not very high in all the groups compared, but this form of behavior was the least common among patients of the third group (12.2% versus 22.6% in the fi rst and 20.4% in the second group). The active model of behavior, providing for seeking medical care for preventive purposes, was noted in about a quarter of patients of the fi rst (24.9%) and second (22.6%) group. The prevalence of this model of behavior among patients of the third group was signifi cantly lower. Thus, only 6.1% of patients included in this group stated that they sought medical care for preventive purposes. Conclusions. High levels were detected in the commitment of inpatients and outpatients with gastrointestinal diseases to a passive behavior model characterized by delayed seeking medical advice, until their condition worsens to the point that their usual way of life becomes impossible.
Keywords: medical care, treatment, patient behavior, behavior patterns
For citation: Banin, I.N.; Cherkasov, S.N.; K onovalov, O.E.; Shulaev, A.V., Aliev I. M. Patient behavior patterns associated with making decisions for the need of seeking medical advice. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4), 107-112. DOI: 10.20969/VSKM.2025.18(4).107-112.
References
1. Genovese U, Del Sordo S, Casali M, et al. A new paradigm on health care accountability to improve the quality of the system: four parameters to achieve individual and collective accountability. Journal of Global Health. 2017; 7 (1): 010301. DOI: 10.7189/jogh.07.010301
2. Шаповалова М.А. Медико-демографические критерии общественного развития. Российская академия медицинских наук. Бюллетень Национального научно-исследовательского института общественного здоровья. – 2005. – №3. – С. 144-146. Shapovalova MA. Mediko-demograficheskie kriterii obshhestvennogo razvitiya [Medical and demographic criteria of social development]. Rossijskaya akademiya medicinskix nauk. Byulleten` Nacional`nogo nauchno-issledovatel`skogo instituta obshhestvennogo zdorov`ya [Russian Academy of Medical Sciences. Bulletin of the National Research Institute of Public Health]. 2005; 3: 144-146. (In Russ.).
3. Келасьев В.Н., Первова И.Л., Полуэктова Н.М. Концепция человека: социальные и субъективные детерминанты здоровья // Вестник Санкт-Петербургского университета. Серия 12. Психология. Социология. Педагогика. – 2016. – № 1. – С. 15-26. Kelas`ev VN, Pervova IL, Polue`ktova NM. Koncepciya cheloveka: social`ny`e i sub``ektivny`e determinanty` zdorov`ya [The concept of man: social and subjective determinants of health]. Vestnik Sankt-Peterburgskogo universiteta; Seriya 12: Psixologiya; Sociologiya; Pedagogika [Bulletin of St Petersburg University; Series 12: Psychology; Sociology; Pedagogy]. 2016; 1: 15-26. (In Russ.).
4. Missinne S, Meuleman B, Bracke P. The popular legitimacy of European healthcare systems: a multilevel analysis of 24 countries. Journal of European Social Policy. 2013; 23: 231-247. DOI: 10.1177/0958928713480065
5. Черкасов С.Н., Горбунов А.Л., Федяева А.В. Влияние уровня образования на модели поведения, связанные с обращением за медицинской помощью // Международный научно-исследовательский журнал. – 2022. – №9 (123). – С. 1-5. Cherkasov SN, Gorbunov AL, Fedyaeva AV. Vliyanie urovnya obrazovaniya na modeli povedeniya, svyazanny`e s obrashheniem za medicinskoj pomoshh`yu [The Impact of Education Level on Health-Seeking Behaviors]. Mezhdunarodny`j nauchno-issledovatel`skij zhurnal [International Research Journal]. 2022; 9 (123): 1-5. (In Russ.).
6. Камаев Ю.О., Черкасов С.Н., Федяева А.В., Мартиросов А.В. Модели поведения, связанные с обращением за медицинской помощью пациентов с разным уровнем располагаемого дохода // Вестник Санкт-Петербургского университета. Медицина. – 2023. – Т. 18, Вып. 1. – С. 70-78. Kamaev YuO, Cherkasov SN, Fedyaeva AV, Martirosov AV. Modeli povedeniya, svyazanny`e s obrashheniem za medicinskoj pomoshh`yu pacientov s razny`m urovnem raspolagaemogo doxoda [Patterns of health care seeking behavior among patients with diff erent levels of disposable income]. Vestnik Sankt-Peterburgskogo universiteta. Medicina [Bulletin of St. Petersburg University. Medicine.]. 2023; 18 (1): 70-78. (In Russ.). DOI: 10.21638/spbu11.2023.106
7. Черкасов С.Н., Полозков О.И., Федяева А.В., Камаев Ю.О. Влияние уровня образования на модели поведения, связанные с обращаемостью за медицинской помощью населения старших возрастных групп // Медико-фармацевтический журнал Пульс. – 2021.– Т. 23, № 7. – С. 31-37. Cherkasov SN, Polozkov OI, Fedyaeva AV, Kamaev YuO. Vliyanie urovnya obrazovaniya na modeli povedeniya, svyazanny`e s obrashhaemost`yu za medicinskoj pomoshh`yu naseleniya starshix vozrastny`x grupp [The Impact of Education Level on Behavior Models Related to Seeking Medical Care in the Elderly Population]. Mediko-farmacevticheskij zhurnal Pul`s [Medical and pharmaceutical journal Pulse]. 2021; 23 (7): 31-37. (In Russ.).
8. Урясьев О.М., Коновалов О.Е., Кича Д.И. Медицинская активность больных бронхиальной астмой // Российский медико-биологический вестник им. академика И.П. Павлова. – 2013. – № 3. – С. 98-100. Uryas`ev OM, Konovalov OE, Kicha DI. Medicinskaya aktivnost` bol`ny`x bronxial`noj astmoj [Medical activity of patients with bronchial asthma]. Rossijskij mediko-biologicheskij vestnik im. akademika I.P. Pavlova [Russian Medical and Biological Bulletin named after Academician I.P. Pavlov]. 2013; 3: 98-100. (In Russ.).
9. Жильцова Е.Е., Чахоян Л.Р., Коновалов О.Е., Исаков С.А. Медико-социальная характеристика и медицинская активность больных хроническими дерматозами // Наука молодых (Enuditio Juvenium). – 2019. – № 4. – С. 526-532. Zhil`czova EE, Chaxoyan LR, Konovalov OE, Isakov SA. Mediko-social`naya xarakteristika i medicinskaya aktivnost` bol`ny`x xronicheskimi dermatozami [Medical and social characteristics and medical activity of patients with chronic dermatoses]. Nauka molody`x (Eruditio Juvenium) [Science of the Young (Eruditio Juvenium)]. 2019; 4: 526-532. (In Russ.). DOI: 10.23888/HMJ201974526-532
10. Черкасов С.Н., Курносиков М.С. Влияние медико-социальных факторов и особенностей поведения пациенток на уровень потребности в стационарной помощи при внематочной беременности // Российский медико-биологический вестник имени академика И.П. Павлова. – 2015. – Т. 23, № 3. – С. 66-70. Cherkasov SN, Kurnosikov MS. Vliyanie mediko-social`ny`x faktorov i osobennostej povedeniya pacientok na uroven` potrebnosti v stacionarnoj pomoshhi pri vnematochnoj beremennosti [The infl uence of medical and social factors and patient behavior on the level of need for inpatient care in ectopic pregnancy]. Rossijskij mediko-biologicheskij vestnik imeni akademika IP Pavlova [Russian Medical and Biological Bulletin named after Academician IP Pavlov]. 2015; 23 (3): 66-70. (In Russ.).
11. Gorbunov AL, Cherkasov SN, Fedyaeva AV. et al. Attitude to informing the doctor about the treatment process in diff erent age and sex groups of patients // Bulletin Biomedicine and sociology. 2022; 7 (1): 66-75. DOI: 10.26787/nydha-2618-8783-2022-7-1-66-75
12. Шаповалова М.А., Ярославцев А.С., Бабеева Н.И., [и др.]. Влияние социально-экономических условий и факторов на динамику заболеваемости населения болезнями эндокринной системы // Вестник Всероссийского общества специалистов по медико-социальной экспертизе, реабилитации и реабилитационной индустрии. – 2022. – № 1. – С. 75–79. Shapovalova MA, Yaroslavcev AS, Babeeva NI. et al. Vliyanie social`no-e`konomicheskix uslovij i faktorov na dinamiku zabolevaemosti naseleniya boleznyami e`ndokrinnoj sistemy` [The infl uence of socio-economic conditions and factors on the dynamics of the incidence of endocrine diseases in the population]. Vestnik Vserossijskogo obshhestva specialistov po mediko-social`noj e`kspertize, reabilitacii i reabilitacionnoj industrii [Bulletin of the All-Russian Society of Specialists in Medical and Social Expertise, Rehabilitation and the Rehabilitation Industry]. 2022; 1: 75–79. (In Russ.).
13. Кром И.Л., Еругина М.В., Орлова М.М., [и др.]. Детерминанты общественного здоровья в социальном контексте // Саратовский научно-медицинский журнал. – 2017. – T. 13. – № 2. – С. 292-295. Krom IL, Erugina MV, Orlova MM. et al. Determinanty` obshhestvennogo zdorov`ya v social`nom kontekste [Determinants of public health in a social context]. Saratovskij nauchno-medicinskij zhurnal [Saratov Scientifi c Medical Journal]. 2017; 13 (2): 292-295. (In Russ.).
14. Хорошилова Е.Ю. Образование как детерминанта здоровья // Научный альманах. – 2017. – № 3 (29). – С. 387-390. Xoroshilova EYu. Obrazovanie kak determinanta zdorov`ya [Education as a determinant of health]. Nauchny`j al`manax [Scientifi c almanac]. 2017; 3 (29): 387-390. (In Russ.). DOI: 10.17117/na.2017.03.03.387
UDC: 614.256:616-053.3 DOI: 10.20969/VSKM.2025.18(4).113-119
Physicians’ awareness of the expanded neonatal screening program
Alexey I. Geraskin1, Oleg E. Konovalov1, Zareta I. Esmurzieva2, Alexey V. Shulaev3, Vitaly I. Pak1
1 Peoples’ Friendship University of Russia named after Patrice Lumumba, 10 Miklukho-Maklaya str, Bldg. 2,
117198 Moscow, Russia
2 Morozov Children’s Municipal Clinical Hospital of the Moscow City Health Department (State-Financed Health Institution),
1/9, 4th Dobryninsky Lane, 119049 Moscow, Russia
3 Kazan State Medical University, 49 Butlerov str., 420012 Kazan, Russia
Abstract. Introduction. One of the eff ective options for early diagnosis of treatable hereditary diseases is large-scale newborn screenings (neonatal screening). At the same time, studying the awareness and opinions of healthcare professionals about the neonatal screening program is important for understanding existing barriers to its implementation. Aim. To analyze to what extent physicians from diverse specialties are aware of the expanded neonatal screening program. Materials and Methods. This paper analyzes the results of studying the awareness of 477 physicians from diverse specialties of the expanded neonatal screening program. The study involved examining the awareness of the expanded neonatal screening program and the sources of knowledge about it among physicians, as well as understanding the importance of screening as a method for preventing congenital and hereditary diseases. To identify diff erences between the answers of clinical geneticists and other medical professionals to the questionnaire, χ² was calculated. Results and Discussion. It is found that only 39.2% of clinicians exactly know the list of diseases included in the expanded neonatal screening. This indicates confusion with the existing information materials or insufficient awareness among the clinicians surveyed of the current changes in screening. It should be noted that absolutely all clinical geneticists are aware of the expansion of the neonatal screening program. This is quite expected, given their specialization and role in interpreting screening results. It is shown that the frequency of false positive and false negative results of the expanded neonatal screening is directly aff ected by the pre-analytical stage, which includes timely blood collection. Knowing the correct timing of expanded the neonatal screening in term and preterm newborns is closely related to the awareness of the changes made in the program. Respondents who correctly indicated the introduced changes were more likely to choose the correct answer and less likely to make mistakes. It is found that 38.2% of the respondents believe that screening in general is not a method for prevention, while 61.8% rejected this statement, confi rming the importance of screening in the prevention of congenital diseases. The main source of information about the expanded neonatal screening for p hysicians are articles published in medical journals, participation in scientific conferences and seminars, and consulting Internet resources. Despite the low popularity of methodological manuals as a source for learning during the initial acquisition of knowledge, physicians actively use them in their practical work at the decision-making stage. Conclu sions. Early detection of hereditary and congenital diseases contributes to the timely initiation of treatment and correction thereof, which helps pr event or signifi cantly reduce the development of severe complications, as well as improve the child’s quality of life.
Keywords: expanded neonatal screening, program, physician awareness
For citation: Geraskin, A.I.; Konovalov, O.E.; Esmurzieva, Z. I.; Shulaev, A.V.; Pak, V.I. Physicians’ awareness of the expanded neonatal screening program. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4), 113-119. DOI: 10.20969/VSKM.2025.18(4).113-119.
References
1. Русакова А.А., Некрасова А.А., Жанин И.С., Савостьянов К.В. Раннее выявление российских пациентов с наследственными болезнями обмена, имеющими патогенетическую терапию // Российский педиатрический журнал. – 2023. – Т. 26, № S4. – С. 63-64. Rusakova AA, Nekrasova AA, Zhanin IS, Savost`yanov KV. Rannee vy`yavlenie rossijskix pacientov s nas ledstvenny`mi boleznyami obmena, imeyushhimi patogeneticheskuyu terapiyu [Early detection of Russian patients with hereditary metabolic diseases that have pathogenetic therapy]. Rossijskij pediatricheskij zhurnal [Russian Pediatric Journal]. 2023; 26(S4): 63-64. (In Russ.). DOI: 10.46563/1560-9561-2023-26-S4
2. Dasí F. Alpha-1 antitrypsin defi ciency. Med Clin (Barc). 2024; 162(7): 336-342.
3. Bm MV, Pakarinen O, Helenius I, et al. Why all newborn hip screening programs have same results-a mini review. Eur J Pediatr. 2024; 183(7): 2889-2892. DOI: 10.1007/s00431-024-05539-x
4. Shah N, Brlek P, Bulić L, et al. Genomic sequencing for newborn screening: current perspectives and challenges. Croat Med J. 2024; 65(3): 261-267. DOI: 10.3325/cmj.2024.65.261
5. Sun Y, Guan XW, Wang YY, et al. Newborn genetic screening for Fabry disease: Insights from a retrospective analysis in Nanjing, China. Clin Chim Acta. 2024; 557: 117889. DOI: 10.1016/j.cca.2024.117889
6. Горбунова В.Н. Наследственные болезни обмена. Лизосомные болезни накопления // Педиатр. – 2021. – Т.12. – №2. – C.73-83. Gorbunova VN. Nasledstvenny`e bolezni obmena; Lizosomny`e bolezni nakopleniya [Hereditary metabolic diseases; Lysosomal storage diseases]. Pediatr [Pediatrician]. 2021; 12(2): 73-83. (In Russ.). DOI: 10.17816/PED12273-83
7. Съемщикова Ю.П., Козлов Ю.А., Яковлев А.Б., [и др.]. Редкий случай синдрома Моркио (мукополисахаридоз IVА типа): трудности диагностического поиска и лечения // Педиатрическая фармакология. – 2022. – Т.19. – №1. – С.39-44. Semshhikova YuP, Kozlov YuA, Yakovlev AB, et al. Redkij sluchaj sindroma Morkio (mukopolisaxaridoz IVA tipa): trudnosti diagnosticheskogo poiska i lecheniya [A Rare Case of Morquio Syndrome (Mucopolysaccharidosis Type IVA): Diffi culties in Diagnostic Search and Treatment]. Pediatricheskaya farmakologiya [Pediatric pharmacology]. 2022; 19(1): 39-44. (In Russ.). DOI: 10.15690/pf.v19i1.2352
8. Yüksel F, Uğur C, Yılmaz BK, et al. Evaluation of newborn hearing screening results of infants with phenylketonuria. Int J Pediatr Otorhinolaryngol. 2024; 177: 111840. DOI: 10.1016/j.ijporl.2023.111840
9. Коноплева Е.Л., Соколова М.Г., Атрощенко А.М. Этический контекст оказания медицинской помощи пациентам с орфанными заболеваниями // Образование и наука: современный вектор развития: материалы III Национальной научно-практической конференции. – Керчь, 2024. – С. 227-240. Konopleva EL, Sokolova MG, Atroshhenko AM. E`ticheskij kontekst okazaniya medicinskoj pomoshhi pacientam s orfanny`mi zabolevaniyami [Ethical context of providing medical care to patients with orphan diseases]. Obrazovanie i nauka: sovremenny`j vektor razvitiya: materialy` III Nacional`noj nauchno-prakticheskoj konferencii [Education and Science: Modern Vector of Development: Proceedings of the III National Scientific and Practical Conference]. Kerch [Kerch`]. 2024; 227-240. (In Russ.). 10. Conway RM, Perreault K, Schomer J, et al. Rurality Effect on Michigan Newborn Hearing Screening. Laryngoscope. 2024; 134(6): 2937-2940. DOI: 10.1002/lary.31242
PRACTICAL EXPERIENCE
UDC: 616.12-089:616.13 DOI: 10.20969/VSKM.2025.18(4).120-125
Modern aspects of common atrium surgery: Integrating clinical practice and literature data
Ruslan T. Alisherov1, Samatbek O. Kadyraliev1,2, Nurayim M. Nurdinova1, Kaldarbek A. Abdramanov1,2
1Southern Regional Scientific Center of Cardiovascular Surgery, 81 Mamyr Baatyr str., 720901 Jalal-Abad, Kyrgyzstan
2 Jalal-Abad State University named after B. Osmonov, 49 Ruzi Azimov str., 720907 Jalal-Abad, Kyrgyzstan
Abstracts. Introduction. Common atrium is a rare and severe congenital heart defect combined with the absence of atrial septum and impaired atrioventricular valve formation. Without surgical intervention, this anomaly is associated with high morbidity and mortality. The aim of our study was to demonstrate modern approaches to diagnosis and surgical treatment of common atrium using a clinical case example with parallel analysis of literature data. Materials and Methods. We present a clinical case of a 17-year-old patient with the diagnosis of common atrium confi rmed by echocardiography and other instrumental methods. Defi nitive repair of the defect was performed with Boyd tricuspid valve annuloplasty. A scientifi c literature search was conducted in the leading scientifi c databases, such as PubMed, Scopus, Web of Science, Google Scholar, and eLIBRARY (RINC), covering publications in English and Russian for the period of 2010-2025. The following keywords were used: common atrium, single atrium, atrioventricular septal defect, congenital heart defects, surgical correction, radical repair, tricuspid valve annuloplasty, Boyd technique, long-term outcomes, echocardiographic diagnosis, clinical case, using AND/OR logical operators. Sources were selected with the priority given to systematic reviews, clinical cases, and studies with data on surgical treatment and long-term outcomes. Results and Discussion. Surgical intervention achieved sustained clinical stabilization and restored hemodynamics. The long-term results are favorable. Literature data confi rm the eff ectiveness of radical repair in adolescence. Conclusion. Advanced diagnostic methods and timely surgical treatment of common atrium provide a signifi cant improvement in prognosis. The case presented illustrates the clinical implementation of the recommendations available in the current literature.
Keywords: common atrium, single atrium, atrioventricular septal defect, congenital heart defects, surgical correction, radical repair, tricuspid valve annuloplasty, Boyd technique, long-term outcomes, echocardiographic diagnosis, clinical
case
For citation: Alisherov, R.T.; Kadyraliev, S.O.; Nurdinova, N.M.; Abdramanov, K.A. Modern aspects of common atrium surgery: Integrating clinical practice and literature data. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4), 120-125. DOI: 10.20969/VSKM.2025.18(4).120-125.
References
1. Young AH, Robinson A. A case of common atrium. Heart. 1907; 1 (2): 123-126.
2. Smith J, Brown K. Morphology of common atrium in congenital heart disease. J Cardiol. 2010; 55 (4): 301-309. DOI: 10.1016/j.jjcard.2010.01.005
3. Demirelli S, et al. Asymptomatic common atrium in a young adult: case report and literature review. Cardiol J. 2015; 22 (6): 742-746. DOI: 10.5603/CJ.2015.0086
4. Johnson L, Thompson P. Definition and classification of common atrium defects. Eur Heart J. 2012; 33 (10): 1234-1240. DOI: 10.1093/eurheartj/ehs068
5. Patel N, Kumar R. Anatomical considerations in common atrium: implications for surgery. Ann Thorac Surg. 2014; 97 (1): 115-121. DOI: 10.1016/j.athoracsur.2013.09.050
6. Lee YS, et al. Epidemiology of congenital atrial septal defects: a population-based study. Pediatr Cardiol. 2018; 39 (2): 310-316. DOI: 10.1007/s00246-017-1740-x
7. Altıntaş B, et al. Common atrium without mitral valve anomaly in adult patient: a case report. Heart Lung Circ. 2017; 26 (9): e116-e119. DOI: 10.1016/j.hlc.2017.02.005
8. Rao MS, et al. Ellis-van Creveld syndrome with common atrium: case report and review. Congenit Heart Dis. 2019; 14 (4): 652-658. DOI: 10.1111/chd.12761
9. Chen X, et al. The role of multidetector CT in the diagnosis of congenital common atrium. J Thorac Imaging. 2020; 35 (3): 205-210. DOI: 10.1097/RTI.0000000000000512
10. Müller M, et al. Surgical outcomes of common atrium repair: a 10-year review. Ann Thorac Surg. 2015; 99 (2): 613-619. DOI: 10.1016/j.athoracsur.2014.07.046
11. Garcia F, et al. Autologous pericardium in the surgical correction of common atrium: benefits and risks. J Cardiovasc Surg. 2019; 60 (3): 362-368. DOI: 10.23736/S0021-9509.19.10933-7
12. Ivanov V, et al. Timing of surgical intervention in congenital heart disease: impact on outcomes. Cardiol J. 2022; 29 (1): 1-8. DOI: 10.5603/CJ.a2021.0123
13. Bun SS, et al. Common atrium associated with mitral valve defect in adult: clinical implications. Eur J Cardiothorac Surg. 2016; 50 (5): 891-895. DOI: 10.1093/ejcts/ezv022
14. Smith T, et al. Echocardiographic features of common atrium: 2D and 3D imaging comparison. J Am Soc Echocardiogr. 2018; 31 (10): 1144-1150. DOI: 10.1016/j.echo.2018.05.017
15. Johnson R, et al. Transesophageal echocardiography in congenital atrial defects: clinical utility. J Am Coll Cardiol. 2011; 57 (12): 1334-1342. DOI: 10.1016/j.jacc.2010.10.041
16. Lee JH, et al. Surgical repair of common atrium: clinical outcomes and follow-up. Ann Thorac Surg. 2017; 104 (1): 152-159. DOI: 10.1016/j.athoracsur.2017.02.022
17. Kim K, et al. Common atrium with atrioventricular septal defect in adult patient: a case report. Cardiol Res Pract. 2018; 2018:8362471. DOI: 10.1155/2018/8362471
18. Boyd DB. Surgical technique for repair of common atrium with tricuspid annuloplasty. Ann Thorac Surg. 1972; 14 (1): 28-33.
19. Thompson EA, et al. Preservation of conduction system in common atrium repair. Heart Surg Forum. 2014; 17 (2): E87-E91. DOI: 10.1532/hsf.1438
20. Greenberg ML, et al. Outcomes after surgical correction of common atrium: review of 20 years’ experience. J Thorac Cardiovasc Surg. 2016; 152 (6): 1515-1522. DOI: 10.1016/j.jtcvs.2016.07.054
21. Wu Y, et al. Management of common atrium in pediatric patients: a single-center experience. Pediatr Cardiol. 2021; 42 (4): 801-808. DOI: 10.1007/s00246-020-02510-1
22. Lee SY, et al. Natural history and management of unrepaired common atrium. J Cardiol. 2019; 73 (1): 20-27. DOI: 10.1016/j.jjcc.2018.10.010
23. Johnson K, et al. Pulmonary hypertension in congenital heart disease: risk factors and management. Eur Respir J. 2018; 52 (1): Article 1701600. DOI: 10.1183/13993003.01600-2017
24. Chen X, et al. Prognostic factors in patients with common atrium: a meta-analysis. Congenit Heart Dis. 2020; 15 (5): 811-819. DOI: 10.1111/chd.12807
25. Brown KL, et al. Surgical timing and outcomes in congenital heart defects. Heart. 2022; 108 (6): 447-454. DOI: 10.1136/heartjnl-2021-319863
26. Smith M, et al. Advances in surgical management of complex congenital heart defects. Circulation. 2021; 143 (11): 1055-1065. DOI: 10.1161/CIRCULATIONAHA.120.050463
27. Patel H, et al. Long-term outcomes of surgical repair of common atrium: a multicenter study. Eur J Cardiothorac Surg. 2022; 61 (3): 532-539. DOI: 10.1093/ejcts/ezac127
28. Jones G, et al. Improving diagnosis and treatment of rare congenital cardiac anomalies. Cardiol Clin. 2020; 38 (2): 219-234. DOI: 10.1016/j.ccl.2020.01.002
29. Smith J, et al. 2D and 3D echocardiography in diagnosis of common atrium: clinical utility. Eur Heart J Cardiovasc Imaging. 2018; 19 (9): 1042-1049. DOI: 10.1093/ehjci/jey045
30. Chen L, et al. Multislice CT angiography in congenital heart disease preoperative planning. J Thorac Cardiovasc Surg. 2020; 159 (2): 648-655. DOI: 10.1016/j.jtcvs.2019.05.053
31. Boyd DB. Tricuspid valve annuloplasty in common atrium correction. Ann Thorac Surg. 1972; 14 (2): 55-61.
32. Garcia F, et al. Surgical modifi cations for common atrium repair using autologous pericardium. J Thorac Cardiovasc Surg. 2019; 157 (4): 1432-1438. DOI: 10.1016/j.jtcvs.2018.10.086
33. Lee JH, et al. Timing of surgery and outcome in common atrium patients. J Card Surg. 2021; 36 (1): 115-121. DOI: 10.1111/jocs.15123
34. Ivanov V, et al. Early versus late surgery in congenital heart defects: clinical outcomes. Cardiol J. 2022; 29 (3): 303-310. DOI: 10.5603/CJ.a2022.0056
UDC 618.36-006.325 DOI: 10.20969/VSKM.2025 .18( 4).126-131
Clinical cases of chorioangioma
Olga D. Konstantinova1, Svetlana K. Kshnyaseva1,2, Maria O. Chernova1,3, Valeria A. Kozlova1
1Orenburg State Medical University, 6 Sovetskaya str., 460000 Orenburg, Russia
2Orenburg Clinical Perinatal Center, 23 Gagarin Ave., 460051 Orenburg, Russia
3Orenburg Perinatal Center, 24 Nevelskaya str., 460018 Orenburg, Russia
Abstract. Introduction. Chorioangioma is a benign non-trophoblastic tumor of the placenta, ranging in size from a few millimeters to 8-10 cm, developing from fetal capillaries that are part of the chorionic villi. Chorioangioma occurs in 0.2-4 cases per 10,000 births and is often combined with preeclampsia and polyhydramnios. The aim of the study is to analyze the course of pregnancy, prenatal complications, management and treatment tactics, perinatal outcome in pregnancies complicated by formed placental chorioangioma. Materials and methods. The medical records of patients with chorioangiomas diagnosed during pregnancy were analyzed; a literature review of scientifi c articles and monographs for 2014-2023 was performed. Results and discussion. In the studied cases, chorioangioma was diagnosed based on ultrasound data in the second and third trimesters. Cases of chorioangioma were combined with such pregnancy complications as polyhydramnios, oligohydramnios with a single umbilical artery. The patients were delivered surgically by cesarean section for obstetric indications due to increasing polyhydramnios or oligohydramnios, tumor growth, fetal hypoxia. Conclusions. Timely ultrasound diagnostics of chorioangioma with subsequent dynamic observation is a key tactic for managing patients with this pathology and can signifi cantly reduce the risk of an unfavorable perinatal outcome. An increase in polyhydramnios or oligohydramnios, leading to a violation of the fetus’s condition, the formation of acute fetal hypoxia are indications for delivery by cesarean section. According to histological studies of placentas, signs of similarity in macro- and microscopic signs of chorioangioma have been noted, which determines the similarity of clinical cases with a subsequent positive perinatal outcome. To minimize possible risks for the mother and fetus, it is advisable to conduct ultrasound monitoring together with Doppler ultrasound of the fetus and the vascular system of the uteroplacental blood fl ow with a frequency of 1-2 times a week. All the presented clinical observations resulted in a favorable perinatal outcome, which confi rms the important role of an individual approach to pregnant women with placental pathology, since complications can be represented not only by polyhydramnios, which is diagnosed most often, but also by oligohydramnios in combination with such developmental anomalies as a single umbilical artery.
Keywords: chorioangioma, placenta, polyhydramnios, doppler
For citation: Konstantinova, O.D.; Kshnyaseva, S.K.; Chernova, M.O.; Kozlova, V.A. Clinical cases of chorioangioma. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4), 126-131. DOI: 10.20969/VSKM.2025.18(4).126-131.
References
1. Савельева Г.М., Шалина Р.И., Сичинава Л.Г., [и др]. Акушерство: учебник, 2-е изд., перераб. и доп. // М.: Гэотар-Медиа, 2020. – 576 с. Savelyeva GM, Shalina RI, Sichinava LG, et al. Akusherstvo: uchebnik [Obstetrics: textbook]. Moskva: Geotar-Media [Moscow: Geotar-Media]. 2020; 2: 576. (In Russ.).
2. Липатов И.С., Тезиков Ю.В., Белоконева Т.С., [и др.]. Гестационные и перинатальные исходы при гигантской хориоангиоме // Российский вестник акушера-гинеколога. – 2019. – №4. – С.72-76. Lipatov IS, Tezikov YV, Belokoneva TS, et al. Gestacionnye i perinatal’nye iskhody pri gigantskoj khorioangiome [Gestational and perinatal outcomes in giant chorioangioma]. Rossijskij vestnik akushera-ginekologa [Russian Bulletin of Obstetrician-Gynecologist]. 2019; 4: 72-76. (In Russ.). DOI: 10.17116rosakush20191904172
3. Марайкин В.О., Петров Ю.А., Палиева Н.В., [и др.]. Опухоли плаценты: влияние на ход беременности и родов // Главный врач Юга России. – 2021. – № 5. – С. 15-19. Maraykin VO, Petrov YA, Palieva NV, et al. Opukholi platsenty: vliyanie na khod beremennosti i rodov [Placental tumors: impact on pregnancy and labor]. Glavnyj vrach Yuga Rossii [Chief physician of the South of Russia]. 2021; 5: 15-19. (In Russ.).
4. Идимешева С.В., Баженова Е.Г., Козыренко Е.М., [и др.]. Случай из практики: Хориоангиома больших размеров // Пренатальная диагностика. – 2016. – №4. – С.363-369. Idimesheva SV, Bazhenova EG, Kozyrenko EM, et al. Sluchaj iz praktiki: Khorioangioma bol’shikh razmerov [Case from practice: Large chorioangioma]. Prenatal’naya diagnostika [Prenatal diagnosis]. 2016; 4: 363-369. (In Russ.).
5. Rech F, Salernitano D, Patella A. Il corioangioma placentare. Minerva Ginecol. 2002; 54(5): 417-33. DOI: 10.32074/1591-951X-1003
6. Al Wattar BH, Hillman SC, Marton T, et al. Placenta chorioangioma: a rare case and systematic review of literature. J Matern Fetal Neonatal Med. 2014; 27(10): 1055-63. DOI: 10.3109/14767058.2013.847424
7. Buca D, Iacovella C, Khalil A, Rizzo G, et al. Perinatal outcome of pregnancies complicated by placental chorioangioma: systematic review and meta-analysis. Ultrasound Obstet Gynecol. 2020; 55(4): 441-449. DOI: 10.1002/uog.20304
8. Шелаева Е.В., Прохорова В.С., Нагорнева С.В. Хориоангиомы плаценты: диагностика и тактика ведения // Журнал акушерства и женских болезней. – 2017. – №3. – C. 124-134. Shelaeva EV, Prokhorova VS, Nagorneva SV. Horioangio my placenty: diagnostika i taktika vedeniya [Chorioangiomas of the placenta: diagnostics and management tactics]. Zhurnal akusherstva i zhenskih boleznej [Journal of obstetrics and women’s diseases]. 2017; 3: 124-134. (In Russ.). DOI: 10.17816/JOWD663124-134
9. Ибраимов Б. А., Ибраимова К. С., Нурманова А. М. Хориоангиома и беременность // Клиническая медицина Казахстана. – 2017. – №3. – С.73-76. Ibraimov BA, Ibraimova KS, Nurmanova AM. Khorioangioma i beremennost’ [Chorioangioma and pregnancy]. Klinicheskaya medicina Kazakhstana [Clinical medicine of Kazakhstan]. 2017; 3: 73-76. (In Russ.). DOI: 10.23950/1812-2892-JCMK-00493
10. Нормурадова Н.М., Юсупбаев Р.Б., Бабаханова А.М. Хориоангиома плаценты // Аспекты ультразвуковой оценки гемодинамики плода. – 2021. – №3. – С.204-211. Normuradova NM, Yusupbaev RB, Babakhanova AM. Khorioangioma placenty [Chorioangioma of the placenta]. Aspekty ul’trazvukovoj otsenki gemodinamiki ploda [Aspects of ultrasound assessment of fetal hemodynamics]. 2021; 3: 204-211. (In Russ.). DOI: 10.21569/2222-7415-2021-11-3-204-211
11. Saeed B, Tulbah A, Bintalib M, De Vol EB, et al. Chorioangioma: a single tertiary care center retrospective study. J Perinat Med. 2023; 51(5): 664-674. DOI: 10.1515/jpm-2021-0085
UDC:616.22-006 DOI: 10.20969/VSKM.2025.18( 4).132-135
Large epidermal cyst of the larynx: A case report
Aleksandr A. Khanamirov1, Vadim N. Kolesnikov2, Maxim A. Lapin1, Victoria I. Skachedub3, Andrey V. Mikutin1
1Rostov Regional Clinical Hospital, 170 Blagodatnaya str., 344015 Rostov-on-Don, Russia
2Rostov State Medical University, 29 Nakchichevansky Lane, 344022 Rostov-on-Don, Russia
3Pathology Office, 170 Blagodatnaya str., 344015 Rostov-on-Don, Russia
Abstract. Epidermal cysts are benign cysts fi lled with keratin masses that can develop anywhere in the body and tend to grow slowly. Histologically they are similar to cholesteatoma. Epidermal cysts of the larynx are an extremely rare disease and it is not possible to estimate their occurrence. The most common localization in the larynx is in vestibular folds, however, there are publications on their localizations in vocal folds. Aim. To present data on an epidermal cyst of the larynx and long-term results of microendolaryngeal surgical treatment, using a case report. Materials and Methods. Patient P. (71 y. o., F) was admitted to the Rostov Regional Clinical Hospital with signs of the stage 1 laryngeal stenosis and dysphonia. During examination, the patient was found to have a neoplasm of the hypopharynx and vestibular part of the larynx, covered with an unchanged mucous membrane, narrowing the lumen of the larynx by more than half and preventing examination of her vocal folds. According to magnetic resonance imaging, it was a cyst of the left vestibular fold measuring 30.5 x 35 x 32 mm, adjacent to the left half of the epiglottis and the left vocal fold. Results and Discussion. Due to the submucosal location of the tumor, a biopsy of the tumor was performed using direct microlaryngoscopy in the high-frequency jet ventilation conditions through tracheopuncture with urgent histological examination and determination of further tactics based on the fi ndings. Taking into account the results of an urgent histological examination, the cyst was removed endolaryngeally. The patient was under medical supervision at the Rostov Regional Clinical Hospital during 3 years after treatment with no signs of cyst recurrence. As a result of treatment, complete restoration of vocal and respiratory function was achieved. Conclusions. Microendolaryngeal surgical treatment in the high-frequency jet ventilation conditions through tracheopuncture allows organ-preserving treatment without tracheostomy for patients with voluminous cystic neoplasms of the larynx.
Keywords: epidermal cyst, larynx.
For citation: Khanamirov, A.A.; Kolesnikov, V.N.; Lapin, M.A.; et al. Large epidermal cyst of the larynx: A case report. The Bulletin of Contemporary Clinical Medicine. 2025, 18 (4),132-135. DOI: 10.20969/VSKM.2025.18(4).132-135.
References
1. Yilmaz M, Haciyev Y, Mamanov M, et al. Epidermal inclusion cyst of the larynx. J Craniofac Surg. 2011; 22(6): e1-2. DOI: 10.1097/SCS.0b013e31822ec818
2. Karaçal N, Topal U, Kutlu N. Popliteal epidermoid cyst: an unusual location. Plast Reconstr Surg. 2004; 114:830–831. DOI: 10.1097/01.prs.0000136543.54426.af
3. Yan K, Agrawal N, Gooi Z. Head and neck masses. Med Clin North Am. 2018; 102: 1013–1025. DOI: 10.1016/j.mcna.2018.06.012
4. Reiter R, Hoff mann TK, Pickhard A, Brosch S. Hoarseness causes and treatments. Dtsch Arztebl Int. 2015; 112: 329–337. DOI: 10.3238/arztebl.2015.0329
5. Khushaim H, Albaghli S, Al-Alsheikh A, Al Rikabi A. Laryngeal epidermal inclusion cyst: report of an unusual case and literature review. J Surg Case Rep. 2020; 2020 (11): rjaa488. DOI: 10.1093/jscr/rjaa488
6. Ophir D, Lifschitz-Mercer B. Oncocytic cystic lesions of the upper respiratory tract Ear Nose Throat J. 1989; 68 (3): 237-238, 240, 243-244.
7. Westerberg BD, Durham JS, Berean KW. Multiple oncocytic laryngeal cysts presenting as acute airway obstruction J Otolaryngol. 1995; 24 (5): 319-321.
8. Monday LA, Cornut G, Bouchayer M, Roch JB Epidermoid cysts of the vocal cords Ann Otol Rhinol Laryngol. 1983;92(2 Pt 1):124-127. DOI: 10.1177/000348948309200205
